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Abstract 
Background: Rabeprazole sodium, a proton pump inhibitor, is expedient for the 
preclusion and management of ulcers, gastro esophageal reflux disease (GERD) and other 
disorders encompassing extreme acid secretion. Numerous methodologies have been 
employed to prepare substantial formulation of rabeprazole sodium. However during 
development process of other drug carriers several complications are challenged such as 
unpredictability and failure to localize the API within preferred region of the GIT for 
desired time and this variability may cause arbitrary bioavailability. 
Purpose of study: Present generous work deals with synthesis and characterization of an 
innovative drug delivery carriers for highly acid labile drug, to overcome the problems of 
acidic degradation, extensive pre systemic metabolism, shorter half life (frequent dosing) 
and relatively low bioavailability (52%) for rabeprazole sodium controlled release at 
specific site in GIT. 
Experimental design: Free radical polymerization technique was employed to 
synthesize crosslinked polymeric networks of varying composition by using 
carboxymethyl arabinoxylan, carboxymethyl cellulose and polyethylene glycol 
(polymer), methacrylic acid and acrylic acid (monomer), potassium persulfate (initiator) 
and N,N Methylene  bisacrylamide (crosslinker). Prepared crosslinked polymeric 
networks  were characterized by swelling analysis at acidic and basic pH, instrumental 
analysis (SEM, FTIR and thermal analysis) and pH responsive in vitro drug release of 
model drug rabeprazole sodium. Acute oral toxicity study of prepared hydrogels were 
implemented consistent with the “Organization of Economic Co-operation and 
Development (OECD) guideline for chemicals toxicity study. On the basis of preliminary 
characterization and in vitro release analysis investigations two formulations (CA5 and 
A6) with maximum in vitro cumulative drug release were selected for in vivo evaluation. 
Healthy rabbits having weight greater than 2.5 ± 0.61 Kg were used for in vivo study. 
Rabbit plasma was analyzed by HPLC. Mobile phase consisted of 60 % of 100 mM 
Ammonium acetate buffer & 40% Acetonitrile and eluted at a flow rate of 1.0 ml/min. 
The pharmacokinetic parameters of Rabeprazole sodium from CMAX-g-AA, CMC-g-
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AA hydrogels and drug solution were analyzed from the plasma levels in rabbits by non 
compartmental pharmacokinetic analysis using the software package kinetica v 4.4. 
Pharmacokinetic data was statistically analyzed by one way ANOVA. 
Results: Carboxymethyl arabinoxyllan anionic polysaccharide obtained from Ispaghola 
husk by alkali extraction, exhibited variety of ideal characteristics for controlled drug 
delivery carrier. Free radical polymerization by KPS can be successfully employed to 
formulate pH responsive copolymeric network of carboxymethyl arabin oxylan with 
acrylic acid and methacrylic acid. FTIR, SEM and thermo gravimetric analysis verify 
graft copolymerization. Porous structure of hydrogel become more prominent at pH 7.4 
by increasing contents of acrylic acid, as compared to methacrylic acid contents. CMAX-
g-AA and CMAX-g-MAA underwent morphological changes during grafting which 
modified its structure and properties as well, which shows more thermal stability as 
compared to the raw back bone. Graft copolymers revealed highly pH responsive 
swelling, consequently drug release. At acidic pH cumulative drug release from CMAX-
g-AA hydrogels decreased (11.52 %, 7.64 %, and 3.91 %) with progressive increase of 
acrylic acid (10 %, 15 % and 20 %) contents. At higher pH carboxylic acid group present 
in graft copolymer became progressively more ionized, hydrogels swelled more rapidly 
ultimately cumulative drug release enhanced (93.18 %, 85.51 % and 79.77 % with 
progressive decreasing acrylic acid contents). As swelling of CMAX-g-AA hydrogel 
increased by increasing concentration of CMAX, swelling was directly proportional to 
drug release (92.83 %, 96.76 %, and 98.44 % at CMAX concentration 1 %, 1.5 % and 2 
%, respectively at basic pH). It has been observed that overall swelling ratio (q) (20.85, 
16.70, and 14.28; 20 %w/w, 30 %w/w and 35 %w/w methacrylic contents respectively) 
of CMAX-g-MAA reduced by increasing concentration of methacrylic acid. 
Hydrophobic nature of methacrylic acid is responsible for reduce swelling. In vitro 
release study has revealed that as contents of methacrylic acid raised (20 %, 30 % and 35 
%), pH sensitivity enhanced (% CDR at basic pH is 84.19 %, 75.9 %, 71.26 % and at 
acidic pH % CDR 10.3 %, 7.7 % and 5.33 %)   but overall swelling reduced so percent 
cumulative drug release has been declined. Degree of swelling depends on crosslinked 
monomer concentration, polymer concentration and also on crosslinking density of 
hydrogels. Swelling of such hydrogels in the stomach is minimal so drug release 
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consequently low at acidic pH. Values of R
2
 obtained using zero order release model 
were viewed higher than other order release model, thus depicting that drug release from 
the series of hydrogels at varying amount of polymer, monomer and crosslinker was zero 
order. 
It was observed that swelling ratio (q) of graft copolymer (CMC-g-AA) increased (35.3, 
37.8, and 43.3)  with an increasing concentration of CMC (0.5 %, 1 %, and 1.5 %) 
respectively but decreased (31.6) at 2 % concentration of CMC. pH sensitive % 
cumulative drug release from CMC-g-Acrylic hydrogel ranges from 3.12% to 10.66% 
during early 24 hrs of dissolution release in simulated acidic pH medium of stomach (i.e. 
pH 1.2) while it range from 50.68% to 80.75% depending upon varying amounts of 
CMC, acrylic acid and cross linker.  It was viewed that maximum  drug released from 
CMC-g-MAA hydrogel at pH 1.2 was (11.69 %, 7.80 %, and 5.59 % respectively) after 
24 hrs with increasing contents of methacrylic acid (from 20- 35 %w/w). However, 63.11 
% to 71.85 % of the total drug loaded was released at pH 8 in 24 hrs. These results are 
correlated with pH responive swelling of CMC-g-MAA hydrogels. 
PEG-g-MAA hydrogels showed the rabeprazole sodium release profile of the hydrogels, 
it was noticed that by increasing PEG contents from 5 %-20 % cumulative drug release 
enhanced from 73 % to 93 %. Methacrylic acid act as swelling retardant because of 
hydrophobic methyl group, by increasing methacrylic acid contents hydrogels exhibited 
highly pH sensitive response but cumulative drug release was reduced due to low degree 
of swelling. Water absorbing property of hydrogel is attractive for their biomedical 
application. The effect of HEMA and AA on the swelling curve of prepared hybrid 
hydrogels PEG (HEMA-co-AA) at acidic and basic pH were studied by varying 
concentrations. Swelling analysis of PEG (HEMA-co-AA) polymeric network exhibited 
that with varying contents of AA (7.5 %, 10 %, 12.5 % and 15 %) swelling ratio (q) in 
acidic medium decreased gradually (3.58, 3.30, 2.66, and 2.24) but at alkaline pH 
swelling ratio (12.89, 14.07, 16.13 and 19.72 respectively) increased. Hydrogels prepared 
with varying contents of HEMA (1 %, 1.5 %, 2 % and 3 %) show low swelling ratio 
(4.03, 3.34, 3.16, 2.24 at acidic pH and 26.94, 24.65, 21.42 and 16.35 at high pH) with 
increasing its contents and concentration of other constituents keeping constant. Present 
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study also investigated that by increasing HEMA contents while PEG and acrylic acid 
contents kept constant, drug release declined. These findings were correlated with 
swelling analysis of PEG (HEMA-co-AA). As HEMA is neutral monomer, which has no 
ionize able groups and exhibited very small swelling in buffer solution. But water 
swelling properties of HEMA could be improved by co-polymerization with more 
hydrophilic monomer like acrylic acid 
Acute toxicity study of hydrogel is the knowledge of interaction of chemical composition 
of the biomaterial and tissue exposure. Acute oral toxicity study of prepared hydrogels 
suggested that no mortality was found within study period. No signs of illness (vomiting, 
eye secretion, running nose, salivation) were observed after hydrogels administration. 
According to globally harmonized system (GHS), LD50 value of testing chemical is 
higher than the 2000 mg/kg dose then it will be categorize under the “Category 5” and 
toxicity score will be “zero.” Therefore, prepared hydrogels can be categorized under the 
Category 5 and toxicity grade is zero.  
The peak plasma concentration (Cmax) and time to reach peak plasma concentration (Tmax) 
was obtained from the visual inspection of the plasma concentration-time curves. The 
area under the plasma concentration curve (AUC0-t) was determined using the trapezoidal 
rule. Cmax values of (CMC-g-AA) CA and (CMAX-g-AA) A and same oral dose of 
rabeprazole sodium were 87.28±12.671, 103.71±16.081 and 61.263±5.37 ng/ml, 
respectively. Observed mean plasma AUC0-24 values for CA (952.25±191 ng.h/ml) and A 
(1084.57±148.68 ng.h/ml) was signiﬁcantly (P < 0.05) higher than drug solution 
(83.67±8.28 ng.h/ml). The Tmax value of graft copolymer matrices CA (4.43 h) and A 
(4h) was signiﬁcantly (P < 0.05) higher than drug solution (1h). The relative 
bioavailability of hydrogel formulations (CA and A) containing rabeprazole sodium than 
free rabeprazole sodium in drug solution, containing the same dose of the same drug, is 
obtained by comparing their respective AUCs (952.25 ng.l/hr for CA and 1084.57 ng.l/hr 
for A hydrogel) were higher. 
Conclusion: The  concept  of  formulating  graft copolymer  containing  Rabeprazole 
sodium offered an appropriate, sensible approach to accomplish a lingering therapeutic  
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outcome  by  continuously  releasing  the  drug  over extended  period  of  time.  Prepared 
hydrogels were nontoxic, safe and biocompatible following oral administration and it 
might be auspicious candidate as innovative oral drug carrier. Graft copolymerization is 
faster and more cost-effective technique to modify imperative properties of the existing 
drugs than developing new drug entities hence this research work will be windfall to 
novel drug carrier system. 
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1. INTRODUCTION 
This significant and substantial piece of research work includes development, 
characterization and evaluation of various polymeric formulations for stable delivery of 
acid labile drug. Rabeprazole sodium having very short half-life (1-1.5 hr), and is highly 
acid-labile so low bioavailability (52%), presents many formulation challenges.  
Low bioavailability is a major imperfection in efficacious drug delivery by oral route of 
administration. To comprehend the reason behind, low bioavailability is essential before 
developing drug delivery system (Thakar et al., 2010). Rabeprazole sodium is an 
inhibitor of gastric proton pump. It restrain gastric acid secretion by particularly blocking 
the H+/K+- ATPase enzyme system at the secretory surface of  gastric parietal cell 
considerably plummeting gastric acid levels and allowing acid‐related disorders to cure, 
as well as mitigate symptoms of chronic conditions, like gastric and duodenal ulceration 
and also in Zollinger Ellison syndrome and reflux esophagitis (Williams and Pounder, 
1999).  
The proton pump inhibitors have closely similar mechanism of action, yet important 
pharmacological differences exist, which can significantly impact certain aspects of their 
clinical efficacy. Rabeprazole has an early onset of effective acid inhibition compared 
with other proton pump inhibitors, exhibit faster response and shorter duration of action 
(Stedman & Barclay, 2000).  
Researchers have struggled to engineer the controlled drug delivery system to regulate 
the bioavailability of drugs. The most striking way to improve bioavailability of acid 
sensitive drugs is pH responsive release. Hydrogels having such desired characteristics, 
make them an ideal vehicle for intelligent drug delivery system (Narayan et al., 2010).  
Latest progressions in hydrogel synthesis techniques have fabricated a new replica in the 
use of these systems for the improvement of new pharmaceutical forms, predominantly 
of those hydrogels that reveal an intelligent behavior (David et al., 2008).  
Intelligent  hydrogels  can recognize and respond to small alteration  in  external 
circumstances  such  as  pH,  temperature,  light,  and  ionic strength. The smart drug 
delivery systems hold  some  vital  characteristic  such  as  predetermined  rate,  self  
controlled,  targeted,  predefined  time  and  monitor  the  delivery (Subham et al,. 2010). 
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Hydrogels are three-dimensional, cross-linked networks of water-soluble polymers, 
which imbibe a large quantity of water while maintaining their dimensional stability by 
either physical or chemical crosslinking (Lin and Metters, 2006). Chemically, 
crosslinked hydrogels (as compared to physical hydrogels) are mechanically stable due 
to the covalent bond. These hydrogels can be prepared by radical polymerization of low 
molecular weight monomers/polymers in the presence of a crosslinking agent (Chauhan 
et al., 2012) 
The distinctive features of hydrogels have promoted meticulous attention in their use in 
drug delivery applications. Highly porous structure can be regulated by crosslinking 
density of hydrogels. Porosity imparts affinity with aqueous medium to swell, thus 
allows drug loading and subsequent release through gel matrix (Hoare and Daniel, 2008).   
For a polymer system to become “sensitive”, a sharp phase volume-transition must 
happen. The foremost prerequisite of the system is the presence of ionizable weak acidic 
or basic moieties attached to a backbone. Transition from collapsed state to expanded 
state also modified by electrostatic repulsion in response to alterations in environmental 
states like pH, temperature, ionic contents etc. Proper selection between polyacid or 
polybase is essential for desired application. Polyacidic polymers will be unswollen at 
low pH, since the acidic groups will be protonated and unionized. When increasing the 
pH, a negatively charged polymer will swell. The opposite behaviour is exhibited in 
polybasic polymers, since the ionization of basic groups will increase when decreasing 
the pH. Typical examples of pH sensitive polymers with anionic groups are poly 
(carboxylic acids) as poly (acrylic acid) (PAA) or poly (methacrylic acid) (Qui and Park, 
2001). 
The pH - responsive hydrogels contain hydrophilic functional groups i.e. -OH, -CONH-, 
-CONH2, -COOH and -SO3H, responsible for water gulping ability of polymer (Hoare 
and Kohane, 2008).These ionic moieties perceive and respond alteration in external pH 
results in sudden volume transition by generating electrostatic repulsive forces between 
ionized groups, which builds a great osmotic swelling force. Swelling of anionic 
hydrogels in the stomach is least, level of swelling increases as the hydrogel passes down 
the intestinal tract due to increase in pH leading to the ionization of carboxylic groups. 
The nature of the ionic groups, the polymer composition, the hydrophobicity of polymer 
backbone, and the crosslinking density modulate the vital characteristics of smart 
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hydrogels (Qiu and Park 2001). Water intake and holding capability made polymeric 
networks to resemble more closely to natural living tissues than synthetic polymers. Such 
smart polymers guide drug release upon variations in external environment either by 
phase alteration or by changes in their bulk (Soppimath et al., 2002). 
 Hydrogels can be designed as per desired functionalities, like swelling and mechanical 
properties, qualifying their diversity of biomedical uses, from contact lenses to 
controlled-release drug delivery and tissue engineering (Susana et al., 2012). In fact, 
smart hydrogels behave like a natural system in its speed, function, and repeatability. 
Design and composition of hydrogels are the key factors to define their functionalities. 
They can be fabricated from natural and synthetic polymer materials (Davis and Anseth, 
2002). Hydrogels can be prepared by several methods by combining distinctive 
properties of natural and synthetic polymers/monomers. Many researchers have been 
proved that copolymerization is most appropriate method to achieve desired mechanical 
properties of hydrogels.  The  mechanical  properties  of  hydrogels  are essential to 
maintain  its  physical  texture  during  the  delivery  of therapeutic moieties for the 
predetermined period of time (Das, 2013).  
In modern era, copolymers have originated new and extremely progressing horizons in 
front of the precincts of conventional drug delivery system to develop into one of the 
focal compounds as drug delivery vehicles. Copolymers are heteropolymers of 
miscellaneous types of monomers and with varying length of structural repeating units. 
The amalgamation of different chemical units in copolymer structures consequences in 
new materials with numerous novel features (Mehrdad et al., 2012). 
Graft copolymerization is versatile technique to improve compatibility between synthetic 
polymers and natural polymer. Graft copolymer offer additional advantages, especially 
stimuli responsive polymer, like higher acid base and thermal resistance, lower 
crystallinity of natural polymers (Kumar et al., 2014). Graft copolymers are prepared by 
first generating free radicals on the biopolymer backbone and then allowing these 
radicals to serve as macroinitiators. The chemical and radiation initiating systems are 
employed to graft copolymerize monomers onto polymers (Sabyasachi et al., 2010). 
A graft copolymer is a macromolecular chain with one or more species connected to the 
main chain as side chain(s). The general structure consist of the main polymer backbone, 
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commonly referred to as the trunk polymer, has branches of another polymeric chain 
emanating from different points along its length. Grafting of synthetic polymer is a 
convenient method to impart desired new properties to a natural polymer with minimum 
loss of the initial properties of substrate (Sabyasachi et al., 2010).  
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2.     Literature review 
 
2.1 Controlled release drug delivery system 
Low bioavailability of drugs by oral route is a major imperfection in efficacious drug 
delivery. To comprehend the reason behind low bioavailability is essential before 
developing drug delivery system ((Beierle et al. 1999; Bardelmeijer et al., 2000; Katsura 
and Inui, 2003). In last few decades modern drug delivery techniques have revolutionized 
the entire approaches to defeat shortcomings of conventional dosage forms. Numerous 
efforts have been made to control the  factors  like  influence  of  pharmacokinetic  
processes  on  drug  efficacy,  as  well  as  the importance of dosing frequency and of drug 
targeting to the site of action. In the mid to late 1960s, the term “controlled drug delivery” 
came about to illustrate new perceptions of drug delivery design. “Class of drug delivery 
system which release drug in a premeditated, predictable, and sustained manner”. 
Controlled release systems designed to create more steadfast absorption and to improve 
bioavailability and augment patient compliance (Kovanya et al., 2012). 
Some of challenges with use of conventional drug delivery system, poor bioavailability, 
in vivo stability, solubility, intestinal absorption, sustained and targeted delivery to site of 
action, therapeutic effectiveness, generalized side  effects, and plasma fluctuations of 
drugs require tool for research and development of such system to achieve unmet clinical 
requirements.  Following attributes  of controlled drug release technique like improve 
bioavailability of  drug  product,  reduction  in  the  dose  frequency  and  prolong 
duration of effective blood levels, reduces  the  fluctuation  of  peak  trough  
concentration  and side effects and possibly improves the specific distribution of drug 
making more attractive approach for rational therapy (Vilar et al., 2012). 
One of the major challenges in pharmaceutical research is site targeted dosage form 
design for acid labile drugs. These formulations can release active substance in the 
proximal part of small intestine  (duodenum)  through  the  enteric  coating  to  treat  
bowel  diseases  by  improving  the systemic absorption of drugs, which are unstable in 
gastric juice or low pH conditions, thus must  be  protected  from  the  gastric  acid  by  
the  coating  with  high  pH soluble  polymers  or aqueous soluble polymers (enteric 
coated polymers) when given orally (Vilar et al., 2012). 
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2.2   Role of polymers in CRDDS 
Naturapolyceutics is based on interdisciplinary approaches that combine natural polymer 
and pharmaceutics for advancement in drug delivery design (Ndidi et al., 2014). 
Polymers have historically a massive function in drug delivery systems. Novelty in 
polymer science has led to the development of new drug delivery systems. Natural 
polymers can be chemically modified for desired applications. Synthetic polymers can be 
produced on the basis of required functionalities depending on needs of drug delivery 
system (Veeran and Betageri, 2011). Biomedical applications of polymers range from 
their use as binders, thickening agent, film coating material, stabilizer, release modifier, 
solubilizer and barrier properties depending upon unique characteristics of polymers 
(Swathimutyam  and  Bala, 2013). 
Natural polymers are an attractive class of excipients for successful, stable and effective 
drug delivery system. These are economical and easily available, safe, biodegradable, and 
ecofriendly and can be modified according to need (Kavitha et al., 2011; Prakash and 
Kumar, 2013). Pharmaceutical applications of natural polymers include, manufacture of 
solid monolithic matrix systems, implants, films, beads, microparticles, nanoparticles, as 
well as for parenteral use.Various natural polymers like cellulose, pectin, inulin, alginate, 
carrageenan, rosin, guar gum, locust bean gum, gum  arabic, psyllium, starch, aloe gel, 
xanthan and chitosan have been  used  for  the  development  of  controlled  or  sustained  
release drug delivery system (Carien et al., 2009)  . 
Polymers utilized for safe and effective controlled drug delivery must possess following 
characteristics (Javad and Zarnegar, 2014). 
• Polymer and its degradation products must be biocompatible 
• Satisfactory mechanical strength 
• Must be degradable and degradation kinetics matching a biological process 
• Processibility using available equipment. 
• Must be soluble in diverse solvents. 
• Having chemical, structural and application diversity. 
• Cost-effective and eco friendly 
•  Acceptable shelf life  
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Table 2.1: Classification of biodegradable polymers used in drug delivery systems 
(Coulembiera et al., 2006). 
Synthetic biodegradable polymers Natural biodegradable polymers 
Polyesters Polyoxalates Starch 
Polyorthoesters Polyiminocarbonates Hyaluronic acid 
Polyanhydrides Polyurethanes Heparin 
Polydioxanones Polyphosphazenes Gelatin 
Poly(cyanoacrylates)  Albumin 
  Dextran 
  Chitosan 
2.3 Polymer modifications 
Polymer modifications are necessary to transform supreme characters to natural materials, 
such as improve thermal stability, multiphase physical responses, compatibility, impact 
response, flexibility, rigidity and aqeous solubility. Thus polymer modification perk ups 
the processibility of polymers (Ndidi et al., 2014). Chemical modification of polymer 
provides multifunctional characteristics like swelling and solubilization depends upon 
addition of functional group (Dodi et al., 2011). Polar functionalities can be introduced 
into natural polymers by chemical or enzymatic reactions to enhance their biodegradation 
profile (Dey et al., 2011). Polymer modification may cause alterations in physical 
characteristic of polymer like, mechanical strength, permeation, solubility, swellability 
and surface features. 
The diverse chemical modifications helpful to control drug delivery are: 
a)  Grafting                                b) Carboxymethylation 
a)  Grafting  
Grafting is an attractive tool to add valuable features to natural polymer with minimum 
loss of its innate properties. Due to abundant availability, economical source, water 
solubility, safe and biocompatibility, natural polymers could be appealing starting 
materials for the synthesis of graft copolymers. Grafting involves the random branching 
of a monomer on the backbone of a polymer. Chemical reagents like initiators or high 
energy radiations are used to create active sites on polymers and functional monomers are 
crosslinked on these sites (Madolia and  Maurya, 2013). 
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b) Carboxymethylation 
Carboxymethylation is an extensively used technique for polymer modification to 
produce a variety of promising characters in polymer. Carboxymethylation adds 
carboxymethyl groups to the natural polymers thereby augmenting their solubility and 
solution clarity renders more suitable candidate for food, cosmetics and pharmaceutical 
applications (Yuen et al., 2009). Carboxymethylation is a flexible conversion of natural 
polymer to water-soluble polymers with a range of imperative traits (Adeyanju et al., 
2014). 
General mechanism of carboxymethylation involves Williamson’s ether synthesis 
procedure. In this technique polymer is alkalized with sodium hydroxide and converted 
with monochloroacetic acid or its salt to its ether derivatives. Carboxymethyl cellulose, 
Carboxymethyl starch, Carboxymethyl chitosan and many other derivatives may be 
produced depending on starting material (Nawaz et al., 2011). 
 
Figure 2.1: General procedure of carboxymethylation of polymer 
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2.4     Graft copolymerization 
Graft copolymerization is expected to be a potential tool for polymer modifications to 
impart desired characteristics (Arpit et al., 2011). Components of graft copolymerization 
may include initiator, polymer and monomer. Nature of the graft copolymer depends on 
time of reaction, polymer and monomer nature.  Initiator in very small amount creates 
active sites either on polymer or monomer. Various initiator systems may be used for 
graft copolymer like, potassium persulfate, ammonium persulfate, benzoyl peroxide, 
azobisisobutyronitrile and ceric ammonium nitrate (Onishi et al., 2004; Sadeghi and 
Hosseinzadeh, 2010; Sadeghi et al., 2011).  
 Techniques of graft copolymerization 
Extensive efforts have been made to build up diverse techniques of graft 
copolymerization of various monomers on polymeric backbone. These techniques include 
chemical, radiation and photochemical polymerization for drug delivery design. 
• Chemical graft co polymerization/Free radical polymerization 
In chemical graft copolymerization, generally polymers react with initiator 
and generate free radicals. These free radicals start the graft 
polymerization of monomers and cross-linker on the substrate. Free radical 
generation mechanism depends on characteristics of initiator used. Initiator 
may generate free radicals by direct or indirect method. Nature, 
concentration and solubility of initiator determine the mechanism of free 
radical polymerization (Misra et al., 1980; Misra et al., 1984). 
• Radiation polymerization 
The irradiation of polymer cause homolytic fission and generate free 
radicals on the polymer. Initiator is not required for this technique. 
Medium of polymerization is critical for this method e.g, if irradiation is 
carried out in air, peroxides may be formed on the polymer. Free radical 
life span depends on nature of the backbone polymer (Chen et al., 2003). 
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• Photochemical grafting 
This technique requires chromophore on polymer backbone to absorb 
light. After light absorption, polymer goes into an excited state and 
converted into reactive free-radicals, hence the grafting process is initiated. 
Photosensitizers may be used for free radical generation e.g. benzoin ethyl 
ether, dyes, such as Na-2,7 anthraquinone sulphonate or acrylated azo dye, 
aromatic ketones (such as benzophenone, xanthone) or metal ions. 
Photochemical grafting can be proceed in two ways, with or without 
sensitizer depend on photosensitive nature of polymer (Bellobono et al., 
1981) 
2.5 Intelligent drug delivery system 
Biocompatible materials having capability to respond certain physiological variables or 
external physicochemical stimuli designed to deliver therapeutic agent are intelligent drug 
delivery system (You et al., 2010). Smart polymers simulate biological systems in a 
rudimentary way where an external signal (e.g. change in pH or temperature) results in an 
alteration in properties. This leads to a conformational change for the soluble polymers 
and a change in the swelling behavior of the hydrogels when ionisable groups are linked 
to the polymer structure results in release of bioactive molecule from the drug delivery 
system (Dirk, 2006). 
Polymer scientists have been striving for preparing such polymers, having capability to 
perceive physiological stimuli and respond accordingly. Smart polymers may undergo 
physical or chemical transformations in response to fluctuations of environmental 
conditions like pH, temperature, light, magnetic or electric field, ionic factors, biological 
molecules etc. These polymers by exhibiting changes in their physical or chemical 
behavior, release entrapped drug in controlled manner (Snezana et al., 2011).  
 Types of intelligent drug delivery system 
• Biological stimuli responsive drug delivery system: (pH Sensitive System, 
Thermo-responsive Systems, Inflammation Responsive Systems, Glucose 
Sensitive Systems, Ionic Cross - linking In Situ Gelling System, Enzymatic 
Cross - linking In Situ Gelling System) 
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• Magnetically controlled drug delivery system 
• Electrically controlled drug delivery system 
• Photo-responsive drug delivery system 
• Ultrasonically modulated system (Nihar et al., 2013) 
2.6   Hydrogels 
Hydrogels are cross-linked polymeric networks comprise of  high number of hydrophilic 
domains, capable of imbibing large amount of water, but do not dissolving in water at 
physiological pH and temperature  because of their net work structure (Yong and Kinam, 
2001). In swollen state hydrogels due to high water contents and soft consistency 
resemble natural living tissue and are biocompatible (Satish et al., 2006). Equilibrium 
swelling capacity of hydrogels depends on hydrogel structure, crosslinking density, ionic 
contents and hydrophilicity of hydrogel (Omidian and Park, 2008). Hydrogels used for 
biomedical applications must be stable after swelling and maintain their structural 
integrity (Dumitriu, 2002). 
Hydrogels have hydrophilic domains, which do not dissolve in aqueous media but swell 
at specific physiological conditions. Swelling of polymeric network governs the release 
mechanism of drug however, its elasticity regulate mechanical strength and stability 
(Peppas et al., 2000).Three dimensional networks of hydrogels can retain large amount of 
water making it biocompatible, elastic and stable drug carrier system. Presence of 
hydrophilic functional groups like -SO3H, -CONH2, -COOH, and –OH are responsible for 
above characteristics (Wang et al., 2006). 
2.6.1 Hydrogels applications as controlled drug-delivery carriers 
Hydrogels polymeric network has distinctive swelling behavior, which extensively 
dictates the pattern of drug delivery. By controlling few crucial aspects like, polymer 
concentration, composition, initiator and cross linker nature and concentration which 
direct density and degree of cross linking hydrogel properties can be ideally modified for 
their desired application. Chemical and physical connections are vital for the 
improvement of enviable interfacial strength (Peppas et al., 2006). 
Researchers have made it possible to achieve unattainable task of ideal drug delivery by 
hydrogel discovery. Researchers have engineered their physical and chemical properties 
at the molecular level to optimize their properties, for attractive applications; 
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• Control permeability for sustained-release applications 
• Made environment-responsive nature for pulsatile-release applications 
• Modify surface functionality for PEG coatings for stealth release 
• Biodegradability  for bioresorbable applications 
•  Surface biorecognition sites for targeted release and bioadhesion 
applications for controlled drug-delivery applications (Peppas et al., 2004). 
 
2.6.2 Hydrogel classification 
Hydrogels can be classified on the basis of various parameters: 
1) Types of hydrogels based on the method of preparation 
A)  Homopolymer hydrogels 
B)  Co-polymer hydrogels  
C)  Multi polymer hydrogels  
2)  Types of hydrogels on the basis of ionic contents hydrogels  
A)  Neutral hydrogels  
B)  Anionic hydrogels  
C)  Cationic hydrogels  
D)  Ampholytic hydrogels  
3)  Structure based types of hydrogels  
A)  Amorphous hydrogels  
B)  Semi-crystalline hydrogels  
C)  Hydrogen bonded hydrogels  
4)  Drug release mechanism based classes of hydrogels 
A)  Diffusion controlled release systems  
B)  Swelling controlled release systems  
C)  Chemically controlled release systems  
D)  Environment responsive systems (Bindu et al., 2012) 
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2.6.3 Technologies adopted in hydrogel preparation 
• Physical hydrogels 
Nature of association in physical hydrogels is physical. These hydrogels 
can be achieved by hydrophobic association, hydrogen bonding, chain 
aggregation and polymer-polymer complexation. For example, acrylic-
based hydrogels treated with calcium, aluminum, iron; sodium alginate 
treated with calcium and aluminum; poly (vinyl alcohol) treated with 
borax. All of these interactions are reversible, and can be disrupted by 
changes in physical conditions or application of stress (Rosiak & Yoshii, 
1999). 
Table 2.2: Methods for preparation of physical and chemical hydrogels 
Physically crosslinked hydrogels (Yoshida et al., 1995; Gacesa, 1988; Goosen et 
al., 1985; Gombotz and Wee, 1998; Mumper et al., 1994) 
• Ionic interactions (alginate etc.) 
• Hydrophobic interactions (PEO–PPO–PEO etc.) 
• Hydrogen bonding interactions (PAAc etc.) 
•  Stereocomplexation (enantiomeric lactic acid etc.) 
• Supramolecular chemistry (inclusion complex etc.) 
Chemically crosslinked hydrogels (Matsuo and Tanaka,1992; Yoshida et 
al.,1995; Edman et al., 1980; Tanaka et al., 1987) 
• Polymerization (acryloyl group etc.) 
• Radiation (γ-ray etc.) 
• Small-molecule crosslinking (glutaraldehyde etc.) 
• Polymer–polymer crosslinking (condensation reaction etc.) 
 
• Chemical hydrogels 
Chemical crosslinking is involved in formation of chemical hydrogels. On 
the contrary, a chemical process, i.e., chemical crosslinking is utilized to 
prepare a chemical hydrogel (Hennink & Nostrum, 2002). They exhibit 
equilibrium swelling, depends on the polymer-water interaction parameter 
and the crosslink density (Rosiak & Yoshii, 1999).  
2.6.4 Drug release mechanisms from hydrogel formulations 
Hydrogels have a distinctive blend of traits which render them valuable in drug delivery 
system. Owing hydrophilic characteristics hydrogels can hold huge amount of water than 
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its own weight. Consequently, drug release phenomenon of hydrogels is awfully special 
as compared to other biomaterials. Both straightforward and complicated models have not 
been developed before to calculate the release of drug from a hydrogel system as a 
function of time.  
Therefore, physicochemical nature of network and method of drug loading will dictate 
release pattern from polymeric matrix. 
Generally two method of drug loading applied 
 Post-loading 
In this technique dried hydrogels are soaked in definite strength of drug 
solution until equilibrium swelling achieved. This procedure promotes the 
maximum amount of liquid uptaken during swelling. In inert network 
system diffusion is chief driving force for drug loading and release will be 
by diffusion/swelling mechanism (Oprea et al., 2010)  
• In  situ loading:   
This method involves simultaneous addition of drug during synthesis of 
hydrogel.  In these systems, the release of drugs can be controlled by 
diffusion, hydrogel swelling, drug–polymer interactions, or degradation of 
labile covalent bonds (Lin and Metters, 2006).   
 Diffusion-controlled delivery systems 
Drug transfer from polymeric matrix to its surrounding is basic mechanism of drug 
release. To find out the pattern and recognize the main controlling factors that direct drug 
release from hydrogels is the key point to predict release profile. Drug diffusion 
coefficients of porous and non porous hydrogels and mesh size of polymeric network. 
Diffusion controlled hydrogel delivery systems can be either reservoir or matrix.   
In hydrogel reservoir system polymeric membrane surround drug molecules.  Fick's law 
of diffusion can be used to describe drug release through polymeric boundary. 
J
  
	


                      (1) 
Where:  
JA - flux of the drug,   
D - Drug diffusion coefficient   
CA - drug concentration. 
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In many cases, the drug diffusion coefficient is assumed to be constant to simplify the 
modeling. Generally drug diffusion coefficient is function of drug concentration, used to 
predict drug flux and correlate the concentration and diffusivity of drug.   
For a matrix system release mechanism cane explained by Fick's second law of diffusion. 


=


                        (2) 
Drug diffusion coefficient in this case is again assumed as a constant (Lowman and 
Peppas 1999).  
Additionally for hydrogel systems diffusivities of  encapsulated  molecules  will  depend  
on  the  degree  of swelling  and  crosslinking  density  of  the  gels.  Therefore , diffusion  
coefficient  used  to  describe  drug  release  will  be sensitive  to  environmental  changes  
or  degradation  of  the polymer network and may vary over the timescale of release. 
 
 Swelling controlled release systems 
Hydrophilic polymeric hydrogels absorb water and exhibit swelling. In these systems, the 
polymer matrix begins to swell and two distinct phases can be observed in the polymer; 
the inner glassy phase and the swollen rubbery phase. The drug molecules are able to 
diffuse out of the rubbery phase of the polymer. Drug release will be swelling controlled. 
Since no drug diffuses out of the glassy region of the polymer.  
Empirical power law may explain the release mechanism in the swelling-controlled 
delivery systems: 


=                         (3) 
Here, Mt and M∞ describe the amounts of drug released at time t, and at equilibrium 
respectively, k is proportionality constant, and n is the diffusional exponent. Ritger and 
Peppas described Fickian and non-Fickian diffusional behavior of drug release of 
hydrogels in terms of the value of the coefficient “n” (Siepmann and Peppas, 2001; Ritger 
and Peppas, 1987). 
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Figure 2.2: Swelling-controlled drug delivery system 
 
 Chemically-controlled delivery systems 
This system is further classified on bases of release mechanism into two classes: 
• Erodible systems: Drug release is controlled by degradation and 
dissolution of polymer. Erosion or diffusion is rate controlling step. If 
erosion is constant than there will be zero order release. Erosion may 
either be heterogeneous or homogeneous depending on polymer 
hydrophilic or hydrophobic nature. 
• Pendent chain systems: Drug is attached with polymer hydrolytically or 
enzymatically labile linkage. Drug release is controlled by degradation of 
linkage (Peppas et al., 2000). 
2.7    Responsive hydrogels 
By fabricating their molecular structure, polymer networks can interact with their 
environment in a preplanned and smart manner. These smart polymers are capable of 
delivering their contents in response to fluctuations in environmental conditions 
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according to physiological requirements at the right time and suitable place (Peppas et al., 
2006). Response mechanism based on chemical composition and structure of polymeric 
network and external environmental conditions like pH or temperature or enzyme level 
etc. Responsive or smart hydrogels may undergo structure conformations in response to 
external stimuli. Swelling of these hydrogels dictates the release of drug. Swelling in 
response to stimuli may allow these polymers to serve as self-regulated and pulsatile drug 
delivery systems (Susana et al., 2012). 
 
Figure 2.3: Responsive Hydrogels 
2.7.1   Temperature sensitive  
Responsive or smart hydrogels may be temperature sensitive exhibit a volume phase 
transition at a certain temperature which causes a sudden change in their state. These 
polymers have lower critical solution temperature (LCST). Poly (N-isopropyl acrylamide) 
(PNIPA) is the most commonly used as temperature responsive polymer (Mallikarjuna et 
al., 2011). 
2.7.2    pH sensitive hydrogels. 
pH sensitive hydrogels containing ionic network (ionizable side groups e.g., carboxylic or 
amine group), which perceive physiological signals and respond (swell), accordingly. In 
these hydrogels pH transition is responsible to expand or collapse the polymeric network 
in aqueous medium. Swelling of pH sensitive hydrogels protects the drug from harsh 
environment of stomach, may release drug in intestinal medium and may release the drug 
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in stomach to optimize therapy depends on composition of hydrogels.  Swelling force of 
ionic hydrogels is stronger than non ionic biomaterial. Swelling cause structure 
modification by absorbing fluid and direct the release of drug from polymeric network 
(Soppimath et al., 2002).  
pH responsive hydrogels are ionic in nature containing  ionizeable acidic or basic group 
renders hydrogel more hydrophilic.  Examples of several frequently studied ionic 
polymers include poly (acrylic acid), poly (methacrylic acid), polyacrylamide (PAAm), 
poly (diethylaminoethyl methacrylate), and poly (dimethylaminoethyl methacrylate). 
Polmers with large numbers of ionizeable groups are polyelectrolytes. Polyacidic 
polymers will be unswollen at electrostatic repulsion forces. With increase in pH 
polyacidic polymers will ionize and show swelling. The reverse action is initiated in 
polybasic polymers, since the ionization of basic groups will increase when decreasing 
the pH (Yong and Kinam, 2001). Hydrogels can swell to beneficial rates when placed into 
an appropriate environment, exhibiting pH-sensitive swelling behavior. Ionic hydrogels 
may either be anionic or cationic depending upon the attached group. Transition in 
external pH ionize the  acidic or basic group, electrostatic repulsion increase uptake of 
solvent in the network causing expansion of polymer (Fariba and Ebrahim, 2009).  
Type of polymer, functional group, crosslinking density, porosity and drying are some 
effective parameters for swelling (Omidian and Park, 2008). Expansion of polymer as a 
result of change in pH of external environment is reversible. This property of rapid 
expansion and collapse of responsive hydrogel promote the controlled release of drug 
from system (Bajpai, 2001). 
2.7.3   Electric signal-sensitive hydrogels 
Electric signals can also be used as stimuli for hydrogels response.  Polymeric network 
respond to electric signals containing polyelectrolytes. These hydrogels undergo volume 
transition when exposed to electrodes (in a bathing solution) under an externally applied 
electric field. The hydrogels may expand/collapse and bend due to osmotic pressures 
variation resulting from the difference in the ionic concentrations between the hydrogels 
and the external solutions. The alterations in shape and structure of hydrogels under an 
externally applied electric field can result in the release of entrenched drug molecule. For 
example, ketoprofen was released from poly (AAm-grafted-xanthan gum) (poly (AAm-g-
XG) hydrogels (Murdan, 2003; Kulkarni and Sa, 2009) 
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2.7.4    Light-sensitive hydrogels 
Photo-sensitive hydrogels have been developed for optical switches and ophthalmology 
drug delivery devices. The magic behind this technique describe that hydrogels absorb 
energy from light and convert it into heat and increase temperature of hydrogel above its 
LCST results in hydrogel shrinking and release of drug from polymeric net work. Light-
sensitive  hydrogels  can  be  used  in  the development of photo-responsive artificial  
muscle or as the  in situ  forming gels for cartilage tissue  engineering (Averitt et al., 
1996).  
2.7.5   Glucose-responsive hydrogels 
Management of blood glucose fluctuations in diabetic patients is most imperative task for 
researchers. Delivery of insulin to regulate blood glucose is different from other drugs in 
a sense release of insulin time and physiological need dependent. Glucose oxidase is 
extensively used enzyme for glucose level detection and release insulin from hydrogels in 
a pulsatile fashion (Yong and Kinam, 2001)   
2.8 Polymers and monomers used in this study 
2.8.1 Carboxymethyl cellulose 
 
 
Figure 2.4: Structural formula of Carboxymethyl cellulose 
 
CMC is produced by reacting alkali cellulose with sodium monochloroacetate under 
rigidly controlled conditions. Carboxymethyl cellulose (SCMC) is a cellulose ether 
hydrophilic polymer. It is pale yellow in appearance, odorless, safe, stable in wide range 
of pH and insoluble in organic solvents. CMC is long-chain polymer. Solution properties 
of CMC depend on average chain length or degree of substitution. As molecular weight 
of polymer increased viscosity of solution increased (Togrul and Arslan, 2003). 
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Carboxymethyl cellulose has diverse applications in a numerous fields because of some 
complimentary characteristics. It is economical, water soluble but insoluble in organic 
solvents used in cosmetics and pharmaceutical products as emulsifier (Arion, 2001). 
Various significant properties of this polymer make it an ideal thickener, suspending aid, 
stabilizer, binder, and film former for numerous formulations (Rowe et al., 2009). 
Sodium Carboxymethyl cellulose is the only smart (show pH responsive behavior) 
derivative of cellulose. It increases swelling of hydrogels. The polyelectrolyte nature of 
NaCMC makes it ideal for the development of superabsorbent hydrogels with a smart 
behavior (Alessandro et al., 2009). 
2.8.2 Polyethylene glycol 
 
Figure 2.5: Structural formula of Polyethylene glycol 
Polyethylene glycol is FDA accepted polymer for diverse biomedical functions because 
of biocompatibility, biodegradability, low toxicity, and non immunogenic nature 
(Veronese and Pasut, 2005). PEG is non ionic hydrophilic and also soluble in organic 
solvents. Its hydrophilic nature improves the drug’s hydrophobicity when conjugated with 
them. It augments the physical and chemical stability of drugs as well (Knop et al., 2010).  
Various drugs require alteration in their pharmacokinetic and pharmacodynamic 
properties for safe and efficient therapeutic use. Conjugation of PEG with such drug 
molecules is forthcoming tactic for development of more efficient drug delivery system 
(Marina et al., 2011).  
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2.8.3 Carboxymethyl arabinoxylan 
Figure 2.6: Structural formula of Arabinoxylan 
The seed husk of Ispaghula (Plantago ovata) is chief source of xylan (arabinoxylan) and 
minor amount of other sugar components Rhap and Galp (Fischer et al., 2004) 
Arabinoxylan (AX) extracted from Ispaghula (Plantago ovata) containing 74.8% Xylp 
and 23.2% Araf. Extraction was carried out by immersing the seed husk in water 
overnight, treated with aqueous sodium hydroxide and finally acetic acid is used to 
coagulate the product. The Arabin oxylan has molecular weight 364,470 g/mol exhibit 
extreme swelling in aqueous medium. The carboxymethylation of arabinoxylane was 
converted by treatment with sodium monochloroacetate in aqueous alkaline medium into 
carboxymethyl arabinoxylan. Various factors, (time and temperature of reaction, molar 
ratio, and alkali concentration) control water solubility and ionic characters of product. 
Aqueous solubility of carboxymethyl arabinoxylan depends upon degree of substitution. 
(Saghir et al., 2008). Carboxymethylation of psyllium arabinoxylan modified its 
fundamental properties. It reduces viscosity of solution; improve crystallinity and thermal 
stability of arabinoxylan (Meenakshi and  Munish, 2015). It has been reported that 
carboxymethylated xylan obtained from birch, beech-, and eucalyptus wood, oat husk, rye 
bran, and corn cob posses anionic properties (Petzold et al., 2006a; Petzold et al., 2006b)  
Arabinoxylans are the foremost polysaccharides obtained by alkali extraction from 
numerous cereal plants. Structural composition of arabinoxylan contain b-(1,4)-linked D-
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xylopyranosyl residues to which arabinofuranosyl moieties are attached. Intestinal 
bacteria are capable to degrade arabinofuranosyl moieties (Grootaert et al., 2007). 
2.8.4 Methacrylic acid 
IUPAC name:   2-propenoic acid, 2-methyl  
Synonyms:    Methacrylic acid (MAA)  
Molecular weight:   86.09 g/mol  
Molecular formula:   C4H6O2 
 
Figure 2.7: Structural formula of Methacrylic acid 
 
According to CEFIC (European Chemical Industry Council) (1995), MAA is used in 
chemical industry for manufacturing of a variety of polymers mainly its ester derivatives. 
Hydrogels comprises of poly (methacrylic acid) (PMA) grafted with poly (ethylene 
glycol) (PEG) exhibit pH responsive behavior (Peppas and Klier, 1991). Methacrylic acid 
controls the hydrolytic and swelling behavior of hydrogels. High contents of methacrylic 
acid increase swelling of hydrogel in alkaline/ intestinal medium and vice versa. (Davaran 
et al., 2001). 
2.8.5 Acrylic acid 
 
Figure 2.8: Structural formula of Acrylic acid 
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Acrylic acid is a colorless liquid with an acrid odor at room temperature. It is miscible 
with water and most organic solvents. Acrylic acid is highly reactive so polymerize very 
easily. The polymerization is catalysed by heat, light, and peroxides and inhibited by 
stabilizers, such as monomethyle ether of hydroquinone or hydroquinone itself. Acrylic 
acid is hydrophilic and become ionize at high pH due to carboxylic group. Acrylic acid 
based hydrogels also having electro sensitive properties (Tanaka et al., 1982). Hydrogels 
prepared with acrylic acid broadly used in mucoadhesive system for drug delivery 
(Young et al., 2014). Acrylic acid has capability to build up different intermolecular 
contacts to produce hydrogels with other polymers. Swelling capacity mainly depend 
upon acrylic acid intermolecular forces. (Bromberg et al., 2004; Devine and 
Higginbotham, 2005). 
2.8.6 Hydroxyethyl methacrylate 
 
Figure 2.9: Structural formula of hydroxyethyl methacrylate 
 
HEMA (2-hydroxyethylmethacrylate) was the former monomer for the preparation of 
hydrogels for drug delivery system. Its swellability may be modified by grafting of 
hydrophilic monomers with HEMA (Wichterle and Lim, 1960). HEMA belongs to esters 
of methacrylic acid. However, HEMA is unique in its hydrophilic nature and relatively 
low volatility. Copolymers of HEMA, as implant hydrogel employed for controlled 
delivery of drugs (Kuzma et al., 1996).  
Numerous HEMA based hydrogels characterized by various techniques have been used as 
iontophoretic drug delivery, biomedical membrane, potential transdermal antibiotic 
carrier, as orthopedic carrier, drugs for ocular delivery (Arica et al., 2005; Eljarrat et al., 
2005; Eljarrat et al., 2004)   
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2.9     Peptic ulcer 
A peptic ulcer is a sore on the inner lining of the esophagus, stomach or duodenum. 
Damage of protective lining of stomach may be superficial or deep if remain untreated. 
Peptic ulcer grows by disturbance in protective mechanism of GI mucosa e.g., mucus and 
bicarbonate secretion imbalance plagued by harmful effect of gastric acid and pepsin. It 
has been reported that 95 percent of peptic ulcer is caused by H. pylori and NSAIDs are 
responsible for remaining present (Mynatt et al., 2009). 
 
Figure 2.10: Peptic ulcers of the esophagus, stomach and duodenum 
 
2.9.1   Etiology of peptic ulcer disease 
 Common 
• Hylicobacter pylori infection 
• Nonsteroidal anti inflammatory drugs (NSAIDs) 
• Stress related mucosal damage 
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 Uncommon 
• Pathological Hypersecretory Conditions, Including Zollinger-
Ellison   Syndrome 
• Tumours (cancer, lymphomas) 
• Viral infections 
• Radiations/chemotherapy 
 Rare 
• Crohn’ s disease of stomach/duodenum 
• Colonization of stomach with Helicobacter Heilmanni 
• Ideopathic (Malfertheiner et al., 2009) 
 Clinical presentation of peptic ulcer 
Clinical presentation of peptic ulcer (Ramakrishnan et al., 2007) 
Typical symptoms Alarm symptoms 
• Epigastric pain 
• Nausea 
• Fullness 
• Bloating 
• Aneamia 
• Malena 
• Heme positive stool 
• Blood vomiting 
• Anorexia or weight loss 
• Persisting upper abdominal 
pain radiating to back 
• Severe, spreading, upper 
abdominal pain 
2.9.2    Treatment of acid related diseases 
• Antacids  
Antacids are primary treatment for acid related disorders. They act by 
alkalinizing the gastric acid. All antacids are available in oral preparations 
containing sodium bicarbonate, calcium carbonate, magnesium hydroxide 
and aluminum hydroxide (Mejia and Kraft, 2009). 
• H2 -receptor antagonists  
Gastric parietal cells contain acetylcholine, gastrin and histamine 
receptors, responsible for acid secretion by different mechanism. 
Antihistaminic drugs (H2 receptor blockers) e.g cimetidine, famotidine, 
nizatidine and ranitidine indicated for GERD, ulcer related with H pylori 
and NSAIDs, and other acid related disorders (Brittain and Jack, 1983).  
 
27 
 
• Proton pump inhibitors Proton  
PPIs are antisecretary class of drugs. PPIs are indicated for the treatment 
of GERD, reflux esophagitis, peptic ulcers and Zollinger-Ellison 
syndrome. In addition, PPIs are used for gastro protection in patients 
using NSAIDs. In combination with two suitable antibiotics, PPIs are also 
used for the eradication of H. pylori infection. Most commonly used PPIs 
are esomeprazole, lansoprazole, omeprazole, pantoprazole and 
Rabeprazole (Pace et al., 2007).  
2.10   Proton pump inhibitors 
Proton pump inhibitors (PPIs) have been commenced in clinical practice for treatment of 
acid related disorders since 1980 as a drug of choice (Welage, 2003). The gastric H/K-
ATPase enzyme is the prime board for the treatment of acid-related diseases. 
Most commonly prescribed PPIs are omeprazole, lansoprazole, pantoprazole and 
Rabeprazole. These are potent gastric acid suppressing agents that block the last step for 
acid secretion by the parietal cell. They all contain a pyridylmethylsulphinyl 
benzimidazole moiety but vary from each other by substitutions on the pyridine or 
benzimidazole rings. All proton pump inhibitors act by same mechanism but differ in 
potency. They inhibit H+K+ ATPas at secretary surface of parietal cells. PPIs bind 
covalently with enzyme and inhibit irreversibly so, anti secretary activity is more potent 
than other anti secretary activity. The PPIs also reduce pepsin output and reducing 
secretory volume, which directly inhibits peptic activity. PPIs only differ from H2 
receptor antagonist by increasing gastric pH so peptic activity diminished and mucosal 
healing promoted (Huang and Hunt, 2001). 
2.10.1 Normal acid secretion mechanism 
Gastric parietal cells when exposed to stimuli e.g., histamine or acetylcholine there will 
be morphological transformation and become excited.  The gastric H/K-ATPase, which is 
responsible for gastric acid secretion, becomes secretory canaliculus from cytoplasmic 
tubular membranes in the stimulated state of the parietal cell. Expanded secretory 
canaliculus produce by union of cytoplasmic vesicles with the rudimentary microvilli. 
The gastric H, K-ATPase shifts from tubulovesicles to apical membrane in the 
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canaliculus of excited state and exudes gastric acid by an electro neutral, ATP-dependent 
hydrogen-potassium exchange (Saches et al., 2007). 
 
 
Figure 2.11: Physiological regulation of gastric acid in oxyntic/parietal cells and various 
targets for anti secretary drugs 
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2.10.2 Mechanism of action of PPIs  
Pharmacological activity of PPIs is due to benzimidazoles and pyridine in their structure. 
They exhibit similar mechanism of action in the following steps: 
a. Activation; All PPIs enter into acid environment of secretory canaliculus 
of the parietal cell. By protonation these are converted into active 
sulphenamide form.  
b. Active sulphenamide compounds react with cysteines present at proton 
pump and block acid secretion. (Pace et al., 2007). 
PPIs act by same mechanism but studies showed that a huge unevenness in their 
pharmacological effects (Lind et al., 2000; Savarino et al., 1998). This pharmacological 
variation may direct to an irregular effect of the treatment. Generally three 
pharmacological attributes may be responsible for such unpredictable response. 
i) Pharmacogenetics 
Pharmacogenetics refers to variation in genetic profile of an individual 
lead to unexpected response of drug. 20 years before, it was revealed that 
PPIs are susceptible to pharmacogenetic disparity (Andersson et al., 1990). 
PPIs are metabolized by CYP2C19 and CYP3A4. Clinical effects of PPIs 
directly related with genotype status of patient.CYP2C19 is the main 
enzyme involved in metabolism of PPIs and shows genetic variation. 
Several single nucleotide polymorphic variants (SNPs) of the CYP2C19 
gene have been recognized that manipulate the capability to control the 
metabolism of PPIs. Mutations in CYP2C19 may cause toxicity in 
individuals because of slow metabolism of PPIs. On the contrary, some 
mutations may increase metabolism result in poor response of PPIs (Furuta 
et al., 1999; Li-Wan-Po et al., 2009; Baldwin et al., 2008; Sim et al., 
2006). 
ii) Pharmacokinetics   
Some significant pharmacokinetic parameters, peak plasma concentration, 
half lives and excretion level of PPIs may vary.  Oral bioavailability of 
omeprazole and esomeprazole and rabeprazole is low due to acid labile 
nature but increase with increase in dose. Pantoprazole, lansoprazole and 
rabeprazole have a constant bioavailability irrespective of repetitive dosing 
(Delhotal, 1995; Stedman, 2000; Hassan, 2000; Andersson, 1990). 
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iii) Pharmacodynamics 
As variability in pharmacokinetic attributes modify the pharmacological 
effects of PPIs. pH metery technique used for studying the efficacy of acid 
inhibitory drugs. Intra gastric pH monitoring shows dose-effect 
relationship of PPIs (Geus et al., 1998; Hassan, 2000).  
2.11   Rabeprazole Sodium 
2.11.1 Introduction 
Rabeprazole sodium belongs to class of substituted benzimidazole proton pump 
inhibitors. Stability of Rabeprazole depends on pH. 
 
Figure 2.12:  Structural formula of Rabeprazole sodium 
Its molecular formula is C18H20N3NaO3S with molecular weight of 381.43. Because of 
acid sensitive nature of Rabeprazole sodium its oral bioavailability is only 52% and half 
life is almost 1.5 hr. It inhibits the gastric acid secretion by blocking H+K+ ATPase 
enzyme at secretary surface of gastric parietal cells. It does not show anticholinergic and 
H2 receptor blocking activity ((Mallikarjuna et al., 2010). 
2.11.2 Pharmacokinetics 
Rabeprazole sodium rapidly absorbed after oral administration. It is acid labile drug so 
having low bioavailability i.e., 52%. AUC and Cmax are dose dependent, and Tmax & half 
life of drug is not affected by repeated doses. Absorption of drug is not influenced by 
food and antacids (Swan et al., 1999). It shows different metabolism pathway than other 
PPIs. It is converted to Rabeprazole thioether by non-enzymatic pathway and other 
metabolites (demethylated Rabeprazole, rabeprazole-sulfone) are in very small amount by 
cytochrome P450 enzymes (Furuta et al., 2005). 
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2.11.3 Pharmacodynamic 
• Mechanism of action 
Rabeprazole sodium belongs  to  anti secretory class of antiulcer dugs, 
which do not show   anticholinergic   or histamine H2- receptor blocking 
activity,  but  stifle gastric  acid  discharge by  blocking gastric  H+,K 
+ATPase at the secretory  surface  of  gastric oxyntic  cells.  H+,K +ATPase 
enzyme considered as acid pump, rabeprazole  has  been regarde as proton 
pump inhibitor.  Rabeprazol obstructs the last step of acid secretion. In 
vitro studies displayed that at pH 1.2 rabeprazole become activated by 
protonation, inhibit transport in gastric vesicles (Langtry and Markham, 
1999). 
2.11.4 Therapeutic indications 
• Healing of Erosive or Ulcerative GERD (Holtman et al., 2002) 
• Long-term Maintenance of Healing of Erosive or Ulcerative GERD 
(Thjodleifsson et al., 2000) 
• Treatment of Symptomatic GERD (Langtry and Markham, 1999) 
• Healing of Duodenal Ulcers (Dekkers eta al., 1999) 
• Helicobacter pyloriEradication in Patients with Peptic Ulcer (Miwa et al., 
1999) 
• Non-Ulcer Dispypsia (Langtry and Markham 1999). 
• Pathological Hypersecretory Conditions, Including Zollinger-Ellison 
Syndrome 
2.11.5 Drug interactions 
There are several mechanism involved in drug interactions of Rabeprazole sodium with 
other drugs. 
Most common reasons include: 
• Competitive inhibition of cytochrome P450 enzyme system 
• Alteration in absorption of other drugs due to change in gastric pH (Gerson 
and Triadafilopoulos, 2001). 
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Table 2.3: Rabeprazole sodium interactions with other drugs 
Drugs Mechanism of interaction Reference 
Digoxin Modulation of Gastric pH 
(increases in the AUC and Cmax 
for digoxin of 19% and 29% 
respectively) 
Humphries, 1998 
Ketoconazole Modulation of Gastric pH 
(Cause 30% decrease in the 
bioavailability of ketoconazole) 
Humphries, et al., 1996 
Diazepam Rabeprazole-mediated 
inhibition of CYP3A4 
Ishizaki et al.,  1995 
Fluvoxamin Extensive metabolisers of 
CYP2C19,  enhanced AUC0-∞ and 
t1/2 of rabeprazole 
Uno et al., 2006 
2.11.6 Use of rebeprazole sodium in specific populations 
• Pregnancy 
Animals study revealed that there are no teratogenic effects of PPIs. 
• Category C drug 
In animal studies drugs show risk to the fetus but for human there is no 
available data. Food and Drug Administration has recommended 
omeprazole as a category C drug in pregnancy, at high dose there are toxic 
effect on embryo and fetus (Ekman et al., 1985). 
• Category B drugs  
In animals studies reveal that there is no teratogenic effect but inadequate 
data for human. FDA has characterized PPIs except omeprazole in 
category B drugs.There is no adequate and well-controlled studies in 
pregnant women. Rabeprazole sodium should be used in pregnancy only if 
the potential benefit justifies the potential risk to the fetus (Richter, 2005). 
• Pediatric Use 
There is no adequate published data available on controlled trials of PPIs 
in children. It has been reported that for effective therapy of gastric acid 
related disorders PPIs are utilized. PPIs have a well tolerability profile in 
adults and children, but long-term tolerability studies are required, 
predominantly in children (Gibbons and Benjamin, 2003). 
• Geriatric Use 
No overall difference in safety and efficacy of Rabeprazole has been 
observed in old patients up to 75 year.  
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2.11.7 Adverse reactions 
Rabeprazole was generally well endured during clinical trials. The practical side effects 
have generally been gentle or temperate and brief in nature. Only headache, diarrhoea, 
abdominal pain, asthenia, flatulence, rash and dry mouth have been linked with the 
application of rabeprazole.  
The adverse events, which may or may not be causally related to rabeprazole, reported in 
clinical trials are listed below in downward array of rate of recurrence.  
• Nervous System: headache, dizziness.  
• Gastrointestinal: diarrhoea, nausea, abdominal pain, flatulence, vomiting, 
constipation.  
• Respiratory: rhinitis, pharyngitis, coughs.  
• Musculoskeletal: non-specific pain, back pain, myalgia.  
• Skin: rash (Pace et al., 2007). 
2.11.8  Dose and administration 
 Treatment of active Gastro-Oesophageal Reflux Disease (GERD): 
The recommended oral dose for this condition is 20 mg tablet to be 
taken once daily for four to eight weeks.  
 Treatment of active Duodenal Ulcer and Gastric Ulcer: : 
The recommended oral dose for both duodenal ulcer and gastric 
ulcer is 20 mg tablet to be taken once daily. This therapy may last 
for 4-8 weeks depending on severity of disease. Rabeprazole has 
also antibacterial activity against H. pylori. Rabeprazole sodium 20 
mg with clarithromycin 500 mg and amoxycillin 1 g twice daily each 
for seven days. Eradication of H. pylori with this regimen has been 
proved most effective (Pace et al., 2007).  
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3. Materials &Methods 
3.1  Materials 
3.1.1 Chemicals 
Rabeprazole sodium (Getz Pharma-Pakistan), Carboxy methylcellulose (CMC) (Sigma 
Aldrich-Finland), Acrylic acid (AA) (Sigma Aldrich-Netherlands), Potassium persulfate 
(AnalaR, BDH-England), N,N Methylene  bisacrylamide (Fluka-Switzerland),Tris 
(hydroxymethyl) aminomethane (Fluka-Switzerland), Methanol (Merck-Germany),  Distilled 
water, Potassium dihydrogen phosphate( Merck-Germany), Ethanol Absolute (Merck- 
Germany), Methacrylic acid (Merck-Germany). Plantago ovate (ispaghula) seed husk was 
purchased from local market of Pakistan. Acetic acid (BDH laboratory-England), Sodium 
hydroxide (Sigma Aldrich-Netherlands), Poly ethylene glycol 600 (BDH Chemicals-
England). 
3.1.2. Instrumentation and apparatus 
High Performance Liquid Chromatographic
1
, UV/Visible Spectrophotometer
2
, 
Sonicator
3
, Dissolution Test Apparatus
4
, Centrifuge Machine
5
, pH Meter
6
, Ultrasonic 
Bath
7
, Electric Balance
8
, Membrane Filter
9
, Magnetic Stirrer
10
, B.P. Apparatus
11
, 
Vacuum Pump
12
, Distillation Plant
13
, Ultra-low Freezer
14
, Micropipettes
15
, Filtration 
Assembly
16
, Measuring Cylinder
17
, Beakers
18
 50, 100, 250, 500 & 1000 mL, Measuring 
Flasks
19
 50, 100, 250, 500 & 1000 mL, Centrifuge Tubes
20
, Sample Test Tubes
21
, 
Disposable Syringes
22
, Vortex Mixer
23
, Incubator
24
, Centrifuge
25
, Fourier Transform 
Infrared Spectroscopy(FTIR)
26
, Scanning Electron Microscopy (SEM)
27
, Differential 
Scanning Calorimeter and Thermo Gravimetric Analyzer (DSC &TGA)
28
, XRD
29
, 
1. Agilent 1100 Series U.S.A 
2. UV-1600 Shimadzu. Germany 
3. Elma, Germany 
4. PTCF II Pharma Test, Germany 
5. Model 4000-China 
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6. WTW pH 300-Germany 
7. Fisher Scientific FS 28 H-Germany 
8. PerciaXB120A 
9. Sartorius (0.45 μm filters)-Germany 
10. Gallen Kamp-England 
11. Model No 500-China 
12. Rotary Vane Pump ILMVAC-Germany 
13. WDA/4 R & M-England 
14. Sanyo-Japan 
15. Softpet- Finland 
16-21. Pyrex-France 
22. BD-Pakistan 
23. Seouline BioScirnce-Korea 
24. Velp Scientifica-Italy 
25. Hettich-Germany 
26. Bruker, Tenser 27-Germany 
27. Quanta 250, FEI 
28. SDT Q-600 (TA New Castle, DE) 
29. Expert pro Panalytical-Germany 
3.2  Methods 
3.2.1 Isolation of arabinoxylan 
Arabinoxylan was isolated from the Ispaghola husk by method of Saghir et al. (2008). 100 g 
of Ispaghula seed husk was soaked in 5 liters of distilled water over night. Aqueous sodium 
hydroxide solution (2.5%) was added to the mixture for pH adjustment at 12 with continuous 
stirring for 2-3 minutes. Husk was separated from the gel by vacuum filtration. Concentrated 
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acetic acid was used to coagulate the sample. The gel obtained was washed with distilled 
water until the pH become constant and freeze dried for 1 week. 
3.2.2 Carboxymethylation of arabinoxylan 
The reported method was adopted after necessary modifications. Arabinoxylan (2.5 g) 
obtained by above procedure was suspended in ethanol. The reaction mixture was 
vigorously stirred at room temperature for 1 h. After addition of 25% aqueous sodium 
hydroxide solution, sodium monochloroacetate was added and the temperature of 
reaction bath was increased to 55ºC. The etherification was performed for 5 h. The 
product was filtered and suspended in 80% (v/v) water/methanol, neutralized with diluted 
acetic acid, and washed with ethanol. The product was dried under vacuum (Saghir et 
al.,2008). 
3.2.3 Graft copolymer preparation 
A general procedure for chemically graft copolymerization was conducted as follows.  
Calculated amount given in Table 3.1 of Carboxymethyl arabinoxylan was dissolved in 
degassed distilled water to obtain a sticky transparent solution at 70 
º
C. Then potassium 
persulfate solution in water was added to Carboxymethyl arabinoxylan solution and 
stirred for 10 min at 70 °C to generate radicals. Following this, reaction mixture was 
cooled down to room temperature. At room temperature, solution containing monomer 
and cross linker was added under magnetic stirring. The final weight of solution was 
made by adding distilled water. Air above the solution in the test tube or any dissolved 
oxygen was removed by bubbling nitrogen for 15-20 min which acts as free radical 
scavenger. For polymerization, solution was heated in water bath at 45
º
C for 1 hr, 50
º
C 
for 2 hr, 55
º
C for 3 hr, 60
º
C for 4 hr and 65
º
C for 8 hrs (Wenbo et al., 2011). Hydrogels 
obtained were cut into 5 mm discs by blade. Washing media (0.1M Sodium hydroxide) 
was used to remove unreacted monomer and catalyst. These discs were thoroughly 
washed with water until the pH of washing media resembles distilled water. After 
washing, the discs were dried first at room temperature and then in oven at 45-50
º
C till 
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constant weight of hydrogels were obtained and further used for characterization and 
drug release study (Sadeghi et al., 2012). 
CMAX-g-MAA, CMC-g-MAA, CMC-g-AA, PEG-g-MAA hydrogels and PEG (HEMA-
co-AA) hybrid hydrogels were also prepared in a similar fashion. Compositions of 
different combinations of hydrogels are given in Tables 3.1 to 3.6. 
 
Table 3.1: Composition of 100g CMAX-g-AA Hydrogel preparation with varying 
monomer polymer and crosslinker concentration. 
Sr.No Formulation 
code 
CMAX 
(g) 
AA (g) Crosslinker % mole ratio of 
monomer 
1 A1 0.5  10  0.2 
2 A2 0.5  15  0.2 
3 A3 0.5 20  0.2 
4 A4 1  15  0.2 
5 A5 1.5  15 0.2 
6 A6 2  15  0.2 
7 A7 0.5  15  0.4 
8 A8 0.5  15  0.6 
9 A9 0.5  15  0.8 
 
Table 3.2: Composition of 100g CMAX-g-MAA Hydrogel preparation with varying 
monomer polymer and crosslinker concentration. 
Sr.No Formulation 
code 
CMAX 
(g) 
MAA (g) Crosslinker % mole ratio of 
monomer 
1 M1 0.5 20 0.25 
2 M2 0.5 30 0.25 
3 M3 0.5 35 0.25 
4 M4 1 25 0.25 
5 M5 1.5 25 0.25 
6 M6 2 25 0.25 
7 M7 0.5 25 0.45 
8 M8 0.5 25 0.65 
9 M9 0.5 25 0.85 
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Table 3.3: Composition of 100g CMC-g-AA Hydrogel preparation with varying 
monomer polymer and crosslinker concentration. 
Sr.No Formulation 
code 
CMC (g) AA (g) Crosslinker % mole ratio of 
monomer 
1 CA1 0.5  10  0.2 
2 CA2 0.5  15  0.2 
3 CA3 0.5  20  0.2 
4 CA4 1  15  0.2 
5 CA5 1.5  15 0.2 
6 CA6 2  15  0.2 
7 CA7 0.5  15  0.4 
8 CA8 0.5  15  0.6 
9 CA9 0.5  15  0.8 
 
Table 3.4: Composition of 100g CMC-g-MAA Hydrogel preparation with varying 
monomer polymer and crosslinker concentration. 
Sr.No Formulation 
code 
CMC (g) MAA (g) Crosslinker % mole ratio of 
monomer 
1 CMA1 0.75 20 0.1 
2 CMA2 0.75 30 0.1 
3 CMA3 0.75 35 0.1 
4 CMA4 1 25 0.1 
5 CMA5 1.5 25 0.1 
6 CMA6 2 25 0.1 
7 CMA7 0.75 25 0.2 
8 CMA8 0.75 25 0.3 
9 CMA9 0.75 25 0.4 
 
Table 3.5: Composition of 100g PEG-g-MAA Hydrogel preparation with varying 
monomer polymer and crosslinker concentration. 
Sr.No Formulation 
code 
PEG (%) MAA (g) Crosslinker % mole ratio of 
monomer 
1 PMA1 5 25  0.30 
2 PMA2 10 25  0.30 
3 PMA3 15 25  0.30 
4 PMA4 20 25 0.30 
5 PMA5 10  20 0.30 
6 PMA6 10  30 0.30 
7 PMA7 10  35  0.30 
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Table 3.6: Composition of 100g PEG (HEMA-co-AA)Hydrogel preparation with 
varying monomer polymer and crosslinker concentration. 
Sr.No Formulation 
code 
PEG 
(%) 
AA 
(g) 
HEMA 
(g) 
Crosslinker % mole ratio of 
monomer 
1 PHA1 10 7.5 2.5 0.25 
2 PHA2 10 10 2.5 0.25 
3 PHA3 10 12.5 2.5 0.25 
4 PHA4 10 15 2.5 0.25 
5 PHA5 10  15 1 0.25 
6 PHA6 10  15 1.5 0.25 
7 PHA7 10  15 2 0.25 
8 PHA8 10  15 3 0.25 
 
3.2.4   Swelling Studies 
3.2.4.1 Preparation of buffer (British Pharmacopoeia Volume V) solutions of different pH 
for swelling studies 
a) Buffer of pH 1.2 
250 mL solution of 0.2M sodium chloride was mixed with 425 mL of 0.2M 
hydrochloric acid. The final volume was made up to 1000 mL with distilled water. 
b) Buffer of pH 7.4 
250 mL solution of 0.2M potassium dihydrogen phosphate (KH2PO4) was mixed with 
195.5 mL of sodium hydroxide solution 0.2M. The final solution was diluted up to 
1000 mL with distilled water. 
3.2.4.2 Swelling analysis 
Smart swelling behavior of hydrogels was investigated in buffer solutions at different pH 
values. Dried hydrogels with a 0.45 g were immersed in 100 mL USP phosphate buffer 
solution of pH 1.2 and pH 7.4 at 37
º
C. Swollen samples were weighed at 0.5, 1, 1.5, 2, 3, 
4, 6, 8, 10, 12, 14, 18, 24, 48, 72 hours and excess media were removed by blotting with a 
piece of filter paper. Studies were performed in triplicate and average values were taken 
for data analysis. Swelling of various samples was continued until they attained constant 
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weight (Raghavendra et al., 2011). Dynamic swelling ratio (q) was calculated using 
following as given in equation 1(Bumsang et al., 2003). 
q = Ws/Wd          (1) 
 
Where q is dynamic swelling ratio, Ws is the weight of swollen gel at time t and Wd is the 
initial weight of dry hydrogel. 
3.2.5 pH responsive/Pulsatile behavior 
For controlled delivery of drug from graft copolymer, the swelling process must be 
reversible to ensure that the release of drug could be initiated and stopped promptly upon 
change in pH. To investigate reversibility of swelling/deswelling process of polymer 
networks with respect to environmental pH change, selected hydrogel samples were 
swollen in a buffer solution of pH 7.4, placed them in a buffer solution of pH 1.2, 
returned them to a buffer solution of pH 7.4, and finally collapsed them in a buffer 
solution of pH 1.2. The consecutive time interval for each cycle was 45 min (Sadeghi, 
2011). 
3.2.6 Drug loading 
Samples showed maximum swelling were selected for drug loading and release study. 
Drug was loaded by incubation after polymerization. Incubation after polymerization 
removed all non reacted monomers and decomposed products of the catalyst.  
Selected hydrogels were soaked in 0.1M sodium hydroxide solution containing 1% 
Rabeprazole sodium for time period until swelling equilibrium achieved. Loaded 
hydrogels were washed after swelling with water to remove surface adhered drug on disc. 
For drug loading, 0.1 M sodium hydroxide solution was selected due to maximum 
swelling ratio of hydrogels and drug stability in that solution. The drug loaded hydrogels 
were freeze dried because drug has thermal stability issues (Oprea et al., 2010). 
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3.2.7 Determination of drug loading 
Two methods were used for determining drug loading in hydrogels. The first method 
used to calculate the amount of drug loaded in hydrogel was determined by following 
equation as given in equation 2: 
Amount of drug = WL-Wo   (2) 
Wo and  WL  are  the  weight  of  dried  hydrogels  before  and  after immersion in drug 
solution, respectively. 
In 2
nd
 method, amount  of  drug  entrapped  in  hydrogels  was  calculated  by  repeatedly 
extracting  the  weighed quantity of powdered loaded  gels  by  using  0.1M sodium 
hydroxide solution. Each time fresh 0.1M sodium hydroxide solution was replaced after 
specific interval until there was no drug in the solution.  Drug concentration was 
determined spectrophotometrically at λmax 284 nm. Amount of drug present in all portions 
was considered as total amount of drug loaded into hydrogel (Kuldeep and Nath, 2012). 
Amount of drug loaded in hydrogel was determined by following as given in equation 3: 
                   
     
  
                                           (3) 
Wo and  WL  are  the  weight  of  dried  hydrogels  before  and  after immersion in drug 
solution, respectively. 
3.2.8 Sol-gel fraction. 
The hydrogels prepared by free radical polymerization were dried to measure the 
gelation. Hydrogels were cut into 4-5 mm thickness and oven dried at 50 
º
C until constant 
weight was obtained. Then few dried hydrogels were extracted with water at room 
temperature in order to extract the insoluble parts of hydrogel until the weight became 
constant. The gel fraction was calculated as given in equation 4 and 5 (Ranjha et al., 
2014):  
              
     
  
      (4) 
Gel fraction (%) = 100- Sol fraction   (5) 
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Where Wo is weight of hydrogel before extraction and W1is weight of hydrogel after 
extraction. 
3.2.9 Determination of the equilibrium water content 
Dried hydrogel samples were soaked in buffer of pH 1.2 and pH 7.4 at 37 
º
C to measure 
water uptake of hydrogel in a thermostatically controlled chamber to the equilibrium 
state. Fully swollen samples were removed and weighed after removal of excess of 
solvent with absorbent paper. The equilibrium water content in swollen samples (Weq) 
was calculated as given in equation 6 (Jagadish et al., 2012). 
                 
     
  
      (6) 
Where Ws is the weight of swollen sample at equilibrium state and Wd is weight of the 
dry sample. 
3.2.10 Release studies 
i) Preparation of standard stock solution 
Rabeprazole sodium (100 mg) was accurately weighed and transferred to a 100 
mL volumetric flask. It was first dissolved  in  25 mL  of  0.1N  NaOH  and  
sonicated  for  about  10-15 min,   then  finally  made  up  to  the volume with 
0.1N NaOH (1000 µg/mL) (Mallikarjuna et al., 2010). 
ii) In vitro release/dissolution studies 
The selected in vitro dissolution conditions were in accordance with US Food and 
Drug Administration, CDER (Center for Drug Evaluation and Research) 
recommended for rabeprazole sodium. Drug release studies were carried out using 
a USP type II dissolution test apparatus (PTCF II Pharma Test, Germany) at 100 
rpm for 24hrs in 0.1M HCl (900mL) maintained at 37±0.5
º
C. 5 mL of sample was 
collected at 0, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 24 hour with an automated sample 
collector (PT-DT7Pharma Test, Germany) after filtering through sinter filters (10 
µm) and same volume of fresh dissolution media was added after each sample 
collection. The collected samples were diluted up to 50 mL and analyzed at 284 
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nm using a UV-spectrophotometer (UV-1600 Shimadzu. Germany).Same studies 
were conducted with 0.6M tris buffer, pH 8.0 (900mL) and tested for drug release 
for 24hrs at same temperature and rotation speed. Samples were taken out and 
volume of fresh tris buffer pH 8.0 was added to kept volume of dissolution 
medium constant and samples were analyzed using UV spectrophotometer at 284 
nm. In-vitro cumulative drug release study was conducted in triplicate (Rakesh et 
al., 2011). 
iii) Release kinetics 
Dissolution profile can be described by different mathematical functions. To 
obtain a more quantitative understanding of the transport kinetics in hydrogel, the 
drug release data was analyzed as a function of time. The  release  models  with 
major  application  and  best  describing  drug release  phenomena  are,  in  
general,  the Higuchi model, zero order model, first order model  and  
Korsemeyer-Peppas  model (Suvakanta et al.,2010). Release models are explained 
in Tables 3.7. 
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Table 3.7: Release models 
Sr.No Release Models Equation Description 
1 Zero order model Q = Q0  + K0t Where Q is the amount of 
drug released or dissolved,Q0  
is  the initial  amount  of  drug  
in  solution  (it  is usually  
zero),  and  K0  is  the  zero  
order release constant.  
 Plot made:  cumulative %  
drug  release  vs. time   
2. First order logQ = logQ0-kt/2.303  
 
Where, Q0is the initial 
concentration of drug and K is 
first order constant. 
Plot  made:  log cumulative of 
% drug remaining vs. time 
3. Higuchi Model         
Where, Qt is the amount of 
drug released in time t and KH 
is Higuchi release rate 
constant. 
Plot  made:  cumulative  %  
drug  release vs. square root 
of time 
4. Korsmeyer-
Peppas Model  
 
  
  
     
 
Where Mt / M∞ is fraction of 
drug released at time t, k is 
the rate constant and n is the 
release exponent. The n value 
is used to characterize 
different release mechanisms. 
Plot made: log cumulative % 
drug release vs.  log  time 
3.2.11 FTIR analysis 
Grafting were confirmed by FTIR spectroscopy. IR spectra for individual components 
and prepared hydrogel  were  recorded  in  a  Fourier  transform  infrared  (FTIR)  
spectrophotometer (Bruker, Tensor-27, Germany). For FTIR analysis hydrogel samples 
were ground to powder. A small quantity of sample was placed in crystal area and 
pressure arm was locked. Bands were in the region from 4000 to 600 cm
-1 
(Lim and Lee, 
2005). 
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3.2.12 SEM analysis 
Surface morphology of crosslinked hydrogel was evaluated by Quanta 250 SEM (FEI), 
operating at 10 kV with secondary electrons, in low vacuum mode. For  a  better  
observation  of  the  pores, swollen hydrogels  were  previously  freeze-dried  in freeze 
dryer  (Christ Alpha  1-4  Germany), for 24 hrs at -55 
º
C. The sample was  prepared  by  
cutting the  dry  hydrogels  with  a  sharp  razor  blade,  in  order  to  expose  the  internal  
structures (Lim and Lee, 2005). 
3.2.13 Thermal analysis 
Thermal behavior of the prepared graft copolymers were studied by Thermogravimetric 
Analyzer model SDT Q 600 series Thermal Analysis System (TA instruments, New 
Castle DE, UK) from room temperature to 600 ºC. The hydrogel samples were ground 
and passed through mesh 40. Sample dry weight was 5-10 mg placed in an open pan 
(platinum 100 μl) attached to a microbalance. Heating rate of 10 ºC/min was used under 
nitrogen atmosphere at a flow rate of 20 mL/min. All the measurements were made in 
triplicate. Thermograms were recorded by software (Guirguis & Moselhey, 2012) 
3.2.14 X-ray Diffraction  
X-ray diffraction patterns were recorded, in reflection, with a Xpert pro Panalytical 
instrument, at room  temperature, using nickel filtered CuKα radiation (λ= 1⋅54050 Å) 
and operating at 30 kV and 10 mA. Powdered samples were filled onto sample holder and 
smoothing the surface with a glass slide. Samples were scanned over range 5-50° 2θ at a 
rate of 1º 2θ/min (Siddhi et al., 2011). 
3.2.15 Acute oral toxicity of prepared hydrogels 
The purified prepared dried hydrogels were grinded into powder and suspended in water 
for acute oral toxicity test. Swiss albino mice (29–35 g) of either sex were used. Animals 
were divided into five groups (n=3), group scheme was given in Table 3.8. OECD 
guidelines for testing of chemicals recommended that minimum number of animals (n=3) 
must be used (OECD, 2001). Animals were kept in clean cages in a 12 h light/dark cycle. 
They were fed with standard laboratory diet and ordinary tap water. Acute oral toxicity 
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studies of CMAX-g-AA, CMAX-g-MAA, CMC-g-AA, CMC-g-MAA hydrogels were 
executed in Swiss albino mice using an MTD (Maximal Tolerance Dose) method ensuing 
the OECD (organization for economic cooperation and development) guidelines for 
analysis of chemicals toxicity. At the instigation of the study the weight variation of 
animals involved in study must be minimal and not go beyond ±20 % of the mean 
weight. Mice were orally administered 1-10 g/Kg/day of hydrogel dispersion. The dose 
was designated as the maximum potential dose that can be administered orally owing to 
high viscosity of the swollen hydrogels at the extreme capacity of oral gavage. Clinical 
manifestations for general conditions (weight, diet, activity, mortality, and signs of 
illness) were carried out twice daily for 2 weeks. On day 15 blood biochemistry and 
necropsies were performed to observe the gross pathological changes. To analyze 
microscopically obtained tissue samples were fixed by conserving in 10 % buffered 
formaldehyde solution for 48 hrs, and then fixed in paraffin, sectioned at 5 μm, and 
imagined by hematoxylin and eosin staining. Primary dermal and eye irritation were also 
observed (Chen et al., 2008). 
Table 3.8: Group scheme for acute oral toxicity study of hydrogels in mice 
Group I Group II Group III Group IV Group V 
Control Treated with 
CA hydrogel 
Treated with 
CMA hydrogel 
Treated with A 
hydrogel 
Treated with M 
hydrogel 
3.2.16 In Vivo analysis 
3.2.16.1 Experimental Design 
Healthy rabbits having weight greater than 2.5 ± 0.61 Kg were used for in vivo study. 
Rabbits were divided into three groups randomly, each group consisting of 10 rabbits. 
The study protocol was approved by Pharmacy Research Ethics Committee, The Islamia 
University of Bahawalpur, Punjab Pakistan. All rabbits were fasted for 12 hours before 
dose administration except free excess to drinking water. Each rabbit was administered 
hydrogel disc containing Rabeprazole sodium equivalent to (5 mg/kg/day) with the help 
of silicone rubber gastric intubation tube with gavage (Amitava et al., 2008). 
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3.2.16.2 Sample Collection 
The rabbit was fixed in rabbit holder with its head protruding outside. Blood samples 
were collected from jugular vein of rabbit in heparinized centrifuge tubes. One sample 
was collected at zero time and then at 0.50, 1, 2, 3, 4, 6, 8, 12, 24 hours after dosing 
Rabeprazole sodium. A 3 mL blood sample was collected each time. Blood samples were 
centrifuged at 5000 rpm for 10 minutes and the separated plasma was stored frozen at -70 
º
C until analysis. 
3.2.16.3 HPLC Conditions 
The HPLC parameters and their conditions are given in Table 3.9. 
Table 3.9: Conditions for HPLC analysis 
Sr. No Parameter Condition 
1. Mobile Phase 0.1M Ammonium acetate Buffer (60 %): Acetonitrile 
(40 %) 
2. Flow Rate 1.0 mL/min 
3. Retention Time 5.4 min 
4. HPLC Detector UV Detector 
5. HPLC Column C18 
6. Column Dimension 4.6 x 250 mm 
7. Injection Volume 20 µl 
8. Run Time 10 min 
9. λmax 284 nm 
3.2.16.4 Preparation of mobile phase 
The mobile phase consisted of 60% of 100 mM Ammonium acetate buffer & 40% 
Acetonitrile and eluted at a flow rate of 1.0 mL/min.  Acetonitrile and Ammonium 
acetate buffer were measured separately and then mixed. After mixing, it was filtered 
through 0.45 µm membrane filter. Mobile phase was degassed by sonication before 
running in HPLC. 
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3.2.16.5 Method for Sample Analysis 
a) Preparation of stock solution 
Initial stock solution of Rabeprazole sodium was prepared by dissolving 1 
gram of Rabeprazole sodium in 100 mL of 0.1N sodium hydroxide. Standard 
solutions were obtained by serial dilution of this stock solution to give 
concentrations over the range of 4000-31.25 ng/mL according to plasma 
spiking. Stock solution was prepared on daily basis.  
b) Preparation of sample 
Prior to injection, rabeprazole sodium was extracted from the plasma samples 
according to the following procedure:  
Chloroform was added into 500 l plasma sample containing Rabeprazole as 
an extraction solvent. Mixture was then vortexed for 1 min by using a vortex 
mixer (Seouline BioScience-Korea), and centrifuged at 5,000 rpm for 5 min by 
centrifuge machine. After centrifugation, organic layer was withdrawn by 
using micropipette and solvent was dried under a gentle stream of nitrogen at 
45
o
C. The residue was reconstituted with 100 µl of mobile phase and 20 µl 
injected into column. 
c) Preparation of Standard Curve 
Standard curve was constructed to predict the anticipated range of Rabeprazole 
sodium plasma concentration found in healthy rabbits. Blank plasma was 
spiked with Rabeprazole sodium solutions to give concentrations of 4000, 
2000, 1000, 500.250, 125, 62.5, 31.25 ng/mL. Extraction procedure was same 
as described above. Injections of 20µl were injected and spectra were taken of 
each concentration. The peak areas were noted for each concentration.  
d) High Performance Liquid Chromatography 
Analysis was performed by using Agilent Liquid Chromatography, with a 
pump series 1100, Agilent UV detector at wavelength of 284 nm. Column was 
used consisting of Silica C18 column (250 mm x 5 µm particle size x 4.6 mm 
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I.D.). The mobile phase was pumped at a rate of 1.0 mL/minute. Sample of 20 
µl were injected, with a run time of 10 minutes. 
e) Pharmacokinetic analysis 
The pharmacokinetic parameters of Rabeprazole sodium analyzed from the 
plasma levels in rabbits by noncompartmental pharmacokinetic analysis using 
the software package kinetic v 4.4. The peak plasma concentration (Cmax) and 
time to reach peak plasma concentration (Tmax) was obtained from the visual 
inspection of the plasma concentration-time curves. The area under the plasma 
concentration curve (AUC0-t) was determined using the trapezoidal rule. 
f) Statistical analysis 
Software Kinitica version 4.4 was used for evaluation of pharmacokinetic 
parameters of rabeprazole sodium. Pharmacokinetic parameters of rabeprazole 
sodium was statistically analyzed by One way ANOVA. 
g) Precision and accuracy 
Percent coefficient of variation (% CV) was calculated to find out intra-day 
and inter-day precision and accuracy of present method for rabeprazole sodium 
in rabbit plasma. The validation run was consisted of calibration curve and 
three replicates of each low and high quantification concentrations. For inter-
day, analysis of three batches of drug rabeprazole sodium was performed on 
three different days. 
h) Quantification and detection limits 
Limit of detection (LOD) and Limit of quantification (LOQ) of rabeprazole 
sodium as mean ± SD were 8.0 ± 0.227 ng/mL and 12.0 ± 0.528 ng/mL. Lower 
quantification limits showed the higher sensitivity of present method. 
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4. Results 
4.1 Characterization of CMAX-g-AA hydrogels 
4.1.1 Swelling studies at pH1.2 and pH 7.4 
To investigate the time and pH dependent swelling pattern of CMAX-g-AA hydrogels, we 
executed swelling analysis of discs CMAX-g-AA with various AA and CMAX 
compositions in 0.1N HCl (pH 1.2) and phosphate buffer (pH 7.4) solutions. Formulations 
were assigned codes (A1-A3), (A4-A6) and (A7-A9) for varying concentration of acrylic 
acid, CMAX and crosslinker respectively. Table 4.1.1 presents the (q) values of series of 
hydrogels with varying concentration of acrylic acid A1 (1 to 7.773), A2 (1 to 5.268) and 
A3 (1 to 2.742) in pH 1.2 and A1 (1 to 47.295), A2 (1 to 53.459) and A3 (1 to 58.181) in 
7.4 buffer solutions at 37 ºC. Table 4.1.2 represented comparative swelling ratio of 
CMAX-g-AA with different contents of CMAX, A4 (1 to 4.777), A5 (1 to 4.181) and A6 
(1 to3.533) at pH 1.2 and A4 (1 to 59.322), A5 (1 to 62.788) and A6 (1 to 64.191) at 
pH7.4. Table 4.1.3 showed effect of crosslinker contents on swelling ratio of hydrogels A7 
(1 to 3.965), A8 (1 to 3.458) and A9 (1 to 3.141) at pH 1.2 and A7 (1 to 48.373), A8 (1 to 
43.626) and A9 (1 to 31.629) at pH 7.4. 
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Table 4.1.1: Comparative swelling ratios of CMAX-g-AA (A) hydrogels using different 
concentrations of acrylic acid (n=3) 
Time 
(Hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 7.4 
 A1 A2 A3 A1 A2 A3 
0 1±0 1±0 1±0 1±0 1±0 1±0 
0.5 1.45±0.19 1.3±0.23 1.03±0.22 4.3±0.21 4.71±0.22 5.02±0.21 
1 1.94±0.22 1.61±0.29 1.06±0.24 7.6±0.24 8.46±0.23 9.04±0.24 
1.5 2.43±0.32 1.91±0.31 1.09±0.19 10.91±0.33 12.21±0.34 13.06±0.33 
2 2.92±0.27 2.21±0.3 1.15±0.22 14.21±0.34 15.96±0.38 17.08±0.45 
3 3.41±0.3 2.51±0.28 1.2±0.32 17.51±0.38 19.71±0.41 21.09±4.21 
4 3.9±0.31 2.82±0.32 1.26±0.33 20.81±0.42 23.46±0.43 25.11±4.76 
6 4.4±0.33 3.12±0.31 1.33±0.35 24.11±0.46 27.21±0.45 29.13±6.73 
8 4.89±0.32 3.42±0.33 1.43±0.35 27.42±0.53 30.96±4.21 33.15±0.53 
10 5.38±0.31 3.72±0.35 1.49±0.36 30.72±0.63 34.7±4.76 37.17±0.63 
12 5.87±0.32 4.03±0.35 1.57±0.34 34.02±0.74 38.45±6.73 41.19±0.74 
14 6.35±0.35 4.33±0.36 1.64±0.34 37.32±0.75 42.2±0.74 45.21±0.75 
18 6.85±0.36 4.63±0.34 1.78±0.33 40.62±0.81 45.95±0.75 49.22±0.81 
24 7.34±0.34 4.93±0.34 2.01±0.33 43.93±0.82 49.7±0.81 53.24±0.82 
48 7.77±0.34 5.24±0.35 2.74±0.34 47.23±0.84 53.45±0.82 58.06±0.84 
72 7.77±0.35 5.27±0.35 2.74±0.34 47.3±0.89 53.46±0.88 58.18±0.89 
 
 
 
 
 
Figure 4.1.1: Comparative swelling of CMAX-g-AA (A) hydrogels using different 
concentrations of monomer 
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Table 4.1.2: Comparative swelling ratios of CMAX-g-AA (A)  hydrogels using different 
concentrations of CMAX (n=3) 
Time 
(Hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 7.4 
 A4 A5 A6 A4 A5 A6 
0 1±0 1±0 1±0 1 1 1 
0.5 1.27±0.23 1.23±0.19 1.18±0.22 5.16±0.24 5.41±0.21 5.47±0.2 
1 1.54±0.21 1.45±0.22 1.36±0.24 9.32±0.33 9.81±0.24 9.93±0.22 
1.5 1.81±0.29 1.68±0.32 1.54±0.33 13.47±0.34 14.22±0.33 14.39±0.31 
2 2.08±0.43 1.9±0.33 1.72±0.51 17.63±0.68 18.63±0.63 18.86±0.62 
3 2.35±0.32 2.13±0.35 1.9±0.62 21.79±0.77 23.03±0.74 23.32±0.73 
4 2.62±0.22 2.35±0.35 2.08±0.73 25.95±0.79 27.44±0.75 27.79±0.77 
6 2.89±0.32 2.58±0.36 2.26±0.77 30.11±0.81 31.85±0.81 32.25±0.8 
8 3.16±0.33 2.81±0.54 2.44±0.65 34.26±0.83 36.26±0.82 36.72±0.83 
10 3.43±0.35 3.03±0.68 2.62±0.74 38.42±0.86 40.66±0.84 41.18±0.85 
12 3.7±0.35 3.26±0.77 2.8±0.79 42.58±0.88 45.07±0.89 45.65±0.87 
14 3.97±0.36 3.48±0.79 2.98±0.85 46.74±0.79 49.48±0.75 50.11±0.77 
18 4.24±0.34 3.71±0.68 3.16±0.77 50.9±0.85 53.88±0.81 54.58±0.8 
24 4.5±0.34 3.93±0.81 3.34±0.8 55.06±0.92 58.29±0.82 59.04±1.17 
48 4.77±0.35 4.16±0.82 3.52±0.83 59.21±1.01 62.75±1.17 64.18±1.34 
72 4.78±0.35 4.18±0.84 3.53±0.85 59.32±1.44 62.79±1.44 64.19±1.52 
 
 
 
Figure 4.1.2: Comparative swelling of CMAX-g-AA hydrogels using different 
concentrations of CMAX 
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Table 4.1.3: Comparative swelling ratios of CMAX-g-AA (A) hydrogels using different 
concentrations of crosslinker (n=3) 
Time 
(Hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 7.4 
 A7 A8 A9 A7 A8 A9 
0 1±0 1±0 1±0 1±0 1±0 1±0 
0.5 1.21±0.23 1.18±0.19 1.15±0.22 4.38±0.24 4.05±0.21 3.19±0.2 
1 1.42±0.22 1.35±0.22 1.3±0.24 7.77±0.33 7.09±0.31 5.38±0.22 
1.5 1.63±0.32 1.53±0.32 1.46±0.32 11.15±0.34 10.13±0.62 7.56±0.31 
2 1.84±0.43 1.7±0.33 1.61±0.33 14.53±0.68 13.18±0.73 9.75±0.62 
3 2.05±0.32 1.88±0.35 1.76±0.35 17.92±0.77 16.22±0.77 11.94±0.73 
4 2.26±0.22 2.05±0.35 1.91±0.35 21.3±0.79 19.27±0.75 14.13±0.77 
6 2.47±0.32 2.23±0.36 2.06±0.68 24.68±0.81 22.31±0.81 16.31±0.75 
8 2.68±0.33 2.4±0.54 2.22±0.77 28.07±0.83 25.36±0.82 18.5±0.81 
10 2.89±0.35 2.58±0.85 2.37±0.74 31.45±0.86 28.4±0.84 20.69±0.82 
12 3.1±0.35 2.75±0.77 2.52±0.79 34.83±0.88 31.45±0.89 22.88±0.84 
14 3.31±0.36 2.93±0.8 2.67±0.85 38.22±0.79 34.49±0.75 25.06±0.77 
18 3.52±0.34 3.11±0.83 2.82±0.77 41.6±0.85 37.54±0.8 27.25±0.83 
24 3.73±0.34 3.28±0.81 2.97±0.8 44.98±0.92 40.58±1.17 29.44±1.19 
48 3.94±0.35 3.46±0.82 3.13±0.83 48.37±1.01 43.62±1.34 31.63±1.44 
72 3.97±0.35 3.46±0.84 3.14±0.85 48.37±1.44 43.63±1.52 31.63±1.48 
  
 
 
Figure 4.1.3: Comparative swelling of CMAX-g-AA hydrogels using different 
concentrations of crosslinker 
0
10
20
30
40
50
60
0 20 40 60 80
S
w
el
li
n
g
 r
a
ti
o
 (
q
) 
Time (hrs) 
A7 pH1.2
A7 pH 7.4
A8 pH1.2
A8 pH 7.4
A9 pH1.2
A9 pH 7.4
 54 
 
4.1.2 Pulsatile behavior of hydrogel 
Since the hydrogels swelling analysis illustrate diverse swelling pattern at acidic and basic 
pH, so we investigated their pH-reversibility in pH 1.2 and pH 7.4 buffer solution (Figure 
4.1.4). A stepwise reproducible swelling variation of the hydrogel at 37ºC with alternating 
acidic and basic pH was observed. At pH 7.4, the hydrogel expanded up to 64.19 g (in 72 
Hrs) due to revolting electrostatic forces, whereas, at pH 1.2, it shriveled in less than 25 
minutes due to protonation of carboxylate groups of acrylic acid. 
 
Figure 4.1.4:On-off switching behavior as reversible pulsatile swelling (pH 7.4) and de- 
swelling (pH 1.2) of CMAX-g-AA (A) hydrogel  
4.1.3 Equilibrium water contents (EWC) and gel fraction 
To evaluate the water content, preweighed dry hydrogels were immersed in deionized 
water at 37ºC to achieve equilibrium swelling. Table 4.1.4 indicated the effect of varying 
composition of hydrogels on equilibrium water contents and gel fraction.  Figure 4.1.5 
showed the gelation content as a function of AA, CMAX and N, N MBA contents in the 
hydrogels. 
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Table 4.1.4: Equilibrium water contents and gel fraction of CMAX-g-AA (A) hydrogels 
using different concentrations of AA, CMAX and crosslinker 
 
 
 
Figure 4.1.5: Gel fraction of CMAX-g-AA (A) hydrogel with different concentrations of 
AA, CMAX and crosslinker 
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Fỏmulation contents % 
Formulation 
code 
Contents 
w/w% 
EWC Gel fraction 
(%) 
Amount of Rabeprazole 
sodium loaded 
(mg per 0.4 g of dry disc) 
By extraction By weight 
A1 AA 10 0.96 68.15 99 100 
A 2 AA 15 0.97 81.01 114 114.8 
A 3 AA 20 0.98 84.11 119 120 
A 4 CMAX 1 0.97 77.67 113 113.8 
A 5 CMAX 1.5 0.97 83.07 123 123.6 
A 6 CMAX 2 0.98 83.22 128 128.9 
A 7 MBA 0.4 0.93 86.84 102 102 
A 8 MBA 0.6 0.91 90.02 91 91.7 
A 9 MBA 0.8 0.85 96.40 83 83.3 
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4.1.4 Instrumental analysis 
a) Scanning electron microscopy 
To evaluate the surface morphology of CMAX-g-AA hydrogels scanning electron 
microscopy was employed. Figure 4.1.6 depicted the surface morphology and inner 
porous structure of lyophilized hydrogels at magnification of 100 X and 200 X and 10 µ, 
30 µ, 300 µ, and 500 µ scale bar respectively. 
 
 
Figure 4.1.6: SEM images of lyophilized hydrogels (CMAX-g-AA) at magnification 
of 100 X and 200 X and 10µ, 30µ, 300µ, and 500µ scale bar 
respectively 
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b) FTIR spectral analysis 
FTIR spectra of polymerized hydrogel and individual components were recorded on a 
Fourier transform infrared (FTIR) spectrophotometer (Bruker, Tensor-27, Germany) using 
a single reﬂectance ATR cell. Figure 4.1.7 represented FTIR spectra of CMAX (polymer), 
acrylic acid (monomer), and CMAX-g-AA (A) (prepared hydrogel). All data were 
recorded at room temperature, in the spectral range of 600–4000cm-1. 
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Figure 4.1.7: FTIR spectra of AA, CMAX, and CMAX-g-AA (A) 
c) Thermal analysis 
The thermal properties of CMAX-g-AA copolymers were studied by means of TGA and 
DSC analyses. The thermogravimetric analysis was conducted in air from 20–1000°C. 
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DTG data summarized in Table 4.1.5 representing Tdi (initial thermal degradation 
temperature), Tdm (medium degradation temperature), Tdf (final decomposition 
temperature) and percent weight loss at Tdf of polymer, monomer and prepared hydrogel. 
Figure 4.1.8 show TGA curve representing percent weight loss with temperature elevation 
of individual constituents (CMAX and AA) and prepared hydrogel. DSC curve displayed 
in Figure 4.1.9. 
Table 4.1.5: DTG data of acrylic acid (AA), CMAX and CMAX-g-AA (A) 
Sample Step Tdi 
(°C) 
Tdm 
(°C) 
Tdf 
(°C) 
Weight loss % 
at Tdf 
A 1 443 461 515 21.51 
II 610 614 616 1.17 
AA I 83 93 100 54.24 
II 101 112 122 22.22 
CMAX I 266 332 382 44.8 
II 431 503 562 25 
 
 
 
 
Figure 4.1.8: TGA curves of acrylic acid (AA), CMAX and CMAX-g-AA (A) 
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Figure 4.1.9: DSC curve of acrylic acid (AA), CMAX and CMAX-g-AA (A) 
d) X-ray Diffraction  
For X-ray diffraction samples was scanned over range5-50° 2θ at a rate of 1º 2θ/min. XRD 
spectrum of unloaded, drug loaded and pure drug are presented in Figure 4.1.10.X-ray 
diffraction spectra of hydrogel produced no peaks. 
 
Figure 4.1.10: X-ray diffraction patterns of CMAX-g-AA hydrogel. 
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4.1.5:In vitro release kinetics of Rabeprazole sodium from CMAX-g-AA 
hydrogel 
To evaluate the pH sensitive release of rabeprazole sodium from CMAX-g-AA hydrogel, 
in vitro release studies were conducted in0.1N HCl (pH 1.2) and Tris buffer(pH 8) 
(recommended by US FDA for rabeprazole sodium dissolution study) at 37ºC. Figure 
4.1.11 exhibited effect of concentration of acrylic acid on percent cumulative percent drug 
release. Effect of different concentrations of CMAX on percent cumulative release of 
rabeprazole sodium was summarized in Table 4.1.7 and graphically presented in Figure 
4.1.12. Crosslinking density may also alter release percent and pattern of drug from 
hydrogels. Table 4.1.8 illustrated effect of crosslinker (N, N MBA) concentration on 
cumulative percent drug release. To determine the release mechanism, in vitro release data 
was fitted in various mathematical models and results were presented in Table 4.1.9. Log 
plot of the cumulative percent drug release versus the time provides the value of n, which 
determined the nature of the dissolution medium diffusion process. 
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Table 4.1.6: Effect of acrylic acid concentration on cumulative percent drug release of 
Rabeprazole sodium 
Time 
(hr) 
A1 pH 1.2 A2 pH 1.2 A3 pH 1.2 A1 pH 8 A2 pH 8 A3 pH 8 
0.5 1.49±0.21 1.08±0.22 0.49±0.23 6.29±1.21 8.85±1.112 9.68±1.23 
1 2.52±0.32 1.71±0.23 0.82±0.21 8.55±1.48 10.19±1.78 13.49±1.45 
1.5 3.44±0.33 2.32±0.34 1.15±0.29 11.95±2.13 11.82±2.08 16.83±1.54 
2 4.36±0.67 2.94±0.45 1.47±0.43 13.28±2.11 13.77±2.23 18.51±1.78 
3 5.26±0.77 3.54±0.54 1.78±0.32 16.86±2.46 16.36±2.48 20.64±1.99 
4 6.16±0.79 4.14±0.78 2.1±0.22 20.75±2.46 19.31±2.50 24.24±2.11 
6 7.04±0.79 4.73±0.87 2.41±0.32 27.53±2.18 22.56±2.38 32.05±2.33 
8 7.92±0.57 5.32±0.90 2.72±0.43 35.6±2.56 29.75±2.56 38.92±2.77 
12 8.79±0.35 5.9±0.56 3.02±0.45 46.53±3.23 42.89±3.33 53.51±3.00 
16 9.64±0.87 6.47±0.33 3.32±0.45 60.06±3.24 57.96±3.34 65.9±2.99 
20 10.54±0.83 7.08±0.35 3.62±0.56 70.31±3.36 71.39±3.46 79.47±3.99 
24 11.52±0.65 7.64±0.65 3.91±0.34 79.77±3.43 85.51±3.54 93.18±4.11 
 
 
 
 
Figure 4.1.11: Effect of acrylic acid concentration on cumulative percent drug release of 
Rabeprazole sodium from hydrogel formulations (A1-A3) 
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Table 4.1.7: Effect of CMAX concentration on cumulative percent drug release of 
Rabeprazole sodium 
Time (hr) A4 pH 1.2 A5 pH 1.2 A6 pH 1.2 A4 pH 8 A5 pH 8 A6 pH 8 
0.5 1.62±0.11 1.04±0.21 1±0.24 7.59±1.22 12.47±1.18 16.12±1.26 
1 2.15±0.32 1.51±0.23 1.57±0.21 11.78±1.78 16.32±1.48 19.29±1.30 
1.5 2.68±0.33 2.02±0.34 2.17±0.29 16.46±2.08 20.95±2.13 23.72±1.78 
2 3.2±0.67 2.48±0.45 2.73±0.43 18.24±1.23 23.03±2.23 25.32±2.08 
3 3.72±0.77 2.9±0.54 3.24±0.77 20.5±3.33 25.19±2.48 27.75±3.24 
4 4.22±0.79 3.28±0.78 3.71±0.79 24.3±3.34 30.2±2.50 30.91±3.36 
6 4.73±0.79 3.69±0.87 4.22±0.79 32.52±3.46 36.57±2.38 37.97±3.43 
8 5.23±0.57 4.1±0.90 4.72±0.43 39.35±2.56 41.65±2.56 45.98±2.77 
12 5.72±0.45 4.5±0.65 5.21±0.45 54.01±3.23 55.46±3.33 58.22±3.00 
16 6.21±0.45 4.89±0.33 5.7±0.45 68.6±3.24 68.45±3.34 72.02±2.23 
20 6.74±0.56 5.33±0.35 6.21±0.56 82.49±3.36 81.19±3.46 84.24±2.48 
24 7.22±0.45 5.75±0.65 6.73±0.34 92.83±3.43 96.76±3.54 98.44±2.50 
 
 
 
 
Figure 4.1.12: Effect of CMAX concentration on cumulative percent drug release of 
Rabeprazole sodium from hydrogel formulations (A4-A6) 
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Table 4.1.8: Effect of MBA concentration on cumulative percent drug release of 
Rabeprazole sodium 
Time 
(hr) 
A7 pH1.2 A8 pH1.2 A9 pH1.2 A7 pH 8 A8 pH 8 A9 pH 8 
0.5 0.62±0.11 0.86±0.20 0.59±0.27 6.49±1.24 5.06±1.17 3.54±1.23 
1 1.2±0.21 1.29±0.23 0.94±0.24 10.46±2.11 8.98±1.44 5.66±1.28 
1.5 1.81±0.23 1.87±0.34 1.35±0.29 14.61±2.23 12.04±2.13 7.86±1.75 
2 2.38±0.34 2.4±0.79 1.69±0.43 16.69±2.48 14.39±2.23 10.45±3.33 
3 2.88±0.29 2.86±0.57 1.98±0.77 19.82±3.33 16.86±2.48 12.61±3.34 
4 3.34±0.43 3.27±0.45 2.2±0.79 22.64±3.34 20.04±2.50 15.55±3.46 
6 3.84±0.79 3.73±0.45 2.47±0.79 29.86±3.46 25.55±2.38 20.62±2.56 
8 4.33±0.57 4.18±0.90 2.75±0.43 34.98±2.56 31.48±2.56 25.3±3.24 
12 4.82±0.45 4.62±0.56 3.02±0.45 48.03±3.23 40.81±3.33 34.43±3.36 
16 5.3±0.56 5.07±0.33 3.29±0.21 59.13±3.24 50.73±3.34 43.66±3.43 
20 5.83±0.45 5.55±0.35 3.61±0.23 70.21±3.36 61.16±3.46 52.91±2.48 
24 6.34±0.45 6.04±0.64 3.93±0.34 82.34±3.42 74.85±3.57 63.51±3.90 
 
 
 
 
Figure 4.1.13: Effect of crosslinker concentration on cumulative percent drug release of 
Rabeprazole sodium from hydrogel formulations (A7-A9) 
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Table 4.1.9: Kinetic parameters of Rabeprazole sodium release from CMAX-g-AA 
hydrogel 
Formulation 
code 
Higuchi First 
order 
Zero 
order 
Korsmayer-peppas 
R
2
 R
2
 R
2
 R
2
 n 
A1 0.971 0.557 0.998 0.997 0.855 
A2 0.941 0.639 0.996 0.982 0.961 
A3 0.983 0.617 0.994 0.999 0.699 
A4 0.977 0.570 0.995 0.998 0.737 
A5 0.972 0.492 0.996 0.989 0.863 
A6 0.972 0.463 0.997 0.991 0.778 
A7 0.981 0.567 0.994 0.995 0.821 
A8 0.975 0.594 0.994 0.994 0.972 
A9 0.976 0.670 0.996 0.997 0.931 
 
4.2 Characterization of CMAX-g-MAA hydrogels 
4.2.1 Swelling studies at pH1.2 and pH 7.4 
To evaluate the pH sensitivity, swelling of prepared hydrogels was carried out in acidic 
(1.2) and basic (7.4) pH buffer solution. Formulations were assigned codes (M1-M3), 
(M4-M6) and (M7-M9) for varying concentration of methacrylic acid, CMAX and 
crosslinker respectively. Effect of varying concentration of methacrylic acid on swelling 
ratio (q), M1 (1 to 5.032), M2 (1 to 4.095) and M3 (1 to 3.140) in pH 1.2 and M1 (1 to 
20.855), M2 (1 to 16.693) and M3 (1 to 14.285) in 7.4 buffer solutions at 37 ºC has been 
given in Table 4.2.1 and graphically presented in Figure 4.2.1. Comparative swelling ratio 
(q) of hydrogels by using different concentrations of CMAX, M4 (1 to 4.658), M5 (1 to 
3.462) and M6 (1 to 2.770) at pH 1.2 and M4 (1 to 18.808), M5 (1 to 22.122) and M6 (1 to 
24.638) at pH 7.4 were given in Table 4.2.2. Table 4.2.3 showed effect of crosslinker 
contents on swelling ratio of hydrogels M7 (1 to 4.005), M8 (1 to 3.342) and M9 (1 to 2.696) 
at pH 1.2 and M7 (1 to 15.371), M8 (1 to 12.131) and M9 (1 to 8.972) at pH 7.4. 
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Table4.2.1: Comparative swelling ratios of CMAX-g-MAA hydrogels using different 
concentrations of MAA (n=3) 
Time 
(Hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 7.4 
 M1 M2 M3 M1 M2 M3 
0 1 1 1 1 1 1 
0.5 1.29±0.23 1.22±0.19 1.15±0.22 2.42±0.24 2.11±0.21 1.94±0.2 
1 1.57±0.22 1.44±0.22 1.3±0.24 3.84±0.33 3.21±0.31 2.88±0.22 
1.5 1.86±0.32 1.66±0.32 1.46±0.32 5.25±0.34 4.32±0.62 3.83±0.31 
2 2.14±0.43 1.88±0.22 1.61±0.33 6.67±0.68 5.43±0.73 4.77±0.62 
3 2.43±0.32 2.1±0.32 1.76±0.35 8.09±0.77 6.53±0.31 5.71±0.73 
4 2.72±0.22 2.33±0.33 1.91±0.35 9.51±0.79 7.64±0.62 6.65±0.77 
6 3±0.32 2.55±0.36 2.06±0.68 10.92±0.81 8.75±0.73 7.6±0.75 
8 3.29±0.33 2.77±0.54 2.21±0.77 12.34±0.83 9.86±0.77 8.54±0.81 
10 3.57±0.35 2.99±0.85 2.37±0.74 13.76±0.86 10.96±0.84 9.48±0.81 
12 3.86±0.35 3.21±0.77 2.52±0.79 15.18±0.88 12.07±0.89 10.42±0.83 
14 4.15±0.77 3.43±0.8 2.67±0.85 16.59±0.89 13.18±0.75 11.37±0.86 
18 4.43±0.8 3.65±0.83 2.82±0.77 18.01±0.75 14.28±0.8 12.31±0.83 
24 4.72±0.83 3.87±0.81 2.97±0.8 19.43±0.8 15.39±1.17 13.25±1.19 
48 5.01±0.81 4.09±0.82 3.13±0.83 20.85±1.17 16.68±1.24 14.19±1.33 
72 5.03±0.81 4.1±0.84 3.14±0.85 20.86±1.34 16.69±1.42 14.29±1.38 
 
 
Figure 4.2.1: Comparative swelling ratios of CMAX-g-MAA hydrogels using different 
concentrations of MAA 
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Table 4.2.2: Comparative swelling ratios of CMAX-g-MAA (M)  hydrogels using 
different concentrations of CMAX (n=3) 
Time 
(Hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 7.4 
 M4 M5 M6 M4 M5 M6 
0 1 1 1 1 1 1 
0.5 1.26±0.23 1.18±0.19 1.13±0.22 2.27±0.24 2.51±0.21 2.69±0.2 
1 1.52±0.22 1.35±0.22 1.25±0.24 3.54±0.33 4.02±0.31 4.37±0.22 
1.5 1.78±0.32 1.53±0.32 1.38±0.32 4.81±0.34 5.52±0.62 6.06±0.31 
2 2.04±0.43 1.7±0.33 1.5±0.33 6.08±0.68 7.03±0.73 7.75±0.62 
3 2.3±0.32 1.88±0.35 1.63±0.35 7.35±0.77 8.54±0.77 9.43±0.73 
4 2.56±0.22 2.05±0.35 1.75±0.35 8.62±0.79 10.05±0.75 11.12±0.77 
6 2.83±0.32 2.23±0.36 1.88±0.68 9.89±0.81 11.56±0.73 12.81±0.75 
8 3.09±0.33 2.4±0.54 2.01±0.77 11.16±0.83 13.06±0.77 14.49±0.81 
10 3.35±0.35 2.58±0.85 2.13±0.77 12.43±0.86 14.57±0.75 16.18±0.82 
12 3.61±0.35 2.75±0.77 2.26±0.68 13.7±0.88 16.08±0.89 17.87±0.84 
14 3.87±0.36 2.93±0.68 2.38±0.65 14.97±0.79 17.59±0.75 19.55±0.77 
18 4.13±0.34 3.1±0.77 2.51±0.77 16.24±0.85 19.09±0.8 21.24±0.89 
24 4.39±0.34 3.28±0.74 2.64±0.8 17.51±0.92 20.6±1.17 22.93±0.75 
48 4.65±0.35 3.46±0.79 2.76±0.73 18.78±1.01 22.11±1.34 24.61±0.8 
72 4.66±0.35 3.46±0.75 2.77±0.75 18.81±1.44 22.12±1.32 24.64±1.18 
 
 
Figure 4.2.2:Comparative swelling ratios of CMAX-g-MAA hydrogels using different 
concentrations of CMAX 
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Table 4.2.3: Comparative swelling ratios of CMAX-g-MAA hydrogels using different 
concentrations of crosslinker 
Time 
(Hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 7.4 
 M7 M8 M9 M7 M8 M9 
0 1 1 1±0 1 1 1 
0.5 1.2±0.19 1.17±0.23 1.04±0.22 2.03±0.21 1.79±0.22 1.57±0.21 
1 1.4±0.22 1.33±0.29 1.16±0.24 3.05±0.24 2.59±0.23 2.14±0.24 
1.5 1.6±0.32 1.49±0.31 1.29±0.19 4.07±0.33 3.38±0.34 2.72±0.33 
2 1.8±0.27 1.66±0.3 1.41±0.22 5.1±0.34 4.18±0.42 3.29±0.45 
3 2±0.3 1.82±0.28 1.54±0.32 6.12±0.38 4.97±0.46 3.86±0.21 
4 2.19±0.31 1.99±0.32 1.66±0.33 7.15±0.42 5.77±0.53 4.43±0.76 
6 2.39±0.33 2.15±0.31 1.79±0.35 8.17±0.46 6.56±0.45 5±0.73 
8 2.59±0.32 2.32±0.32 1.92±0.35 9.2±0.53 7.36±0.21 5.57±0.53 
10 2.79±0.31 2.48±0.35 2.04±0.36 10.22±0.63 8.15±0.76 6.15±0.63 
12 2.99±0.32 2.65±0.36 2.17±0.34 11.25±0.74 8.95±0.73 6.72±0.74 
14 3.19±0.35 2.81±0.36 2.29±0.34 12.27±0.75 9.74±0.74 7.29±0.75 
18 3.39±0.36 2.98±0.34 2.42±0.33 13.3±0.81 10.54±0.75 7.86±0.81 
24 3.59±0.34 3.14±0.34 2.54±0.33 14.32±0.82 11.33±0.81 8.43±0.82 
48 3.79±0.34 3.31±0.35 2.67±0.34 15.34±0.84 12.13±0.82 9±0.84 
72 4.01±0.35 3.34±0.35 2.7±0.34 15.37±0.89 12.13±0.88 8.97±0.89 
 
 
 
Figure 4.2.3: Comparative swelling ratios of CMAX-g-MAA hydrogels using different 
concentrations of MBA (crosslinker) 
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4.2.2: Pulsatile behavior of hydrogel 
Effect of copolymer composition on the swelling behavior was examined in (pH 1.2) 
and(pH 7.4) buffer solutions. Mechanism of water transport through the gel was 
significantly affected by pH modulation. Reversible pH responsive swelling behavior is 
key element for controlled delivery of drug through hydrogels. So, to evaluate the 
reversible swelling behavior, hydrogels samples (M6)swelled in buffer solution of pH 7.4, 
until equilibrium swelling was attained (almost 72 Hrs). Afterwards swollen hydrogels 
were placed in a buffer solution of pH 1.2 the hydrogels collapsed within few minute (less 
than 25 mins).Again they were returned to a buffer solution of pH 7.4, and finally 
collapsed in a buffer solution of pH 1.2. Figure 4.2.4 showed that swollen networks 
relapsed to comparatively shrunken networks whenever the pH decreased. 
 
 
Figure 4.2.4:On-off switching behavior as reversible pulsatile swelling (pH 7.4) and 
deswelling (pH 1.2) of CMAX-g-MAA hydrogel  
4.2.3: Equilibrium water contents and gel fraction of CMAX-g-MAA 
hydrogels 
Uses of hydrogels are centered on their water absorption property, the water content of a 
hydrogel was one of utmost fundamentals, affecting its worth and functionality. 
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Equilibrium water content was evaluated by immersing hydrogels in deionized water and 
results were presented in Table 4.2.4, exhibiting water absorption modulation by varying 
composition of hydrogels. Gel fraction was also affected by hydrogel composition as 
shown in Figure 4.2.5. 
Table 4.2.4: Equilibrium water contents, gel fraction and drug loaded of CMAX -g-MAA 
hydrogels using different concentrations of MAA, CMAX and crosslinker 
 
 
 
Figure 4.2.5: Gel fraction of CMAX-co-MAA hydrogel with different concentrations of 
MAA, CMAX and crosslinker 
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Formulation 
code 
Contents 
w/w% 
EWC Gel fraction 
(%) 
Amount of Rabeprazole 
sodium loaded 
(mg per 0.4 g of dry disc) 
By extraction By weight 
M1 MAA 20 0.95 59.67 89 90 
M2 MAA 30 0.93 88.45 87 87.9 
M3 MAA 35 0.91 90.32 83 83.7 
M4 CMAX 1 0.95 87.17 90 91.3 
M5 CMAX 1.5 0.95 74.83 94 95 
M6 CMAX 2 0.95 90.35 97 98.4 
M7 MBA 0.45 0.92 86.84 81 81.8 
M8 MBA 0.65 0.85 91.83 77 78 
M9 MBA 0.85 0.81 95.64 71 71.9 
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4.2.4: Instrumental analysis 
a) Scanning electron microscopy 
Surface morphology of hydrogel was examined by scanning electron microscopy of 
lyophilized hydrogels to evaluate the porous structure. SEM images were summarized in 
Figure 4.2.6. 
 
 
Figure 4.2.6: SEM images of lyophilized hydrogels (CMAX-g-MAA) at magnification of 
100 X and 200 X and 30µ, 100µ, 300µ, and 500µ scale bar respectively 
 
b) FTIR spectrum analysis 
Fourier transform infrared spectroscopy (FTIR) was used to characterize the presence of 
specific chemical groups added in the copolymeric matrix. Figure 4.2.7 showed FTIR 
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spectra of polymer (CMAX), monomer (methacrylic acid) and prepared hydrogel 
formulation (M). All spectra were recorded in 4000-600cm
-1
 range. 
 
Figure 4.2.7: FTIR spectrum of CMAX, MAA, and prepared hydrogel (M) 
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c) Thermal analysis 
The thermal properties of CMAX-g-MAA copolymer and CMAX (polymer), and 
monomer (MAA) were studied by means of DSC and TG analyses. The 
thermogravimetric analysis was conducted in nitrogen flow from 20–1000°C. TGA curve 
exhibited percent weight loss as a result of elevation of temperature of CMAX,MAA and 
prepared hydrogel M shown in Figure 4.2.8. DSC curve exhibited percent heat flow with 
subsequent increase in temperature displayed in Figure 4.2.9. DTG data was presented in 
Table 4.2.5. 
 
Table 4.2.5: DTG data of acrylic acid (AA), CMAX and CMAX-g-AA hydrogel (A) 
Sample Step Tdi (°C) Tdm (°C) Tdf (°C) Weight loss %at Tdf 
M 1 66 94 152 21.51 
II 435 462 536 31.05 
MAA I 48 130 144 97.02 
CMA
X 
I 266 332 382 44.8 
II 431 503 562 25 
 
 
Figure 4.2.8:TGA curves of methacrylic acid (MAA), CMAX and CMAX-g-AA 
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Figure 4.2.9:DSC curves of methacrylic acid (MAA), CMAX and CMAX-g-AA 
d) X-ray Diffraction  
The XRD pattern of prepared hydrogel (M), rabeprazole sodium (Rab) and drug loaded 
formulation (MD) depicted in Figure 4.2.10 revealed that there was no peak observed, which 
shows amorphous nature of prepared hydrogel. 
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2θ 
Figure 4.2.10: X-ray diffraction patterns of CMAX, Rab, and drug loaded formulation 
(CMAX-g-MAA) hydrogel 
4.2.5: In vitro release kinetics of Rabeprazole sodium from CMAX-g-MAA 
hydrogel 
In vitro drug release from the CMAX-g-MAA hydrogels was conducted out in triplicate in 
acidic (0.1N HCl) and basic (0.6M Tris buffer) medium. Cumulative percent drug release 
was determined and effect of various graft copolymer component on rabeprazole sodium 
was observed. Effect of methacrylic acid, CMAX and N,N MBA concentration on percent 
cumulative percent drug release was examined and data was summarized in Tables 
4.2.6,4.2.7 and 4.2.8 respectively. Drug release kinetics was determined by fitting data 
into mathematical release models and release mechanism was proposed by calculating 
diffusion exponent, findings were given in Table 4.2.9. 
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Table 4.2.6: Effect of methacrylic acid concentration on cumulative percent drug release 
of Rabeprazole sodium 
Time 
(hr) 
M1 pH 
1.2 
M2 pH 
1.2 
M3 pH 
1.2 
M1 pH 8 M2 pH 8 M3 pH 8 
0.5 1.49±0.45 0.85±0.24 0.77±0.21 14.6±1.23 8.85±1.11 6.91±1.31 
1 2.04±0.56 1.24±0.45 1±0.21 16.79±1.98 10.19±1.87 8.97±1.45 
1.5 2.9±0.34 1.74±0.33 1.35±0.11 18.9±1.76 11.82±1.67 10.98±1.76 
2 3.76±0.21 2.23±0.34 1.69±0.19 20.49±2.34 13.77±1.98 12.8±2.00 
3 4.61±0.11 2.94±0.92 2.03±0.56 24.72±3.46 16.36±2.01 15.52±1.78 
4 5.45±0.09 3.64±0.13 2.37±0.98 28.53±3.76 19.31±2.47 18.62±2.56 
6 6.28±0.87 4.34±0.35 2.88±0.76 33.64±2.98 22.56±3.91 23.25±3.09 
8 7.1±0.98 5.02±0.35 3.38±0.23 38.6±2.65 29.75±2.98 29.07±2.88 
12 7.92±0.88 5.71±0.49 3.87±0.12 50.17±3.23 41.8±3.01 40.58±2.66 
16 8.72±0.34 6.38±0.13 4.36±0.36 60.17±3.24 54.73±3.41 49.79±2.76 
20 9.52±0.12 7.05±0.28 4.85±0.23 73.72±1.99 64.95±2.99 62.65±3.02 
24 10.3±0.23 7.7±0.99 5.33±0.76 84.19±3.98 75.9±3.11 71.26±3.41 
 
 
 
Figure 4.2.11:Effect of methacrylic acid concentration on cumulative percent drug release 
of Rabeprazole sodium 
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Table 4.2.7: Effect of CMAX concentration on cumulative percent drug release of 
Rabeprazole sodium 
Time 
(hr) 
M4 pH1.2 M5pH1.2 M6 pH1.2 M4 pH 8 M5 pH 8 M6 pH 8 
0.5 0.71±0.35 0.68±0.27 0.51±0.09 12.69±1.43 13.19±1.35 20.11±1.46 
1 0.92±0.23 0.83±0.39 0.66±0.29 17.41±1.49 17.97±1.67 22.53±1.25 
1.5 1.24±0.21 0.99±0.33 0.8±0.34 20.04±1.66 20.48±1.98 24.93±1.76 
2 1.56±0.19 1.14±0.41 0.95±0.36 22.47±2.64 22.81±2.91 27.15±2.52 
3 1.88±0.34 1.28±0.77 1.09±0.48 24.93±3.26 25.92±2.91 30.15±2.78 
4 2.19±0.11 1.43±0.29 1.24±0.76 27.74±3.86 29.37±2.67 33.46±2.56 
6 2.65±0.38 1.73±0.34 1.53±0.23 31.95±2.88 34.4±3.12 38.31±3.09 
8 3.11±0.68 2.02±0.36 1.81±0.12 37.27±2.85 41.49±2.68 45.16±2.88 
12 3.57±0.76 2.31±0.48 2.1±0.73 47.83±3.53 53.08±3.12 56.36±2.66 
16 4.02±0.41 2.6±0.26 2.38±0.21 56.79±3.24 64.12±1.67 67.04±2.76 
20 4.47±0.23 2.89±0.76 2.65±0.19 68.44±1.69 78.21±3.21 80.67±3.02 
24 4.91±0.31 3.17±0.87 2.93±0.34 79.78±3.48 87.93±3.51 90.06±3.41 
 
 
 
Figure 4.2.12: Effect of CMAX concentration on cumulative percent drug release of 
Rabeprazole sodium 
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Table 4.2.8: Effect of crosslinker concentration on cumulative percent drug release of 
Rabeprazole sodium 
Time (hr) M7 pH 
1.2 
M8 pH1.2 M9 pH 
1.2 
M7 pH 8 M8 pH 8 M9 pH 8 
0.5 0.61±0.34 0.7±0.37 0.76±0.07 7.56±1.43 5.79±1.95 2.49±1.56 
1 0.79±0.69 0.95±0.36 0.97±0.29 10.82±1.49 8.2±1.67 4.82±1.55 
1.5 0.96±0.24 1.2±0.69 1.17±0.36 13.77±1.66 10.31±1.47 7.13±1.84 
2 1.14±0.62 1.45±0.41 1.37±0.36 16.94±2.64 12.06±1.98 9.43±2.78 
3 1.31±0.34 1.69±0.77 1.56±0.48 19.18±3.26 13.17±2.78 12.02±2.78 
4 1.48±0.34 1.93±0.45 1.76±0.76 21.58±3.86 15.15±2.67 14.06±2.98 
6 1.83±0.83 2.17±0.37 1.95±0.23 26.24±3.88 19.55±3.62 17.49±3.09 
8 2.17±0.68 2.41±0.43 2.14±0.54 30.27±3.85 23.81±2.94 20.74±2.88 
12 2.51±0.76 2.64±0.48 2.33±0.73 37.7±3.93 32.21±3.21 28.94±2.88 
16 2.84±0.47 2.87±0.43 2.52±0.26 47.35±3.28 41.87±3.81 36.02±3.76 
20 3.18±0.46 3.1±0.76 2.7±0.67 56.93±2.69 51.99±2.89 46.95±3.02 
24 3.51±0.91 3.33±0.83 2.88±0.78 69.5±3.89 62.84±3.91 55.51±3.91 
 
 
 
Figure 4.2.13: Effect of crosslinker concentration on cumulative percent drug release of 
Rabeprazole sodium 
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Table 4.2.9: Kinetic parameters of Rabeprazole sodium release from CMAX-g-MAA 
hydrogels 
Formulation 
code 
Higuchi First 
order 
Zero order Korsmayer-peppas 
R
2
 R
2
 R
2
 R
2
 n 
M1 0.972 0.480 0.997 0.985 0.819 
M2 0.958 0.614 0.999 0.987 0.810 
M3 0.970 0.620 0.998 0.994 0.867 
M4 0.972 0.461 0.995 0.980 0.846 
M5 0.976 0.471 0.996 0.976 0.766 
M6 0.972 0.414 0.998 0.984 0.716 
M7 0.970 0.531 0.990 0.979 0.960 
M8 0.954 0.633 0.997 0.989 1.004 
M9 0.968 0.681 0.993 0.984 1.053 
4.3 Characterization of CMC-g-AA hydrogels 
4.3.1 Swelling studies at pH1.2 and pH 7.4 
The effect of acrylic acid, carboxymethyl cellulose and crosslinker on the swelling curve 
of prepared hydrogels was evaluated by immersing hydrogels disc at pH 1.2 and 7.4 at 
temperature 37 ºC. Formulations were assigned codes (CA1-CA3), (CA4-CA6) and (CA7-
CA9) for varying concentration of acrylic acid, CMC and crosslinker respectively. Effect 
of varying concentration of acrylic acid on swelling ratio (q), CA1 (1 to 5.19), CA2 (1 to 
3.58) and CA3 (1 to 4.23) in pH 1.2 and CA1 (1 to 26.82), CA2 (1 to 35.32) and CA3 (1 
to 40.69) in 7.4 buffer solutions at 37 ºC has been given in Table 4.3.1 and graphically 
presented in Figure 4.3.1.Comparative swelling ratio (q) of hydrogels by using different 
concentrations of CMC, CA4 (1 to 4.84), CA5 (1 to 6.43) and CA6 (1 to 5.95) at pH 1.2 
and CA4 (1 to 37.81), CA5 (1 to 43.36) and CA6 (1 to 31.61) at pH 7.4 were given in 
Table 4.3.2.  
Table 4.3.3 showed effect of crosslinker contents on swelling ratio of hydrogels CA7 (1 
to5.79), CA8 (1 to 4.86) and CA9 (1 to 3.49) at pH 1.2 and CA7 (1 to 32.35), CA8 (1 to 28.61) 
and CA9 (1 to 23.74) at pH 7.4. 
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Table 4.3.1: Comparative swelling ratios of CMC-g-AA hydrogels using different 
concentrations of acrylic acid (n=3) 
 
 
 
Figure 4.3.1: Comparative swelling ratios of CMC-g-AA hydrogels using different 
concentrations of monomer 
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Time  
(Hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 7.4 
 CA1 CA2 CA3 CA1 CA2 CA3 
0 1 1 1 1 1 1 
0.5 1.12±0.19 1.17±0.23 1.19±0.22 2.16±0.21 2.62±0.22 2.82±0.21 
1 1.25±0.22 1.34±0.29 1.38±0.24 3.32±0.24 4.24±0.23 4.65±0.24 
1.5 1.37±0.32 1.51±0.31 1.57±0.19 4.48±0.33 5.86±0.34 6.47±0.33 
2 1.5±0.27 1.68±0.3 1.76±0.22 5.64±0.34 7.48±0.38 8.3±0.45 
3 1.62±0.3 1.85±0.28 1.95±0.32 6.8±0.38 9.1±0.41 10.12±4.21 
4 1.75±0.31 2.02±0.32 2.14±0.33 7.96±0.42 10.72±0.43 11.95±4.76 
6 1.87±0.33 2.194±0.31 2.33±0.35 9.13±0.46 12.34±0.45 13.77±6.73 
8 2±0.32 2.36±0.33 2.52±0.35 10.29±0.53 13.96±4.21 15.6±0.53 
10 2.13±0.31 2.53±0.35 2.71±0.36 11.45±0.63 15.58±4.76 17.42±0.63 
12 2.25±0.32 2.7±0.35 2.9±0.34 12.61±0.74 17.2±6.73 19.25±0.74 
14 2.38±0.35 2.87±0.36 3.09±0.34 13.77±0.75 18.82±0.74 21.07±0.75 
18 2.5±0.36 3.04±0.34 3.28±0.33 14.93±0.81 20.44±0.75 22.9±0.81 
24 2.63±0.34 3.21±0.34 3.59±0.33 16.07±0.82 22.06±0.81 27.1±0.82 
48 3.69±0.34 3.3±0.35 3.91±0.34 21.22±0.84 29.02±0.82 33.32±0.84 
72 5.19±0.35 3.58±0.35 4.23±0.34 26.82±0.89 35.32±0.88 40.69±0.89 
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Table 4.3.2: Comparative swelling ratios of CMC-g-AA (CA) hydrogels using different 
concentrations of polymer (n=3) 
Time (Hrs) Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH7.4 
 CA4 CA5 CA6 CA4 CA5 CA6 
0 1 1 1 1 1 1 
0.5 1.62±0.23 1.38±0.19 1.2±0.22 3.79±0.24 3.97±0.21 2.82±0.2 
1 1.74±0.22 1.57±0.22 1.41±0.32 6.59±0.33 6.94±0.31 4.65±0.22 
1.5 1.78±0.32 1.76±0.32 1.62±0.43 9.38±0.34 9.91±0.62 6.47±0.34 
2 1.85±0.43 1.95±0.22 1.83±0.32 11.07±0.68 11.72±0.73 8.3±0.68 
3 2.03±0.32 2.14±0.32 2.04±0.35 12.32±0.77 13.83±0.31 10.13±0.77 
4 2.12±0.22 2.33±0.33 2.25±0.35 14.67±0.79 15.24±0.62 11.95±0.77 
6 2.28±0.32 2.52±0.36 2.46±0.68 16.36±0.81 17.38±0.73 13.78±0.75 
8 2.37±0.33 2.71±0.35 2.66±0.77 17.17±0.83 18.57±0.77 15.6±0.81 
10 2.45±0.35 3.09±0.68 2.87±0.74 18.33±0.86 20.06±0.84 17.43±0.81 
12 2.7±0.35 3.47±0.77 3.08±0.79 19.27±0.88 21.87±0.89 19.26±0.83 
14 2.99±0.35 3.86±0.74 3.29±0.85 20.32±0.89 24.27±0.75 21.08±0.86 
18 3.31±0.68 4.24±0.79 3.5±0.77 23.4±0.75 26.66±0.8 22.91±0.83 
24 3.56±0.77 4.62±0.81 3.71±0.8 26.96±0.8 29.63±1.17 24.73±0.86 
48 4.15±0.74 5.38±0.82 4.63±0.83 32.86±1.17 36.73±1.24 28.28±0.88 
72 4.84±0.79 6.43±0.84 5.95±0.85 37.81±1.34 43.36±1.42 31.61±1.38 
 
 
 
Figure 4.3.2: Comparative swelling ratios of CMC-g-AA hydrogels using different 
concentrations of polymer 
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Table 4.3.3: Comparative swelling ratios of CMC-g-AA (CA) hydrogels using different 
concentrations of crosslinker (n=3) 
Time 
(Hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH7.4 
 CA7 CA8 CA9 CA7 CA8 CA9 
0 1 1 1 1 1 1 
0.5 1.32±0.23 1.25±0.22 1.17±0.22 4.1±0.24 4.07±0.21 2.52±0.2 
1 1.64±0.22 1.51±0.32 1.35±0.24 5.28±0.33 5.25±0.31 4.04±0.22 
1.5 1.96±0.32 1.77±0.43 1.53±0.32 6.15±0.34 5.96±0.62 5.56±0.31 
2 2.12±0.43 1.9±0.32 1.71±0.33 7.38±0.68 7.29±0.73 7.08±0.62 
3 2.27±0.32 2.03±0.35 1.96±0.35 9.92±0.77 9.52±0.31 7.83±0.73 
4 2.43±0.22 2.16±0.35 1.99±0.35 11.15±0.79 10.69±0.62 8.59±0.62 
6 2.59±0.32 2.29±0.68 2.14±0.68 13.13±0.81 12.36±0.73 9.35±0.73 
8 2.75±0.33 2.55±0.77 2.23±0.77 16.02±0.83 13.62±0.77 10.87±0.75 
10 3.07±0.35 2.81±0.74 2.41±0.74 17.77±0.86 15.42±0.84 12.39±0.75 
12 3.39±0.35 3.06±0.83 2.59±0.79 19.8±0.88 16.9±0.89 13.91±0.8 
14 3.71±0.77 3.32±0.86 2.77±0.85 21.59±0.89 18.67±0.75 15.43±1.17 
18 4.03±0.8 3.58±0.88 2.95±0.77 23.65±0.75 21.39±0.8 16.95±0.83 
24 4.35±0.83 4.09±0.8 3.13±0.8 25.77±0.8 23.49±1.17 18.47±1.19 
48 5±0.81 4.84±0.83 3.31±0.83 29.44±1.17 26.52±1.24 21.51±1.33 
72 5.79±0.81 4.86±0.85 3.49±0.85 32.35±1.34 28.61±1.42 23.74±1.38 
 
 
 
Figure 4.3.3: Comparative swelling ratios of CMC-g-AA hydrogels using different 
concentrations of crosslinker 
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4.3.2 Pulsatile behavior of hydrogels 
The pH-reliant swelling reversibility of CMC-g-AA hydrogel was scrutinized in buﬀered 
solutions. A distinctive result of the pulsatile reversible swelling of CMC-g-AA was 
shown in Figure 4.3.4, proved the hydrogel swelling reversibility upon alteration in pH. 
 
 
Figure 4.3.4: On-off switching behavior as reversible pulsatile swelling (pH 7.4) and 
deswelling (pH 1.2) of CMC-g-AA hydrogel 
 
4.3.3: Equilibrium water contents (EWC) and gel fraction 
To evaluate the equilibrium water content, dry hydrogels were immersed in deionized 
water at 37 ºC to achieve equilibrium swelling (72 Hrs). Table 4.3.4 indicated the effect of 
varying composition of hydrogels on equilibrium water contents and gel fraction.  Figure 
4.3.5 showed the gel fraction as a function of AA, CMC and N, N MBA contents in the 
hydrogels. 
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Table 4.3.4: Equilibrium water contents and gel fraction of CMC-g-AA hydrogels using 
different concentrations of AA, CMC and crosslinker 
Formulation 
code 
Contents 
w/w% 
EWC Gel fraction 
(%) 
Amount of Rabeprazole sodium 
loaded 
(mg per 0.4 g of dry hydrogel disc) 
By extraction By weight 
CA1 AA 10 0.96 80.24 74 75 
CA2 AA 15 0.97 92.92 90 91 
CA3 AA 20 0.98 93.07 98 99 
CA4 CMC 1 0.99 87.17 99 99 
CA5 CMC 1.5 0.98 94.87 102 100 
CA6 CMC 2 0.97 74.149 82 83 
CA7 MBA 0.4 0.97 86.84 85 86 
CA8 MBA 0.6 0.96 93.64 72 73 
CA9 MBA 0.8 0.96 96.78 59 60 
 
 
 
 
 
Figure 4.3.5: Gel fraction of CMC-g-AA hydrogel with different concentrations of AA, 
CMC and crosslinker 
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4.3.4 Instrumental analysis 
a) Scanning electron microscopy 
Scanning electron micrographs were attained from freeze-dried hydrogels depicted in 
Figure 4.3.6. 
 
 
Figure 4.3.6:  SEM images of lyophilized hydrogels (CMAX-g-MAA) at magnification of 
100 X and 200 X and 50µ, 100µ, 300µ, and 500µ scale bar respectively 
 
b) FTIR Analysis 
In this study, attenuated total reflectance (ATR) technology along with OPUS data 
collection software was employed to compute Fourier transform infrared (FTIR) spectra of 
all samples using Bruker FTIR (Tensor 27 series, Germany).FTIR spectrum of pure 
components (AA and CMC) and prepared formulations (CA) were recorded at 600 to 
4000 cm
-1
are shown in Figure 4.3.7. 
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Figure 4.3.7: FTIR spectra of CMC, acrylic acid (AA) and prepared hydrogel (CA) 
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c) Thermal analysis 
Thermal stability of the hydrogel (CA) and separate components(CMC and acrylic 
acid)were studied by TGA analyzer in the temperature range from 0 ºC to 600 ºC under 
inert nitrogen atmosphere. TGA curve of CMC (carboxymethyl cellulose), AA (acrylic 
acid) and CA (CMC-g-AA) hydrogel formulation depicted in Figure 4.3.8. DSC curves 
of CMC, AA and CA hydrogel formulation are described in Figure 4.3.9. 
 
Figure 4.3.8: TGA curves of AA, CMC and hydrogel formulation (CA) 
 
Figure 4.3.9: DSC curves of AA, CMC and hydrogel formulation (CA) 
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4.3.5: In vitro release kinetics of Rabeprazole sodium from CMC-g-AA 
hydrogel 
Cumulative percent drug release of CMC-g-AA has been evaluated at acidic and basic pH 
to estimate pH dependent release of rabeprazole sodium. Drug release was also influenced 
by individual constituents of hydrogels and cross linking density of hydrogels. Drug 
release from CMC-g-AA by using different concentrations of acrylic acid, CMC and 
MBA has been expressed in Table 4.3.5, 4.3.6 and 4.3.7 respectively. 
Table 4.3.5: Effect of acrylic acid concentration on cumulative percent drug release of 
Rabeprazole sodium 
Time 
(hr) 
CA1 pH 
1.2 
CA2 pH 
1.2 
CA3 pH 
1.2 
CA1 pH8 CA2 pH 8 CA3 pH 8 
0.5 1.84±0.03 0.89±0.05 1±0.08 8.78±1.12 11.33±1.19 12.25±1.28  
1 3.05±0.21 1.4±0.31 1.55±0.21 13.51±1.34 16.67±1.28 17.83±1.39  
1.5 3.85±0.34 1.77±0.26 2.09±0.34 17.97±1.56 21.93±1.56 22.92±1.68  
2 5.24±0.45 2.14±0.28 2.57±0.39 22.2±1.78 27.13±2.98 26.82±1.68  
3 5.83±0.34 2.51±0.29 3.05±0.43 28±1.98 32.28±2.78 31.61±1.99  
4 6.59±0.27 2.87±0.51 3.53±0.53 31.55±1.87 37.38±2.66 36.01±1.67  
6 7.16±0.56 3.23±0.42 4±0.20 35.89±1.67 42.42±2.33 41.57±1.78  
8 7.72±0.45 3.58±0.76 4.46±0.52 41.4±1.59 47.41±2.77 46.02±2.56  
12 8.46±0.43 3.93±0.45 4.97±0.61 44.07±1.87 51.98±2.76 52.63±3.32  
16 9.2±0.09 4.28±0.56 5.42±0.41 48.08±1.67 56.86±2.34 61.18±3.24  
20 9.93±0.45 4.62±0.45 5.87±0.43 51.3±1.59 61.87±2.76 67.56±3.07  
24 10.66±0.41 4.96±0.56 6.27±0.09 57.72±1.89 70.19±2.34 77.69±3.87  
  
 
Figure 4.3.10:Effect of acrylic acid concentration on cumulative percent drug release of 
Rabeprazole sodium 
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Table 4.3.6: Effect of CMC concentration on cumulative percent drug release of 
Rabeprazole sodium 
Time 
(hr) 
CA4 
pH 1.2 
CA5  
pH 1.2 
CA6  
pH 1.2 
CA4  
pH8 
CA5  
pH 8 
CA6  
pH 8 
0.5 1.68±0.18 1.72±0.15 0.31±0.13 12.92±1.08 14.42±1.21 8.82±1.14 
1 2.29±0.21 2.74±0.31 1.15±0.21 16.66±1.34 18.45±1.28 14.18±1.34 
1.5 2.84±0.34 3.8±0.26 1.63±0.34 19.53±1.89 23.37±1.56 17.41±1.67 
2 3.43±0.39 4.22±0.28 2.1±0.28 23.25±1.67 28.16±2.98 20.67±1.78 
3 3.91±0.34 4.68±0.29 2.57±0.29 27.42±1.78 33.26±3.32 24.35±2.56 
4 4.39±0.45 5.14±0.51 3.03±0.51 32.75±1.78 37.99±3.24 27.76±1.78 
6 4.87±0.28 5.97±0.42 3.49±0.42 37.89±2.56 43.83±3.87 30.85±2.56 
8 5.34±0.29 6.66±0.76 3.9±0.45 43.84±2.77 48.18±2.77 35.74±1.87 
12 5.8±0.51 7.28±0.45 4.31±0.43 54.71±2.76 56.27±2.76 41.15±1.87 
16 6.26±0.42 7.91±0.56 4.75±0.45 61.43±2.34 62.25±2.34 49.33±1.78 
20 6.72±0.53 8.57±0.78 5.24±0.56 69.23±3.46 70.19±3.01 55.41±2.56 
24 7.26±0.64 9.22±0.67 5.71±0.78 78.36±3.54 80.75±2.99 59.01±2.77 
 
 
 
 
Figure 4.3.11:Effect of CMC concentration on cumulative percent drug release of 
Rabeprazole sodium 
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Table 4.3.7: Effect of crosslinker concentration on cumulative percent drug release of 
Rabeprazole sodium 
Time 
(hr) 
CA7  
pH 1.2 
CA8  
pH 1.2 
CA9  
pH 1.2 
CA7  
pH8 
CA8 
pH 8 
CA9  
pH 8 
0.5 1.11±0.28 1.11±0.21 0.49±0.19 8.27±1.11 7.7±1.28 7.15±1.02 
1 1.48±0.21 1.53±0.31 0.82±0.21 13.32±1.34 13.15±1.18 11.16±1.24 
1.5 1.32±0.34 1.73±0.26 1.14±0.34 18.31±1.29 18.39±1.46 15.12±1.47 
2 2.09±0.39 2±0.28 1.3±0.28 23.15±1.72 23.19±2.38 19.03±1.68 
3 2.71±0.21 2.26±0.29 1.54±0.29 28.19±1.55 27.53±3.32 23.95±2.36 
4 3.01±0.31 2.52±0.51 1.77±0.51 32.98±1.78 31.96±3.14 27.78±1.27 
6 3.35±0.26 2.78±0.42 2±0.42 37.47±2.56 36.15±3.37 32.52±1.57 
8 3.64±0.28 3.17±0.76 2.23±0.21 42.01±2.57 40.42±2.47 35.56±1.97 
12 3.93±0.51 3.42±0.19 2.46±0.31 46.5±2.86 44.64±2.86 39.41±1.93 
16 4.21±0.42 3.61±0.21 2.68±0.26 51.04±2.84 48.95±2.74 44.34±1.58 
20 4.54±0.67 3.79±0.34 2.9±0.28 55.53±2.94 53.85±3.11 47.26±2.65 
24 4.82±0.24 3.97±0.28 3.12±0.48 63.17±3.04 58.01±2.69 50.68±2.45 
 
 
 
 
Figure 4.3.12: Effect of crosslinker concentration on cumulative percent drug release of 
Rabeprazole sodium 
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Table 4.3.8: Kinetic parameters of Rabeprazole sodium release 
Formulation 
code 
Higuchi First 
order 
Zero 
order 
Korsmayer-peppas 
R
2
 R
2
 R
2
 R
2
 n 
CA1 0.991 0.381 0.945 0.990 0.60 
CA2 0.971 0.354 0.887 0.988 0.53 
CA3 0.959 0.365 0.860 0.986 0.46 
CA4 0.999 0.432 0.964 0.997 0.54 
CA5 0.988 0.373 0.929 0.990 0.55 
CA6 0.994 0.412 0.947 0.991 0.58 
CA7 0.970 0.382 0.884 0.989 0.54 
CA8 0.963 0.370 0.867 0.994 0.41 
CA9 0.965 0.394 0.865 0.993 0.33 
 
4.4 Characterization of CMC-g-MAA hydrogels 
 
4.4.1 Swelling studies at pH1.2 and pH 7.4 
Equilibrium swelling of CMC-g-MAA graft copolymer was determined by swelling the 
dried hydrogels discs in acidic and basic pH buffer solution at 37ºC.Formulations were 
assigned codes (CMA1-CMA3), (CMA4-CMA6) and (CMA7-CMA9) for varying 
concentration of methacrylic acid, CMC and crosslinker respectively. Effect of varying 
concentration of methacrylic acid on swelling ratio (q), CMA1 (1 to 6.684), CMA2 (1 to 
4.182) and CMA3 (1 to 3.667) in pH 1.2 and CMA1 (1 to 30.040), CMA2 (1 to 23.516) 
and CMA3 (1 to 20.387) in 7.4 buffer solutions at 37 ºC has been given in Table 4.4.1 and 
graphically presented in Figure 4.4.1. Comparative swelling ratio (q) of hydrogels by 
using different concentrations of CMC, CMA4 (1 to 6.204), CMA5 (1 to 7.659) and 
CMA6 (1 to 10.813) at pH 1.2 and CMA4 (1 to 26.451), CMA5 (1 to 24.890) and CMA6 
(1 to 24.493) at pH 7.4 were given in Table 4.4.2. Table 4.4.3 showed effect of crosslinker 
contents on swelling ratio of hydrogels CMA7 (1 to 5.386), CMA8 (1 to 3.089) and CMA9 
(1 to 2.898) at pH 1.2 and CMA7 (1 to 18.960), CMA8 (1 to 13.664) and CMA9 (1 to 10.993) 
at pH 7.4. 
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Table 4.4.1: Comparative swelling ratios of CMC-g-MAA (CMA) hydrogels using 
different concentrations of MAA (n=3) 
Time 
(Hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 7.4 
 CMA1 CMA2 CMA 3 CMA 1 CMA 2 CMA 3 
0 1 1 1 1 1 1 
0.5 1.37±0.23 1.21±0.19 1.19±0.22 3.07±0.24 2.61±0.21 2.38±0.2 
1 1.73±0.22 1.42±0.22 1.38±0.24 5.14±0.33 4.21±0.31 3.77±0.22 
1.5 2.1±0.32 1.64±0.32 1.57±0.32 7.22±0.34 5.82±0.62 5.15±0.31 
2 2.46±0.43 1.85±0.33 1.76±0.33 9.29±0.68 7.43±0.73 6.53±0.62 
3 2.83±0.32 2.06±0.35 1.95±0.35 11.36±0.77 9.03±0.77 7.91±0.73 
4 3.19±0.22 2.27±0.35 2.14±0.35 13.43±0.79 10.64±0.75 9.3±0.77 
6 3.56±0.32 2.49±0.36 2.33±0.68 15.51±0.81 12.25±0.81 10.68±0.75 
8 3.92±0.33 2.7±0.54 2.52±0.77 17.58±0.83 13.85±0.82 12.06±0.81 
10 4.29±0.35 2.91±0.85 2.7±0.74 19.65±0.86 15.46±0.84 13.44±0.82 
12 4.65±0.35 3.12±0.77 2.89±0.79 21.72±0.88 17.06±0.89 14.83±0.84 
14 5.02±0.36 3.33±0.8 3.08±0.85 23.79±0.79 18.67±0.75 16.21±0.77 
18 5.38±0.34 3.55±0.83 3.27±0.77 25.87±0.85 20.28±0.8 17.59±0.83 
24 5.75±0.34 3.76±0.81 3.46±0.8 27.94±0.92 21.88±1.17 18.97±1.19 
48 6.11±0.35 3.97±0.82 3.65±0.83 30.01±1.01 23.49±1.34 20.36±1.44 
72 6.68±0.35 4.18±0.84 3.67±0.85 30.04±1.44 23.52±1.52 20.39±1.48 
 
 
Figure 4.4.1: Comparative swelling ratios of CMC-g-MAA hydrogels using different 
concentrations of MAA 
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Table 4.4.2: Comparative swelling ratios of CMC-g-MAA hydrogels using different 
concentrations of CMC 
Time 
(Hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 7.4 
 CMA4 CMA 5 CMA 6 CMA 4 CMA 5 CMA 6 
0 1 1 1 1 1 1 
0.5 1.37±0.23 1.37±0.19 1.65±0.22 2.78±0.24 2.71±0.21 2.68±0.2 
1 1.74±0.22 1.74±0.22 2.31±0.24 4.6±0.33 4.41±0.31 4.35±0.22 
1.5 2.11±0.32 2.11±0.32 2.96±0.32 6.42±0.34 6.12±0.62 6.03±0.31 
2 2.48±0.43 2.47±0.22 3.62±0.33 8.24±0.68 7.82±0.73 7.7±0.62 
3 2.85±0.32 2.84±0.32 4.27±0.35 10.06±0.77 9.53±0.31 9.38±0.73 
4 3.22±0.22 3.21±0.33 4.93±0.35 11.88±0.79 11.24±0.62 11.05±0.77 
6 3.59±0.32 3.58±0.36 5.58±0.68 13.7±0.81 12.94±0.73 12.73±0.75 
8 3.96±0.33 3.95±0.54 6.23±0.77 15.52±0.83 14.65±0.77 14.4±0.81 
10 4.32±0.35 4.32±0.85 6.89±0.74 17.34±0.86 16.35±0.84 16.08±0.81 
12 4.69±0.35 4.68±0.77 7.54±0.79 19.16±0.88 18.06±0.89 17.76±0.83 
14 5.06±0.77 5.05±0.8 8.2±0.85 20.98±0.89 19.77±0.75 19.43±0.86 
18 5.43±0.8 5.42±0.83 8.85±0.77 22.79±0.75 21.47±0.8 21.11±0.83 
24 5.8±0.83 5.79±0.81 9.51±0.8 24.61±0.8 23.18±1.17 22.78±1.19 
48 6.17±0.81 7.46±0.82 10.16±0.83 26.43±1.17 24.88±1.24 24.46±1.33 
72 6.2±0.81 7.66±0.84 10.81±0.85 26.45±1.34 24.89±1.42 24.49±1.38 
 
 
Figure 4.4.2: Comparative swelling ratios of CMC-g-MAA hydrogels using different 
concentrations of CMC 
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Table 4.4.3:Comparative swelling ratios of CMC-g-MAA hydrogels using different 
concentrations of crosslinker (n=3)  
Time 
(Hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 7.4 
 CMA7 CMA 8 CMA 9 CMA 7 CMA 8 CMA 9 
0 1 1 1 1 1 1 
0.5 1.31±0.23 1.15±0.19 1.2±0.22 3.25±0.24 1.93±0.21 1.73±0.2 
1 1.63±0.22 1.3±0.22 1.33±0.24 4.46±0.33 2.82±0.31 2.44±0.22 
1.5 1.94±0.32 1.44±0.32 1.46±0.32 5.66±0.34 3.71±0.62 3.15±0.31 
2 2.25±0.43 1.59±0.33 1.59±0.33 6.87±0.68 4.6±0.73 3.86±0.62 
3 2.57±0.32 1.74±0.35 1.72±0.35 8.07±0.77 5.49±0.77 4.57±0.73 
4 2.88±0.22 1.89±0.35 1.85±0.35 9.28±0.79 6.38±0.75 5.28±0.77 
6 3.19±0.32 2.04±0.36 1.97±0.68 10.48±0.81 7.27±0.73 6±0.75 
8 3.51±0.33 2.18±0.54 2.1±0.77 11.69±0.83 8.16±0.77 6.71±0.81 
10 3.82±0.35 2.33±0.85 2.23±0.77 12.9±0.86 9.05±0.75 7.42±0.82 
12 4.13±0.35 2.48±0.77 2.36±0.68 14.1±0.88 9.94±0.89 8.13±0.84 
14 4.45±0.36 2.63±0.68 2.49±0.65 15.31±0.79 10.83±0.75 8.84±0.77 
18 4.76±0.34 2.78±0.77 2.62±0.77 16.51±0.85 11.72±0.8 9.55±0.89 
24 5.07±0.34 2.92±0.74 2.75±0.8 17.72±0.92 12.61±1.17 10.26±0.75 
48 5.39±0.35 3.07±0.79 2.87±0.73 18.92±1.01 13.5±1.34 10.97±0.8 
72 5.39±0.35 3.09±0.75 2.9±0.75 18.96±1.44 13.66±1.32 10.99±1.18 
 
 
Figure 4.4.3: Comparative swelling ratios of CMC-g-MAA hydrogels using different 
concentrations of MBA (crosslinker) 
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4.4.3: Pulsatile behavior of hydrogel 
Transition of the swelling/de-swelling behavior was proved by recurrently cycling the 
CMC-g-MAA hydrogel (CMA6) between buffers at pH 1.2 and pH 7.4. As shown in 
Figure 4.4.4, the hydrogel quickly constricted when placed in a pH 1.2 buffer but slowly 
resumed to nearly the original swollen size at pH 7.4. 
 
 
Figure 4.4.4: On-off switching behavior as reversible pulsatile swelling (pH 7.4) and 
deswelling (pH 1.2) of CMC-g-MAA hydrogel 
4.4.3: Equilibrium water contents and gel fraction 
Water absorbed by CMC-g-MAA copolymeric hydrogels was quantitatively signified by 
the equilibrium water content (EWC).  EWC values of the hydrogels were calculated and 
tabulated in Table 4.4.4. By extraction of prepared hydrogels insoluble part (gelled part) 
was collected and washed with water to remove unreacted contents. Calculated gel 
fraction of hydrogel was summarized in Table 4.4.4. 
 
 
0
5
10
15
20
25
30
0 10 20 30 40 50 60 70 80
S
w
el
li
n
g
/d
es
w
el
li
n
g
 
Time (min) 
pH 7.4 
pH 1.2 
 96 
 
Table 4.4.4: Equilibrium water contents and gel fraction of CMC-g-MAA hydrogels using 
different concentrations of MAA, CMC and crosslinker 
Formulation 
code 
Contents 
w/w % 
EWC Gel fraction 
(%) 
Amount of Rabeprazole 
sodium loaded 
(mg per 0.4 g of dry disk) 
By extraction By weight 
CMA1 MAA 20 0.96 67.41 48 49.3 
CMA 2 MAA 30 0.93 88.45 45 45.9 
CMA 3 MAA 35 0.90 92.33 41 41.7 
CMA 4 CMC 1 0.95 89.54 52 52.8 
CMA 5 CMC 1.5 0.96 92.65 59 60.2 
CMA 6 CMC 2 0.97 74.14 66 67.3 
CMA 7 MBA 0.45 0.89 84.64 39 39.4 
CMA 8 MBA 0.65 0.86 86.38 37 38 
CMA 9 MBA 0.85 0.66 93.75 34 35 
 
 
 
 
Figure 4.4.5:Gel fraction of CMC-g-MAA hydrogel with different concentrations of 
MAA, CMC and crosslinker 
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4.4.4: Instrumental analysis 
a) Scanning electron microscopy 
SEM images deliver evidence about pore size and geometry and 
homogeneity/heterogeneity of graft copolymeric network. SEM images of CMC-g-MAA 
hydrogels were presented in Figure 4.4.6. 
 
 
Figure 4.4.6: SEM images of lyophilized hydrogels (CMC-g-MAA) at magnification 
of 100 X and 200 X and 10µ, 30µ, 300µ, and 500µ scale bar respectively 
 
b) FTIR analysis 
The chemical structures for new CMC-g-MAA hydrogels and their individual components 
were confirmed by FTIR analysis. FTIR spectra of CMC (carboxymethyle cellulose), 
MAA (methacrylic acid) and CMA (formulation) shown in Figure 4.4.7 confirmed that 
modifications of CMC with methacrylic acid by grafting. 
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Figure 4.4.7: FTIR spectra of CMC, MAA, and prepared hydrogel (CMA) 
 
 99 
 
c) Thermal analysis 
Thermal stability of the copolymer (CMA) and individual constituents CMC and 
methacrylic acid were studied by TGA analyzer in the temperature range from 0 ºC to 600 
ºC under inert nitrogen atmosphere. DTG data was summarized in Table 4.4.5. TGA curve 
of CMC (carboxymethyl cellulose), MAA (methacrylic acid) and CMA (CMC-g-MAA) 
hydrogel formulation depicted in Figure 4.4.8. DSC curve of CMC, MAA and CMA 
hydrogel formulation described in Figure 4.4.9. 
Table 4.4.5: DTG data of methacrylic acid (MAA), CMC and CMC-g-MAA hydrogel 
(CMA) 
 
 
Figure 4.4.8:TGA curves of methacrylic acid (MAA), CMC and CMC-g-MAA(CMA) 
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Figure 4.4.9: DSC curves of methacrylic acid (MAA), CMC and CMC-g-MAA 
4.4.5:In vitro release kinetics of Rabeprazole sodium from CMC-g-MAA 
hydrogel 
Release of rabeprazole sodium from CMC-g-MAA was carried out at acidic and basic pH 
to evaluate the pH sensitive release. Effect of methacrylic acid on cumulative release of 
rabeprazole sodium was described in Table 4.4.6. Effect of CMC and crosslinker (MBA) 
on drug release was demonstrated in Table 4.4.7 and 4.4.8 respectively. Release kinetics 
of drug can be determined by fitting in vitro release data into mathematical release models 
and calculate diffusion exponent ‘n’ to find out the release pattern of drug from hydrogel 
given in Table 4.4.9. 
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Table 4.4.6: Effect of methacrylic acid concentration on cumulative percent drug release 
of Rabeprazole sodium from CMA hydrogel 
Time (hr) 
 
CMA1 
pH1.2 
CMA2 
pH1.2 
CMA3 
pH1.2 
CMA1 
pH 8 
CMA2 
pH 8 
CMA3 
pH 8 
0.5 1.67±0.43 0.93±0.24 1.26±0.76 4.66±1.23 4.24±1.11 4.68±1.31 
1 2.15±0.56 1.32±0.45 1.68±0.54 7.87±1.98 5.56±1.87 6.64±1.45 
1.5 2.61±0.34 1.71±0.33 2.09±0.76 10.93±1.31 8.03±1.67 10.71±1.76 
2 3.08±0.21 2.10±0.34 2.49±0.56 14.89±1.45 10.48±1.98 13.68±2.00 
3 4.12±0.11 2.74±0.92 2.89±0.98 18.82±1.76 14.08±2.01 20.46±1.78 
4 5.15±0.76 3.37±0.13 3.29±0.45 24.23±2.00 18.54±2.47 24.96±2.56 
6 6.06±0.54 4.13±0.35 3.68±0.56 31.67±2.98 26.44±3.91 31.30±3.09 
8 6.95±0.76 4.88±0.49 4.07±0.34 36.62±2.65 32.23±2.98 37.69±2.88 
12 8.07±0.88 5.62±0.13 4.46±0.21 44.49±3.23 39.59±3.01 45.06±2.66 
16 9.29±0.34 6.36±0.28 4.84±0.23 56.18±2.88 48.66±3.41 52.56±2.76 
20 10.27±0.12 7.08±0.99 5.21±0.76 64.01±2.66 57.65±2.99 59.47±3.02 
24 11.69±0.23 7.80±0.23 5.59±0.23 71.85±2.76 66.78±3.11 63.11±3.41 
 
 
 
Figure 4.4.10:Effect of methacrylic acid concentration on cumulative percent drug release 
of Rabeprazole sodium 
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Table 4.4.7: Effect of CMC concentration on cumulative percent drug release of 
Rabeprazole sodium from hydrogel CMA 
Time (hr) CMA 4 
pH1.2 
CMA5 
pH1.2 
CMA 6 
pH1.2 
CMA4 
pH 8 
CMA5 
pH 8 
CMA6 
pH 8 
0.5 1.84±0.35 1.91±0.27 1.41±0.67 5.31±1.43 5.48±1.35 5.42±1.46 
1 2.14±0.73 2.24±0.39 1.93±0.29 7.24±1.49 7.47±1.67 8.01±1.25 
1.5 2.44±0.21 2.73±0.33 2.58±0.35 10.05±1.66 9.66±1.67 9.97±1.76 
2 2.73±0.19 3.21±0.41 3.09±0.73 12.83±2.64 11.83±2.88 11.90±2.52 
3 3.52±0.34 3.92±0.77 3.65±0.21 19.18±3.26 17.16±2.85 16.44±2.78 
4 4.60±0.11 4.80±0.29 4.51±0.19 26.38±3.86 21.23±1.35 20.72±2.56 
6 5.67±0.83 5.91±0.34 5.21±0.23 33.32±2.88 30.81±3.12 29.86±3.09 
8 6.73±0.68 7.170.73 5.9±0.12 40.77±2.85 37.92±2.68 39.00±2.88 
12 7.78±0.76 8.49±0.21 6.59±0.73 50.11±1.35 47.33±3.21 46.90±2.66 
16 8.82±0.41 9.80±0.19 7.27±0.21 57.90±1.67 56.66±3.51 55.14±2.88 
20 9.94±0.23 11.50±0.76 8.08±0.19 65.21±1.67 66.83±2.49 63.36±2.85 
24 11.34±0.31 13.80±0.87 9.03±0.34 73.59±1.98 75.88±3.71 75.01±1.35 
 
 
 
Figure 4.4.11: Effect of CMC concentration on cumulative percent drug release of 
Rabeprazole sodium 
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Table 4.4.8: Effect of crosslinker concentration on cumulative percent drug release of 
Rabeprazole sodium 
Time 
(hr) 
CMA7 
pH1.2 
CMA8pH1.2 CMA9 
pH1.2 
CMA7 pH 
8 
CMA8 pH 
8 
CMA9 
pH 8 
0.5 1.51±0.67 1.06±0.37 0.87±0.34 5.40±1.56 3.46±1.25 3.75±1.43 
1 1.88±0.29 1.32±0.36 0.87±0.69 10.16±1.55 8.05±1.37 7.91±1.49 
1.5 2.25±0.36 1.71±0.69 1.29±0.24 12.49±1.84 11.03±1.47 10.46±1.66 
2 2.61±0.36 2.10±0.68 1.71±0.36 14.67±2.78 13.97±1.98 12.98±2.64 
3 3.34±0.34 2.61±0.76 2.13±0.48 18.18±2.78 18.01±2.78 16.88±3.26 
4 4.06±0.34 3.11±0.47 2.54±0.76 22.76±3.86 21.74±2.67 20.47±2.98 
6 4.78±0.83 3.61±0.46 2.95±0.23 28.52±3.88 26.96±3.62 25.42±3.09 
8 5.73±0.41 4.11±0.43 3.35±0.54 36.66±3.85 36.73±2.94 31.19±2.88 
12 6.55±0.77 4.60±0.48 3.75±0.34 43.51±3.93 42.68±3.21 40.87±2.88 
16 7.48±0.45 5.08±0.43 4.15±0.69 50.76±3.28 49.51±3.71 47.44±3.76 
20 8.28±0.37 5.69±0.76 4.54±0.24 57.93±2.69 58.19±2.79 55.58±3.02 
24 8.83±0.91 6.29±0.83 4.93±0.78 67.41±3.89 64.75±3.91 61.47±3.91 
 
 
 
Figure 4.4.12: Effect of crosslinker concentration on cumulative percent drug release of 
Rabeprazole sodium 
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Table 4.4.9: Release kinetic parameters of Rabeprazole sodium from hydrogel CMA 
Formulation 
code 
Higuchi First 
order 
Zero 
order 
Korsmayer-peppas 
R
2
 R
2
 R
2
 R
2
 n 
CMA1 0.997 0.567 0.971 0.995 0.604 
CMA 2 0.992 0.639 0.982 0.993 0.783 
CMA 3 0.994 0.541 0.936 0.996 0.439 
CMA 4 0.996 0.572 0.954 0.988 0.598 
CMA 5 0.993 0.613 0.980 0.994 0.718 
CMA 6 0.990 0.618 0.987 0.997 0.774 
CMA 7 0.996 0.540 0.971 0.994 0.711 
CMA 8 0.997 0.560 0.962 0.992 0.654 
CMA 9 0.998 0.575 0.974 0.992 0.631 
 
4.5 Characterization of PEG-g-MAA hydrogels 
4.5.1 Swelling studies at pH1.2 and pH 7.4 
The reliance of the swelling aptitude of PEG-g-MAA hydrogels on PEG and methacrylic 
acid concentration was evaluated by preparation of hydrogels with varying contents of 
PEG and methacrylic acid at physiological temperature. Formulations were assigned codes 
(PMA1-PMA4) and (PMA5-PMA7) for varying concentration of PEG and methacrylic 
acid respectively. Effect of varying concentration of PEG on swelling ratio (q), PMA1 (1 
to 4.854), PMA2 (1 to 4.438) and PMA3 (1 to 3.038) and PMA4 (1 to 2.692) in pH 1.2 
and PMA1 (1 to 11.464), PMA2 (1 to 13.766), PMA3 (1 to 16.422) and PMA4 (1 
to17.443) in 7.4 buffer solutions at 37 ºC has been given in Table 4.5.1 and graphically 
presented in Figure 4.5.1. Comparative swelling ratio (q) of hydrogels by using different 
concentrations of methacrylic acid, PMA5 (1 to 4.867), PMA6 (1 to 3.515) and PMA7 (1 
to 2.212) at pH 1.2 and PMA5 (1 to 17.039), PMA6 (1 to 12.468) and PMA7 (1 to 10.765) 
at pH 7.4 were given in Table 4.5.2.  
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Table 4.5.1: Comparative swelling ratios of PEG-g-MAA hydrogels using different 
concentrations of PEG 
Time 
(Hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 7.4 
 PMA1 PMA 2 PMA 3 PMA4 PMA 1 PMA 2 PMA 3 PMA4 
0 1 1 1 1 1 1 1 1 
0.5 1.23±0.23 1.2±0.19 1.12±0.22 1.1±0.24 1.62±0.21 1.75±0.2 1.91±0.21 1.97±0.23 
1 1.45±0.22 1.4±0.22 1.24±0.32 1.2±0.33 2.23±0.31 2.5±0.22 2.81±0.32 2.93±0.83 
1.5 1.68±0.32 1.61±0.32 1.36±0.43 1.3±0.34 2.85±0.62 3.25±0.34 3.72±0.86 3.9±0.86 
2 1.91±0.43 1.81±0.22 1.48±0.32 1.4±0.68 3.46±0.73 4±0.68 4.63±0.83 4.87±0.88 
3 2.13±0.32 2.01±0.32 1.6±0.35 1.5±0.77 4.08±0.31 4.76±0.77 5.54±0.86 5.84±1.38 
4 2.36±0.22 2.21±0.33 1.72±0.35 1.6±0.79 4.69±0.62 5.51±0.77 6.44±0.88 6.8±1.44 
6 2.59±0.32 2.42±0.36 1.84±0.68 1.7±0.81 5.31±0.73 6.26±0.75 7.35±1.38 7.77±1.17 
8 2.81±0.33 2.62±0.35 1.96±0.77 1.8±0.83 5.92±0.77 7.01±0.81 8.26±1.17 8.74±1.44 
10 3.04±0.35 2.82±0.68 2.08±0.74 1.9±0.86 6.54±0.84 7.76±0.81 9.16±1.24 9.71±1.41 
12 3.27±0.35 3.02±0.77 2.2±0.79 2±0.88 7.16±0.89 8.51±0.83 10.07±1.42 10.67±1.48 
14 3.49±0.35 3.22±0.74 2.32±0.85 2.1±0.89 7.77±0.75 9.26±0.86 10.98±1.41 11.64±0.8 
18 3.72±0.68 3.43±0.79 2.44±0.77 2.19±0.75 8.39±0.8 10.01±0.83 11.89±1.34 12.61±1.17 
24 3.95±0.77 3.63±0.81 2.56±0.8 2.29±0.8 9±1.17 10.76±0.86 12.79±1.46 13.57±1.24 
48 4.4±0.74 4.03±0.82 2.8±0.83 2.49±1.17 10.23±1.24 12.26±0.88 14.61±1.26 15.51±1.42 
72 4.85±0.79 4.44±0.84 3.04±0.85 2.69±1.34 11.46±1.42 13.77±1.38 16.42±1.39 17.44±2.17 
 
 
Figure 4.5.1: Comparative swelling ratio of PEG-g-MAA hydrogels using different 
concentrations of PEG 
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Table 4.5.2: Comparative swelling ratios of PEG-g-MAA (PMA) hydrogels using different 
concentrations of MAA 
Time 
(Hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 7.4 
 PMA5 PMA6 PMA7 PMA5 PMA6 PMA7 
0 1 1 1 1 1 1 
0.5 1.23±0.23 1.15±0.22 1.07±0.22 1.94±0.24 1.68±0.21 1.57±0.2 
1 1.46±0.22 1.3±0.32 1.14±0.24 2.89±0.33 2.35±0.31 2.15±0.22 
1.5 1.68±0.32 1.44±0.43 1.21±0.32 3.83±0.34 3.02±0.62 2.72±0.31 
2 1.91±0.43 1.59±0.32 1.29±0.33 4.77±0.68 3.7±0.73 3.3±0.62 
3 2.14±0.32 1.74±0.35 1.36±0.35 5.72±0.77 4.37±0.31 3.87±0.73 
4 2.37±0.22 1.89±0.35 1.43±0.35 6.66±0.79 5.05±0.62 4.45±0.62 
6 2.59±0.32 2.04±0.68 1.5±0.68 7.6±0.81 5.72±0.73 5.02±0.73 
8 2.82±0.33 2.18±0.77 1.57±0.77 8.55±0.83 6.4±0.77 5.6±0.75 
10 3.05±0.35 2.33±0.74 1.64±0.74 9.49±0.86 7.07±0.84 6.17±0.75 
12 3.28±0.35 2.48±0.83 1.71±0.79 10.44±0.88 7.75±0.89 6.74±0.8 
14 3.5±0.77 2.63±0.86 1.78±0.85 11.38±0.89 8.42±0.75 7.32±1.17 
18 3.73±0.8 2.78±0.88 1.86±0.77 12.32±0.75 9.1±0.8 7.89±0.83 
24 3.96±0.83 2.92±0.8 1.93±0.8 13.27±0.8 9.77±1.17 8.47±1.19 
48 4.41±0.81 3.22±0.83 2.07±0.83 15.15±1.17 11.12±1.24 9.62±1.33 
72 4.87±0.81 3.52±0.85 2.21±0.85 17.04±1.34 12.47±1.42 10.77±1.38 
 
 
 
Figure 4.5.2: Comparative swelling ratios of PMA-g-MAA hydrogels using different 
concentrations of MAA  
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4.5.2: Pulsatile behavior of hydrogel 
PEG-g-MAA hydrogels also showed reproducible swelling-deswelling cycles at pH levels 
of 1.2 and 7.4, as demonstrated in Figure 4.5.3. At pH 7.4, the hydrogel swelled due to 
anion-anion repulsive electrostatic forces, while, at pH 1.2, it shrank within a few minutes 
due to the protonation of the carboxylate groups of methacrylic acid. Hydrogel 
formulation exhibited maximum swelling ratio (q) was selected for evaluation of 
reproducible swelling behavior. 
 
 
 
Figure 4.5.3: On-off switching behavior as reversible pulsatile swelling (pH 7.4) and 
deswelling (pH 1.2) of PEG-g-MAA hydrogel 
 
4.5.3: Equilibrium water contents and gel fraction of hydrogels 
Hydrogels were prepared in water and swollen to equilibrium in deionized water. 
Equilibrium water contents values were used for the determination of diffusional behavior 
of water. It was found that swelling of hydrogels dwindled with increasing methacrylic 
acid, and it increased with the increasing content of PEG in hydrogels as expressed in 
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Table 4.5.3: Equilibrium water contents gel fraction and amount of drug loaded of PEG-
g-MAA hydrogels using different concentrations of PEG and MAA 
Formulation 
code 
Contents 
w/w % 
EWC Gel fraction 
(%) 
Amount of Rabeprazole 
sodium loaded 
(mg per 0.4 g of dry disk) 
By extraction By weight 
PMA1 PEG 5 0.89 51.63 80 80 
PMA2 PEG10 0.93 63.07 94.6 95 
PMA3 PEG15 0.94 80.24 94 94.8 
PMA4 PEG20 0.95 87.17 97 98 
PMA5 MAA 20 0.95 63.88 75 76 
PMA6 MAA 30 0.93 76.42 55 55.9 
PMA7 MAA 35 0.91 82.68 47 47 
 
 
 
 
Figure 4.5.4: Gel fraction of PEG-g-MAA hydrogel with different concentrations of 
methacrylic acid and PEG 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
PEG 5
(%w/w)
PEG 10
(%w/w)
PEG 15
(%w/w)
PEG 20
(%w/w)
MAA 20
(%w/w)
MAA 30
(%w/w)
MAA 35
(%w/w)
G
el
 F
ra
ct
io
n
 
 
 
 
Formulation contents % 
 109 
 
4.5.4 Instrumental analysis 
a) Scanning electron microscopy 
Micro porous structure of hydrogel dictate the drug release pattern. Surface morphology of 
hydrogel was examined by scanning electron microscopy. Microphotographs were 
presented in Figure 4.5.5. 
 
 
 
Figure 4.5.5: SEM images of lyophilized hydrogels (PEG-g-MAA) at magnification of 
100 X and 200 X and 50µ, 100µ, 300µ, and 500µ scale bar respectively 
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b)FTIR spectrum analysis 
FTIR spectrum analysis technique was used to evaluate the chemical structural changes in 
graft copolymer. Figure 4.5.5 exhibited the FTIR spectra of methacrylic acid(MAA), PEG 
(polyethylene glycol 600) and PMA hydrogel formulation.  
 
Figure 4.5.6:FTIR spectra of PEG, methacrylic acid (MAA) and prepared formulation 
(PMA) 
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c) Thermal analysis 
 
The thermal properties of prepared hydrogel (PMA), and individual components (PEG and 
MAA) were studied by means of TGA and DSC analysis shown in Figure 4.5.6 and 4.5.7. 
 
Figure 4.5.7: TGA curves of PEG, MAA, and PMA (PEG-g-MAA) hydrogel formulation 
 
 
Figure 4.5.8: DSC curves of PEG, MAA, and PMA (PEG-g-MAA) hydrogel formulation 
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4.5.5: In vitro release kinetics of Rabeprazole sodium from PEG-g-MAA 
hydrogel 
To evaluate the pH sensitive rabeprazole sodium release for controlled drug delivery from 
PEG-g-MAA hydrogel, in vitro drug release was estimated at acidic and basic pH at 37 
ºC. Effect of hydrogel composition on cumulative percent drug release was examined and 
summarized in Table 4.5.4 and 4.5.5.  
Table 4.5.4: Effect of PEG concentration on cumulative percent drug release of 
Rabeprazole sodium from hydrogel  
 
 
Figure 4.5.9: Effect of PEG concentration on cumulative percent drug release of 
Rabeprazole sodium from hydrogel PMA 
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Time 
(hr) 
PMA1 pH 
1.2 
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1.2 
PMA3 pH 
1.2 
PMA4 pH 
1.2 
PMA1 pH 
8 
PMA2 pH 
8 
PMA3 pH 
8 
PMA4 pH 
8 
0.5 1.43±0.23 1.55±0.32 1.79±0.37 1.79±0.67 8.03±1.43 12.55±1.95 12.93±1.56 12.68±1.28 
1 2.27±0.45 2.27±0.43 2.27±0.36 2.39±0.29 12.78±1.49 16.65±1.67 20.04±1.55 23.04±1.18 
1.5 2.73±0.26 2.73±0.43 2.73±0.69 2.97±0.36 18.69±1.66 20.08±1.47 25.76±1.84 28.58±1.46 
2 3.19±0.25 3.19±0.53 3.19±0.41 3.55±0.36 24.6±2.64 23.47±1.98 31.41±2.78 34.04±2.38 
3 4.12±0.55 4.12±0.65 4.12±0.77 4.59±0.48 30.33±3.26 29.37±2.78 38.03±2.78 37.44±3.32 
4 5.03±0.63 5.03±0.78 5.27±0.45 5.62±0.76 34.86±3.86 34.27±2.67 43.56±2.98 42.78±3.14 
6 5.94±0.64 5.94±0.91 6.29±0.37 6.76±0.23 39.11±3.88 39.31±3.62 48.73±3.09 48.77±3.37 
8 6.84±0.26 6.95±0.84 7.19±0.43 7.76±0.54 43.78±3.85 44.43±2.94 54±2.88 53.85±2.47 
12 7.84±0.27 8.19±0.36 8.53±0.48 8.99±0.73 48.76±3.93 52.7±3.21 61.81±2.88 63.41±2.86 
16 9.06±0.27 9.52±0.94 9.86±0.43 10.44±0.26 56.38±3.28 62.44±3.81 71.19±3.76 74.48±2.74 
20 10.16±0.34 10.61±0.65 10.96±0.76 11.3±0.67 63.8±2.69 71.9±2.89 80.28±3.02 84.27±3.11 
24 11.8±0.87 12.26±0.56 12.37±0.83 13.28±0.78 73.76±3.89 83.16±3.91 91.29±3.91 93.84±2.69 
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Table 4.5.5: Effect of MAA concentration on cumulative percent drug release of 
Rabeprazole sodium from hydrogel PMA 
Time 
(hr) 
PMA5 
pH1.2 
PMA6 
pH1.2 
PMA7 
pH1.2 
PMA5 pH 
8 
PMA6 pH 
8 
PMA7 pH 
8 
0.5 1.6±0.11 1.6±0.21 1.88±0.24 7.75±1.22 10.16±1.18 6.57±1.26 
1 2.67±0.32 2.49±0.23 2.6±0.21 16.09±1.78 15.04±1.48 9.59±1.30 
1.5 3.19±0.33 2.84±0.34 2.9±0.29 18.79±2.08 18.6±2.13 12.86±1.78 
2 3.97±0.67 1.86±0.45 1.56±0.43 21.87±1.23 22.13±2.23 15.63±2.08 
3 4.47±0.77 3.94±0.54 12.27±0.77 25.19±3.33 27.19±2.48 19.86±3.24 
4 4.98±0.79 4.28±0.78 4.33±0.79 28.51±3.34 31.16±2.50 24.67±3.36 
6 5.47±0.79 4.6±0.87 4.47±0.79 33.66±3.46 35.69±2.38 29.4±3.43 
8 5.96±0.57 4.93±0.90 4.85±0.43 36.99±2.56 41.22±2.56 34.55±2.77 
12 6.45±0.45 5.24±0.56 5.13±0.45 44.43±3.23 47.01±3.33 42.37±3.00 
16 6.93±0.45 5.56±0.33 5.41±0.45 54.45±3.24 51.74±3.34 49.74±2.23 
20 7.4±0.56 5.87±0.35 5.68±0.56 64.8±3.36 58.78±3.46 54.94±2.48 
24 7.87±0.45 6.18±0.65 5.94±0.34 71.68±3.43 64.66±3.54 60.12±2.50 
 
 
 
Figure 4.5.10: Effect of MAA concentration on cumulative percent drug release of 
Rabeprazole sodium from hydrogel PMA 
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Table 4.5.6: Release kinetíc of rabeprazole sodium from PMA hydrogel 
Formulation 
code 
Higuchi First 
order 
Zero 
order 
Korsmeyer-peppas 
R
2
 R
2
 R
2
 R
2
 n 
PMA1 0.979 0.409 0.919 0.980 0.674 
PMA 2 0.993 0.432 0.973 0.987 0.715 
PMA 3 0.988 0.372 0.936 0.985 0.621 
PMA 4 0.990 0.364 0.950 0.989 0.571 
PMA 5 0.991 0.436 0.971 0.992 0.666 
PMA 6 0.991 0.397 0.930 0.995 0.547 
PMA 7 0.994 0.496 0.952 0.992 0.507 
 
4.6: Characterization of PEG (HEMA-co-AA) hydrogels 
4.6.1 Swelling studies at pH1.2 and pH 7.4 
Swelling behavior of PEG(HEMA-co-AA) have been observed in acidic and basic pH. 
Effect of hydrogels components on swelling behavior has also been studied. Formulations 
were assigned codes (PHA1-PHA4) and (PHA5-PHA8) for varying concentration of 
acrylic acid and HEMA respectively. Effect of varying concentration of acrylic acid on 
swelling ratio (q), PHA1 (1 to 3.587), PHA2 (1 to 3.304) and PHA3 (1 to 2.662) and 
PHA4 (1 to 2.249) in pH 1.2 and PHA1 (1 to 12.895), PHA2 (1 to 14.070), PHA3 (1 to 
16.134) and PHA4 (1 to 19.723) in 7.4 buffer solutions at 37 ºC has been given in Table 
4.6.1 and graphically presented in Figure 4.6.1. Comparative swelling ratio (q) of 
hydrogels by using different concentrations of HEMA, PHA5 (1 to 4.043), PHA6 (1 to 
3.346), PHA7 (1 to 3.164) and PHA8 (1 to 2.249)at pH 1.2 and PHA5 (1 to 26.945), PHA6 
(1 to 24.659), PHA7 (1 to 21.429) and PHA8 (1to 16.354) at pH 7.4 were given in Table 
4.6.2.  
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Table 4.6.1: Comparative swelling ratios of PEG (HEMA-co-AA) (PHA) hydrogels using 
different concentrations of AA 
Time 
(Hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 7.4 
 PHA1 PHA2 PHA3 PHA4 PHA1 PHA2 PHA3 PHA4 
0 1 1 1 1 1 1 1 1 
0.5 1.15±0.19 1.14±0.23 1.1±0.22 1.07±0.21 1.7±0.22 1.77±0.21 1.89±0.23 2.1±0.24 
1 1.3±0.22 1.27±0.29 1.2±0.24 1.15±0.24 2.4±0.23 2.54±0.24 2.78±0.32 3.2±0.28 
1.5 1.46±0.32 1.41±0.31 1.29±0.19 1.22±0.33 3.1±0.34 3.31±0.33 3.67±0.33 4.3±0.31 
2 1.61±0.27 1.54±0.3 1.39±0.22 1.29±0.34 3.8±0.42 4.08±0.45 4.56±0.61 5.41±0.42 
3 1.76±0.3 1.68±0.28 1.49±0.32 1.37±0.38 4.5±0.46 4.84±0.21 5.45±0.73 6.51±0.47 
4 1.91±0.31 1.81±0.32 1.59±0.33 1.44±0.42 5.2±0.53 5.61±0.76 6.34±0.77 7.61±0.77 
6 2.07±0.33 1.95±0.31 1.69±0.35 1.51±0.46 5.9±0.45 6.38±0.73 7.23±0.75 8.71±0.75 
8 2.22±0.32 2.08±0.32 1.78±0.35 1.59±0.53 6.6±0.21 7.15±0.53 8.12±0.67 9.81±0.67 
10 2.37±0.31 2.22±0.35 1.88±0.36 1.66±0.63 7.3±0.76 7.92±0.63 9.01±0.75 10.91±0.87 
12 2.52±0.32 2.36±0.36 1.98±0.34 1.74±0.74 8±0.73 8.69±0.74 9.9±0.67 12.01±0.83 
14 2.67±0.35 2.49±0.36 2.08±0.34 1.81±0.75 8.7±0.74 9.46±0.75 10.79±0.77 13.12±0.65 
18 2.83±0.36 2.63±0.34 2.17±0.33 1.88±0.81 9.4±0.75 10.23±0.81 11.68±0.71 14.22±0.74 
24 2.98±0.34 2.76±0.34 2.27±0.33 1.96±0.82 10.1±0.81 11±0.82 12.57±0.75 15.32±0.79 
48 3.28±0.34 3.03±0.35 2.47±0.34 2.1±0.84 11.5±0.82 12.53±0.84 14.35±0.78 17.52±0.84 
72 3.59±0.35 3.3±0.35 2.66±0.34 2.25±0.89 12.9±0.88 14.07±0.89 16.13±0.81 19.72±0.85 
 
 
 
Figure 4.6.1: Comparative swelling ratios of PEG (HEMA-co-AA) hydrogels using 
different concentrations of AA  
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Table 4.6.2:Comparative swelling ratios of PEG(HEMA-co-AA) hydrogels using 
different concentrations of HEMA 
Time 
(Hrs) 
Swelling ratio (q) at pH 1.2 Swelling ratio (q) at pH 7.4  
 PHA5 PHA6 PHA7 PHA8 PHA5 PHA6 PHA7 PHA8 
0 1 1 1 1 1 1 1 1 
0.5 1.18±0.19 1.14±0.23 1.13±0.22 1.07±0.23 2.53±0.21 2.39±0.23 2.17±1.17 1.9±0.21 
1 1.36±0.22 1.28±0.29 1.26±0.24 1.15±0.21 4.05±0.32 3.78±1.17 3.37±1.44 2.81±0.32 
1.5 1.54±0.32 1.41±0.31 1.38±0.19 1.22±0.29 5.58±1.44 5.18±1.44 4.58±1.17 3.71±1.17 
2 1.72±0.27 1.55±0.3 1.51±0.22 1.29±0.43 7.11±2.13 6.57±2.13 5.78±1.44 4.61±1.26 
3 1.9±0.3 1.69±0.28 1.64±0.32 1.37±0.32 8.63±2.5 7.96±2.23 6.98±2.13 5.52±1.44 
4 2.07±0.31 1.83±0.32 1.76±0.33 1.44±0.22 10.16±2.31 9.35±2.29 8.19±2.5 6.42±2.13 
6 2.25±0.33 1.97±0.31 1.89±0.35 1.51±0.32 11.68±2.41 10.74±2.31 9.39±2.31 7.32±2.19 
8 2.43±0.32 2.1±0.33 2.02±0.35 1.59±0.33 13.21±2.38 12.13±2.5 10.59±2.41 8.23±2.23 
10 2.61±0.31 2.24±0.35 2.15±0.36 1.66±0.35 14.74±2.31 13.53±2.41 11.8±2.38 9.13±2.31 
12 2.79±0.32 2.38±0.35 2.27±0.34 1.74±0.35 16.26±2.5 14.92±2.48 13±2.33 10.03±2.5 
14 2.97±0.35 2.52±0.36 2.4±0.34 1.81±0.36 17.79±2.41 16.31±2.5 14.21±2.34 10.94±2.41 
18 3.15±0.36 2.66±0.34 2.53±0.33 1.88±0.34 19.31±2.34 17.7±2.33 15.41±2.46 11.84±0.81 
24 3.33±0.34 2.79±0.34 2.66±0.33 1.96±0.34 20.84±2.46 19.09±2.34 16.61±2.59 12.74±0.82 
48 3.69±0.34 3.07±0.35 2.91±0.34 2.1±0.35 23.89±1.26 21.88±2.36 19.02±2.55 14.55±1.17 
72 4.04±0.35 3.35±0.35 3.16±0.34 2.25±0.35 26.95±1.39 24.66±2.47 21.43±2.65 16.35±1.44 
 
 
 
Figure 4.6.2: Comparative swelling ratios of PEG (HEMA-co-AA) hydrogels using 
different concentrations of HEMA  
0
5
10
15
20
25
30
0 20 40 60 80
S
w
el
li
n
g
 r
a
ti
o
 (
q
) 
Time (Hrs) 
PHA5 pH1.2
PHA5 pH 7.4
PHA6  pH1.2
PHA6  pH 7.4
PHA7  pH 7.4
PHA8  pH1.2
PHA48 pH 7.4
 117 
 
5.6.2: Pulsatile behavior of hydrogels 
Reversible swelling behavior of PEG(HEMA-co-AA) has been evaluated at pH 1.2 and 
pH 7.4. Figure 4.6.3 represented on off swelling behavior of hydrogels at pH 7.4 and pH 
1.2. 
 
Figure 4.6.3: On-off switching behavior as reversible pulsatile swelling (pH 7.4) and 
deswelling (pH 1.2) of PEG(HEMA-co-AA hydrogel 
4.6.3: Equilibrium water contents and gel fraction 
Water absorbed by PEG (HEMA-co-AA) copolymeric hydrogels was quantitatively 
symbolized by the equilibrium water content (EWC). The EWC values of the hydrogels 
were calculated and tabulated in Table 4.6.3. Calculated gel fraction of hydrogel was 
summarized in Table 4.6.3. 
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Table 4.6.3: Equilibrium water contents, gel fraction and amount of drug loaded of PEG 
(HEMA-co-AA) hydrogels using different concentrations of AA and HEMA 
Formulation 
code 
Contents 
w/w % 
EWC Gel 
fraction 
(%) 
Amount of Rabeprazole sodium 
loaded 
(mg per 0.4 g of dry disk) 
By extraction By weight 
PHA1 7.5 0.84 74.74 41 42 
PHA2 10 0.88 79.51 46 46.9 
PHA3 12.5 0.93 87.29 56 57.2 
PHA4 15 0.94 94.77 60 61 
PHA5 1 0.92 70.37 67 67.8 
PHA6 1.5 0.88 82.53 67 68 
PHA7 2 0.81 91.88 67 68.4 
PHA8 3 0.53 94.55 40 40.3 
 
 
Figure 4.6.4: Gel fraction of PEG (HEMA-co-AA) hydrogel with different concentrations 
of AA and HEMA 
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4.6.4: Instrumental analysis 
a) Scanning electron microscopy 
SEM analysis was executed to analyze the morphological manners of swollen hydrogels. 
The SEM photomicrographs of lyophilized hydrogels were shown in Figures 4.6.5.  
 
 
 
Figure 4.6.5: SEM images freeze dried PEG(HEMA-co-AA)at magnification of 100 
X and 200 X and 30µ, 50µ, 300 µ, and 500 µ scale bar respectively 
 
 
b) FTIR spectrum analysis 
FTIR spectrum over the wavelength range 600–4000 cm–1was recorded. FTIR spectrum of 
PHA hydrogel and its separate components have been depicted in Figure 4.6.6 with main 
peaks assignment. 
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Figure 4.6.6:FTIR spectra of PEG, AA, HEMA and prepared hydrogel (PHA)  
 
c) Thermal analysis 
Thermal stability of prepared hydrogels and its formulation constituents was examined by 
analyzing TGA and DSC curves. The thermal analysis of hydrogel by TGA demonstrated 
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stability of the polymeric network upto 600 ºC shown in Figure 4.6.7 and DSC curve in 
Figure 4.6.8. 
 
Figure 4.6.7:  TGA curves of PEG, HEMA, AA PHA (hydrogel formulation 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.8:  DSC curves of PEG, HEMA, AA PHA (hydrogel formulation) 
4.6.5: In vitro release kinetics of Rabeprazole sodium from PEG (HEMA-
co-AA) hydrogel 
To evaluate the pH sensitive and controlled release of rabeprazole sodium from PEG 
(HEMA-co-AA) hydrogel, in vitro release studies were conducted in 0.1N HCl (pH 1.2) 
and Tris buffer (pH 8) at 37 ºC. Figure 4.6.9 exhibited effect of concentration of acrylic 
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acid on cumulative percent drug release. Effect of different concentration of HEMA on 
percent cumulative release of rabeprazole sodium has been summarized in Table 4.6.5. 
Table 4.6.4: Effect of AA concentration on cumulative percent drug release of 
Rabeprazole sodium from hydrogel PHA 
 
 
Figure 4.6.9: Effect of AA concentration on cumulative percent drug release of 
Rabeprazole sodium from hydrogel PHA 
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Time (hrs) 
PHA1 pH 8
PHA2 pH 8
PHA3 pH 8
PHA4 pH 8
PHA1 pH1.2
PHA2 pH1.2
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Time 
(hr) 
PHA1 
pH 1.2 
PHA2 
pH 1.2 
PHA3 
pH 1.2 
PHA4 
pH 1.2 
PHA1 
pH 8 
PHA2 
pH 8 
PHA3 
pH 8 
PHA4 
pH 8 
0.5 1.2±0.3 1.07±0.4 0.88±0.7 0.82±0.2 9.92±1.4 5.33±2.0 7.44±1.6 13.15±1.0 
1 1.55±0.7 1.38±0.4 1.14±0.3 1.06±0.2 13.85±1.5 6.49±1.7 9.53±1.6 15.43± 
1.5 1.9±0.2 1.69±0.7 1.39±0.4 1.3±0.3 16.52±1.7 9.11±1.5 13.31±1.8 19.25±1.5 
2 2.25±0.6 2±0.4 1.65±0.4 1.54±0.4 19.16±2.6 11.7±2.0 16.28±2.8 24.24±1.7 
3 2.82±0.3 2.52±0.8 2.07±0.5 1.93±0.8 25.64±3.3 17.92±2.8 18.61±2.8 29.83±2.4 
4 3.39±0.3 3.03±0.5 2.49±0.8 2.32±0.8 30.91±3.9 23.05±2.7 24.93±3.0 33.05±1.3 
6 3.96±0.8 3.53±0.4 2.9±0.2 2.71±0.8 39.59±3.9 30.2±3.6 31.37±3.1 38.84±1.6 
8 4.52±0.7 4.03±0.4 3.31±0.5 3.09±0.4 44.74±3.9 37.28±2.9 41.13±2.9 47.58±1.9 
12 5.19±0.8 4.62±0.5 3.8±0.7 3.55±0.4 50.5±3.9 50.42±3.2 52.4±2.9 58.13±2.0 
16 5.85±0.5 5.21±0.4 4.28±0.3 4±0.4 60.78±3.9 60.41±3.8 64.22±3.8 70.6±1.6 
20 6.39±0.5 5.7±0.8 4.68±0.7 4.37±0.6 68.69±2.7 68.45±2.9 74.01±3.0 81.4±2.7 
24 7.04 6.27±0.8 5.15±0.8 4.81±0.3 71.99±3.9 77.09±3.9 82.61±3.9 90.6±2.5 
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Table 4.6.5: Effect of HEMA concentration on cumulative percent drug release of 
Rabeprazole sodium from hydrogel PHA 
Time 
(hr) 
PHA5 
pH 1.2 
PHA6 
pH 1.2 
PHA7 
pH 1.2 
PHA8 
pH 1.2 
PHA5 
pH 8 
PHA6 
pH 8 
PHA7 
pH 8 
PHA8 
pH 8 
0.5 0.77±0.2 0.73±0.3 0.7±0.4 1.1±0.7 6.97±1.4 8.56±2.0 7.97±1.6 6.25±1.3 
1 0.99±0.5 0.95±0.4 0.91±0.4 1.47±0.3 9.03±1.5 10.31±1.7 9.36±1.6 8.69±1.2 
1.5 1.22±0.3 1.16±0.4 1.11±0.3 1.83±0.4 13.24±1.7 13.38±1.5 12.65±1.8 12.05±1.5 
2 1.44±0.3 1.38±0.4 1.32±0.4 2.18±0.4 17.04±2.6 17±2.0 16.28±2.8 15.39±2.4 
3 1.81±0.6 1.73±0.7 1.65±0.8 2.53±0.5 21.85±3.3 21.6±2.8 20.88±2.8 21.82±3.3 
4 2.17±0.6 2.08± 1.99±0.4 2.88±0.8 29.01±3.9 28.43±2.7 27.71±3.0 30.46±3.1 
6 2.54±0.3 2.42±0.8 2.32±0.4 3.22±0.2 36.4±3.9 35.49±3.6 34.77±3.1 37.6±3.4 
8 2.9±0.3 2.77±0.4 2.65±0.5 3.56±0.7 48.16±3.9 46.71±2.9 46±2.9 47.73±2.5 
12 3.32±0.3 3.17±0.9 3.04±0.4 3.9±0.3 60.32±3.9 61.84±3.2 57.62±2.9 56.6±2.9 
16 3.75±0.3 3.58±0.7 3.43±0.3 4.23±0.7 73.97±3.3 71.38±3.8 70.66±3.8 64.78±2.7 
20 4.09±0.3 3.91± 3.74±0.8 4.56±0.7 82.17±2.7 79.19±2.9 78.49±3.0 73.1±3.1 
24 4.51±0.9 4.31±0.6 4.12±0.8 4.89±0.8 90.54±3.9 87.19±3.9 85.8±3.9 78.9±2.7 
 
 
 
Figure 4.6.11: Effect of HEMA concentration on cumulative percent drug release of 
Rabeprazole sodium from hydrogel PHA 
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Table 4.6.6: Release kinetics of rabeprazole sodium from hydrogel PHA 
Formulation 
code 
Higuchi First 
order 
Zero 
order 
Korsmeyer-peppas 
R
2
 R
2
 R
2
 R
2
 n 
PHA1 0.994 0.457 0.941 0.991 0.402 
PHA 2 0.995 0.619 0.979 0.998 0.606 
PHA 3 0.991 0.576 0.984 0.996 0.619 
PHA 4 0.993 0.468 0.982 0.992 0.612 
PHA 5 0.996 0.567 0.970 0.993 0.501 
PHA 6 0.993 0.557 0.967 0.991 0.501 
PHA 7 0.993 0.568 0.967 0.990 0.505 
PHA 8 0.992 0.536 0.939 0.977 0.501 
4.7 Acute oral toxicity study of prepared hydrogels 
General conditions of all groups were observed. Body weights, water and food intake, 
common signs of illness, dermal and ocular irritation and mortality of both the control and 
treatment groups were recorded accordingly during the whole treatment period mentioned 
in Table 4.7.1. 
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Table 4.7.1: Clinical observations of acute oral toxicity test for hydrogels formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Observations Group I 
(Control) 
Group II 
(CA 
hydrogel 
treated) 
10 
g/kg/b.w 
Group III 
(CMA 
hydrogel 
Treated) 
10g/kg/b.w 
Group IV 
(A hydrogel 
treated) 
10g/kg/b.w 
Group V 
(M hydrogel 
treated ) 
10g/kg/b.w 
Signs of illness Nil Nil Nil Nil Nil 
Body weight (g) 
Pretreatment 
Day1 
Day7 
Day14 
 
29.8±2.4 
29.8±3.4 
30.6±2.3 
31.4±3.2 
 
28.3±4.5 
28.5±3.2 
33.5 ±1.2 
34.5±2.1 
 
31.8±1.0 
33.3±2.2 
34.6±1.2 
36.1±1.8 
 
20.8±1.0 
21.1±1.1 
22.6±1.6 
22.8±1.9 
 
27.2±3.5 
27.5±2.2 
29.5 ±3.2 
30.4±1.2 
Water 
intake(mL) 
Pretreatment 
Day1 
Day7 
Day14 
 
 
8 ±1 
10 ±1.5 
9 ±1.3 
10 ±1.4 
 
 
10 ±1.5 
8 ±1.8 
12 ±1.3 
9 ±1.6 
 
 
10 ±1.4 
12±1.2 
10 ±1.5 
8.5 ±1.4 
 
 
9 ±1.2 
11 ±1.7 
9 ±2.8 
10 ±2.6 
 
 
9.5 ±2.5 
12 ±3.5 
13 ±2.5 
12 ±1.5 
Food Intake (g) 
Pretreatment 
Day1 
Day7 
Day14 
 
5 ±0.7 
7 ±0.8 
5 ±1.0 
7.5±1.0 
 
5.5 ±1.5 
7.5 ±0.8 
6.5 ±1.0 
6.5 ±1.2 
 
8.5 ±0.3 
7.4 ±0.4 
8.5 ±0.2 
8.0 ±0.6 
 
6.6 ±1.0 
5.6 ±1.0 
6.6 ±0.8 
5.8±0.4 
 
5.6 ±1.0 
7.6 ±1.0 
6.8 ±0.8 
5.8±0.4 
Dermal toxicity 
Dermal irritation 
 
Nil 
 
Nil 
 
Nil 
 
Nil 
 
Nil 
Ocular toxicity 
Simple Irritation 
or corrosion 
 
Nil 
 
Nil 
 
Nil 
 
Nil 
 
Nil 
Mortality Nil Nil Nil Nil Nil 
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4.7.1 Biochemical blood analysis 
Purpose of biochemical blood analysis was to investigate whether hydrogel prepared by 
free radical polymerization could result in to the blood system’s defect. Whole blood 
samples from rat were collected for biochemical blood analysis which was determined by 
a hematology Analyzer. Biochemical blood analysis in our study included the following 
variables: white blood cell count (WBC), red blood cell count (RBC), hemoglobin (HB), 
platelet count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), 
mean corpuscular hemoglobin concentration (MCHC) summarized in Table 4.7.2 and 
liver function test, lipid profile and kidney function test has been shown in Table 4.7.3. 
Table 4.7.2: Biochemical blood analysis 
Haematology 
 
Group I 
(Control) 
Group II 
(CA 
hydrogel 
treated) 
1-10 g/kg 
Group III 
 (CMA 
hydrogel 
treated) 
1-10g/kg 
Group IV 
(A hydrogel 
treated) 
1-10g/kg 
Group V 
(M 
hydrogel 
treated ) 
1-10g/kg 
Hb g/dL 14.1±1 14.3±2.5 14.5±2 13.2 ±1.5 11.2±1.5 
WBCs x 10
3
 / µl 4.9±0.51 5.1±0.48 4.9±0.83 4.1±0.76 6.6±0.34 
RBCs x 10
6
 / µl 8.46±1.1 8.85±0.4 8.52±1.5 8.30±0.40 8.26±0.37 
Platelets x 10
3
/µl 1398±1.3 1089±1.5 1584±1.5 1319±4 1081±3 
Monocytes% 2±0.34 1±0.45 1±0.87 2±0.78 2±.54 
Neutrophils% 24±3.95 21±2.43 23±4.87 25±3.45 27±3.21 
Lymphocytes% 94±0.95 95±1.87 96±3 87±5.23 94±3.45 
MCV 54±1.55 54.5±2.47 53.5±3.37 52.4±2.23 52.3±3.12 
MCH 16.3±0.12 16.2±0.50 17±0.51 15.9±0.57 16.8±0.95 
MCHC  g/dl 30±0.47 31.8±0.57 30.3±0.54 32.1±1.2 28.6±2.50 
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Table 4.7.3: Liver, kidney and lipid profile of mice treated with hydrogel formulations 
Biochemical 
analysis 
Group I 
(Control) 
Group II 
(CA 
hydrogel 
treated) 
1-10 g/kg 
Group III 
 (CMA 
hydrogel 
treated) 
1-10g/kg 
Group IV 
(A hydrogel 
treated) 
1-10g/kg 
Group V 
(M 
hydrogel 
treated ) 
1-10g/kg 
ALT(IU/l) 54 53 66 63 55 
AST (IU/l) 246 144 184 185 213 
Creatinine 
(mg/dl) 
0.42 0.39 0.37 0.44 0.46 
Urea(mg/dl) 72 59 39 29 38 
Uric 
acid(mg/dl) 
3.5 2.9 3.4 4.8 5.7 
Cholesterol(m
g/dl) 
82 116 130 64 137 
Triglyceride(m
g/dl) 
110 90 115 97 85 
 
4.7.2  Histopathological study 
To evaluate acute toxicity caused by hydrogel formulations accurately, histopathological 
modifications of major organs were tested. Observed organ weight of mice was given in 
Table 4.7.4.Histological examination of stomach, heart, liver, spleen, kidney and intestine 
of mice of control group (a), after hydrogel treatment. (b)  of group II, (c) of group III, (d) 
of group IV, and (e) of group V have been depicted in Figures 4.7.1, 4.7.2, 4.7.3, 4.7.4, 
4.7.5 and 4.7.6 respectively. 
Table 4.7.4: Effect of oral administration of hydrogel on the organ weight (gms) of mice  
Treatment 
groups 
Heart Liver Lung Kidney Stomach Spleen 
Control 0.54 ± 0.12 6.10 ±0.20 0.74 ± 0.07 0.813 ±0.05 1.78 ± 0.1 0.57 ± 0.01 
Group I 0.60 ± 0.71 6.48 ±0.27 0.64±0.22 0.96 ± 0.07 1.05 ±0.18 0.61 ± 0.02 
Group II 0.56  ± 0.01 6.11 ±0.12 0.62 ± 0.21 1.20 ± 0.07 1.79 ± 0.1 0.52 ± 0.11 
Group III 0.54  ± 0.02 5.62 ±0.24 0.68 ± 0.03 0.87 ± 0.05 1.38 ± 0.4 0.56  ± 0.04 
Group IV 0.53 ± 0.01 5.70 ±0.22 0.49 ± 0.01 1.62 ± 0.12 1.6 ± 0.20 0.57±0.20 
Group V 0.58± 0.32 5.89± 0.61 0.54± 0.21 1.37± 0.06 1.99± 0.19 0.89± 0.11 
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(a) (b) (c)  
(d) (e)  
Figure 4.7.1. Histological examination of stomach of mice of control group (a), after 
hydrogel treatment. (b)  of group II, (c) of group III, (d) of group IV, and 
(e) of group V. 
(b)  (c)  
d (e)  
Figure 4.7.2. Histological examination of heart of mice of control group (a), after 
hydrogel treatment. (b)  of group II, (c) of group III, (d) of group IV, and (e) 
of group V. 
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(a) (b) (c)  
(d) (e)  
Figure 4.7.3. Histological examination of liver of mice of control group (a), after hydrogel 
treatment, (b) of group II, (c) of group III, (d) of group IV, and (e) of group 
V. 
 
a)  b) c)  
d)  e)  
Figure 4.7.4. Histological examination of spleen of mice of control group (a), after 
hydrogel treatment, (b) of group II, (c) of group III, (d) of group IV, and (e) 
of group V 
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a)  b) c)  
d)  e)  
Figure 4.7.5. Histological examination of kidney of mice of control group (a), after 
hydrogel treatment. (b)  of group II, (c) of group III, (d) of group IV, and 
(e) of group V 
a) b)  c)  
d)  e)  
Figure 4.7.6. Histological examination of intestine of mice of control group(a), after 
hydrogel treatment. (b)  of group II, (c) of group III, (d) of group IV, and 
(e) of group V 
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4.8 Pharmacokinetic evaluation of rabeprazole sodium  
4.8.1: Standard curve 
The standard curve of Rabeprazole sodium was constructed using known plasma 
drug concentrations within ranges of 31.25 ng/mL to 1000 ng/mL and linear 
regression was applied to fit straight line. Mean R
2 
values was also determined 
0.999. 
 
 
Figure 4.8.1:Standard curve of rabeprazole sodium in rabbit plasma 
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Rabbits were divided into three groups having 10 rabbits in each group. CA (CMC-g-
AA), A (CMAX-g-AA), and drug solution of same strength(5 mg/kg/day) as that of 
hydrogels disc were administered to Group A, Group B and Group C respectively. Mean 
plasma concentration of CA (CMC-g-AA), A (CMAX-g-AA), and drug solution were 
summarized in Table 4.8.1, 4.8.2 and 4.8.3 respectively. Representative chromatograms 
in Figure 4.8.2 showed that retention time of rabeprazole sodium was 5.4 min in simple 
solution analysis. Figure 4.8.3 depicted the retention time of rabeprazole sodium in 
spiked plasma analysis was also 5.4 min. 
 
Figure 4.8.2: Chromatogram of rabeprazole sodium 
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Figure 4.8.3: Chromatogram of spiked plasma with rabeprazole sodium 
Table 4.8.1: Intra-day and Inter-day precision and accuracy of Rabeprazole sodium 
in rabbit plasma 
Rabeprazole 
Intra day 
Parameter 
LQC 
(ng/mL) 
HQC 
(ng/mL) 
Nominal Conc. 15 1000 
Mean 13.07 995.27 
S.D. 0.11 0.82 
Precision CV (%) 0.4 0.1 
Accuracy (%) 97.2 99.5 
Inter day 
Parameter LQC 
(ng/mL) 
HQC 
(ng/mL) 
Nominal Conc. 15 1000 
Mean 13.39 992.60 
S.D. 0.28 1.28 
Precision CV (%) 0.9 0.1 
Accuracy (%) 95.1 99.3 
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Table 4.8.2: Mean plasma concentration of Rabeprazole sodium after 
administration of CA (CMC-g-AA) hydrogel in rabbits (n=10) 
Group A 
Time (hr) Mean Conc. (ng/mL)±SEM 
0 0 
0.5 0 
1 0 
2 0 
3 30.727±6.907 
4 85.299±3.926 
5 86.333±4.006 
6 85.602±4.079 
8 63.349±4.957 
12 31.140±2.252 
 
 
 
Figure 4.8.4: Plasma profile of Rabeprazole sodium after administration of CA (CMC-g-
AA) hydrogel formulation 
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Table 4.8.3: Mean plasma concentration of Rabeprazole sodium after administration of A 
(CMAX-g-AA) hydrogel in rabbits (n=10) 
Group B 
Time (hr) Mean Conc. (ng/mL) ±SEM 
0 0 
0.5 0 
1 0 
2 0 
3 38.152±6.773 
4 103.717±4.588 
5 103.717±4.588 
6 103.717±4.588 
8 86.625±3.455 
12 39.209±4.622 
 
 
 
Figure 4.8.5: Plasma profile of Rabeprazole sodium after administration of A (CMAX-g-
AA) hydrogel formulation 
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Table 4.8.4:Mean plasma concentration of Rabeprazole sodium after administration of 
oral drug solution in rabbits (n=10) 
Group C 
 Time (Hrs)  Mean conc.(ng/mL) ±SEM 
0 0 
0.25 6.128±0.65 
0.5 20.133±1.44 
0.75 43.289±1.38 
1 61.263±1.70 
1.5 39.320±1.44 
2 18.148±0.95 
3 8.003±0.30 
4 0.946±0.35 
 
 
 
Figure 4.8.6: Plasma profile of Rabeprazole sodium after administration of oral drug 
solution  
Pharmacokinetic parameters of Rabeprazole sodium following administration of CMC-g-
AA, CMAX-g-AA hydrogel formulations and oral drug solution were described in Table 
4.8.4. Pharmacokinetic parameters of Rabeprazole sodium were statistically analyzed by 
one way ANOVA, results were summarized in Table 4.8.5. 
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Table 4.8.5: Mean values of pharmacokinetic parameters of Rabeprazole sodium 
following administration of two different formulations (hydrogel) and oral 
drug solution. 
Sr No. Parameters CA (Hydrogel) A (Hydrogel) Drug 
solution 
1 Cmax(ng/mL) 87.287 103.717 61.263 
2 Tmax( Hrs) 4.3 4 1 
3 AUCo-t(ng/mL.h) 952.2552 1084.576 83.672 
4 MRT (Hrs) 10.605 9.700 1.481 
5 Clast(ng/mL) 38.256 42.962 2.192 
6 Tlast(Hrs) 12 12 4 
7 t1/2(Hrs) 5.367 4.536 0.553 
 
 
 
 
Figure 4.8.7: Combined plasma profile of Rabeprazole sodium after administration of oral 
drug solution, CA (CMC-g-AA) and A (CMAX-g-AA) hydrogel 
formulations 
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Table 4.8.6: ANOVA table for pharmacokinetic parameters of hydrogels (formulation 
codes A &CA) and drug solution 
source 
df 
Sum of 
squares 
Mean square F P-value 
Cmax 2 9470 4735 28.1611 
0.0000 
P < 0.05 
AUC0-t 2 5912508 2956254 151.1963 
0.0000 
P < 0.05 
MRT 
2 505 252 354.9876 
-0.0000 
P < 0.05 
Tmax 2 66.600 33.300 428.1429 
-0.0000 
P < 0.05 
df=Degree of freedom 
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5.  Discussion   
5.1  Characterization of CMAX-g-AA hydrogels 
5.1.1 Effect of variation of pH, monomer, polymer and cross-linker on 
swelling behavior of CMAX-g-AA hydrogel 
5.1.1.1 Effect of monomer concentration on swelling 
The swelling ratio depends upon the accessible free spaces of the expanded polymer 
matrix, polymer chain relaxation, and accessibility of ionizable functional groups i.e., 
carboxylic group. Dynamic swelling behavior of the hydrogels with varying 
concentrations (10%w/w, 15%w/w and 20%w/w) of acrylic acid was studied as a 
function of pH. Swelling profiles of the samples are given in Table 4.1.1. Initially 
swelling rate was slow but increased gradually at pH 7.4. CMAX-g-AA exhibit 
obviously pH dependent behavior, because of carboxylic acid side group.  At higher 
pH carboxylic acid group on the acrylic acid became progressively more ionized, 
hydrogels swelled more rapidly.  Rate of fluid uptake was considerably higher for the 
polymeric network in solutions with pH>5 than for the network in lower pH. Since 
pKa value of acrylic acid is 4.5-5.0, acrylic acid hydrogels swell extensively at higher 
pH. pH of surrounding medium is an important feature to evaluate swelling capacity in 
CMAX-g-AA hydrogel.  Acrylic acid impart pH responsive behavior to CMAX-g-AA 
hydrogel. Swelling profile of formulations A1, A2 and A3 given in Table 4.1.1 
indicated that swelling ratio (q) at alkaline pH (47.295, 54.37and 60.28 of A1, A2 and 
A3 respectively) increased with increase concentration of acrylic acid and (7.36, 
5.49and 2.74 of A1, A2 and A3 respectively) decreased swelling at acidic pH. The 
effect of acrylic acid on swelling behavior has been studied by many researchers, 
enhanced acrylic acid contents in hydrogels increase hydrophilicity and pH sensitivity. 
As the contents of acrylic acid increased more carboxyl groups for ionization 
available, resulted in chain relaxation of coiled molecule due to electrostatic repulsion 
of carboxyl group, hydrogels exhibited high swelling rate at alkaline pH and low at 
acidic pH (Hossein, 2010; Huang et al., 2007; Jafari and Hamid, 2005). 
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5.1.1.2 Effect of polymer concentration on swelling 
Effect of varying concentrations of CMAX also has been investigated on swelling 
capacity and pH responsive behavior of CMAX-g-AA hydrogel. It has been observed 
that as the contents of CMAX enhanced in formulations, there was increased swelling 
at alkaline pH. Swelling ratio of CMAX-g-AA hydrogel given in Table 4.1.2 has 
shown the swelling fashion at pH 1.2 (4.777, 4.181, and 3.533) and at pH 7.4 (59.322, 
62.788 and 64.191) by raising CMAX contents from 1 %w/w, 1.5 %w/w and 2 %w/w 
respectively. Degree of swelling was highly pH dependent and increased by increasing 
concentration of CMAX. It may be assumed that increased contents of CMAX impart 
hydrophilicity to hydrogel. As it has been reported that carboxymethylation of 
Arabinoxylan modified its fundamental properties like hydrophilicity and anionic 
nature depending on degree of substitution (Saghir et al., 2008). Same behavior was 
depicted with carboxymethyl cellulose, but at high concentration above 2% w/w 
polymer ratio (high viscosity of medium) reduced crosslinking density of hydrogel. In 
contrast to CMC (carboxymethyl cellulose), CMAX reduce solution viscosity 
(Meenakshi and Munish,2015). 
5.1.1.3 Effect of crosslinker concentration on swelling 
Degree of swelling depends on crosslinked monomer concentration, polymer 
concentration and also on crosslinking density of hydrogels. Effect of crosslinker 
concentration on swelling phenomenon has been studied by keeping the monomer and 
polymer contents constant. Table 4.1.3 and Figure 4.1.3 depicts the degree of swelling 
with varying concentration of N, N methylene bisacrylamide used as crosslinker. Over 
all swelling was reduced with increasing contents of N, N MBA (0.2% w/w to 0.8% 
w/w), imparted hydrophobicity to hydrogels by reducing porosity (dense network) of 
hydrogels. With high contents of crosslinker swelling ratio decreased upto 50% 
(31.629) as that of high contents of (20 %w/w) acrylic acid, (60.28) and at 2 %w/w 
contents of CMAX (64.19) at pH 7.4. 
Relationship between degree of swelling and crosslinker concentration has been 
explained by Flory equation 
     
                 (1) 
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Here K and n are constant values for individual hydrogels. 
It has been reported that crosslinker concentration and swelling have inverse relation. 
By increasing N, N MBA concentration swelling was reduced. Concentration of 
crosslinker determines the crosslinking density of hydrogel. High contents of 
crosslinker fabricated harder and dense network, obstruct water absorption hence 
negative effect on swelling capacity and enhanced mechanical strength of hydrogel 
(Elliott et al., 2004; Pourjavadi and Mahdavinia, 2006).   
5.1.2 Pulsatile behavior of hydrogel 
The oscillatory swelling studies were also performed to scrutinize whether the 
response to the environmental pH was reversible and to check how rapid graft 
copolymer could retorted to the stimuli. Synthesized CMAX-g-AA hydrogels showed 
inverse reproducible behavior of swelling in acidic and alkaline medium. At pH 7.4, 
the hydrogel sample (A6) swelled up to 64 g/g due to anion-anion repulsive 
electrostatic forces, while at pH 1.2, it shrank within a few minutes due to protonation 
of the carboxyl groups. Equilibrium swelling was observed in long duration (in 72 
hours) as compared to deswelling (25-35 minutes). The hydrogels experienced a 
number of swelling-deswelling cycles without representing any distortion in their 
shapes. This quick swelling deswelling manner of the hydrogels renders them 
appropriate nominee for controlled drug delivery systems. Since the presence of 
counter ions in the buffer solutions, the swelling capacity of hydrogel was 
significantly depleted. The maximum swelling capacity in the second cycle of the pH-
reversibility curve of Figure 4.1.4 was lower than that of the first cycle due to 
enhancement tendency of the polymer network to mix with the solution. Such on-off 
switching behavior via reversible swelling and deswelling has been reported for other 
ionic hydrogels (Pourjavadi et al., 2006; Sadeghi & Hosseinzadeh, 2008). 
5.1.3 Equilibrium water contents and gel fraction of CMAX-g-AA 
copolymer 
For all the prepared hydrogels (series A1-A9) with varying concentrations of acrylic 
acid, CMAX and N, N MBA equilibrium water contents was determined as shown in 
Table 4.1.4. EWC have been evaluated for comparison of EWC at equilibrium 
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swelling state (0.85-0.98) with the EWC of the human body cells (0.6). For biomedical 
utility of hydrogel EWC determination is an essential parameter (Maryam et al., 
2014). 
EWC of hydrogels (A1-A9) ranging from 0.85 to 0.98 with different concentrations of 
acrylic acid, CMAX and crosslinker depend on the factors which favor the 
hydrophilicity. So high water contents of the gel at equilibrium state can be elucidated 
by hydrophilicity/hydrophobicity ratio of hydrogel. Thus, CMAX-g-AA copolymeric 
hydrogels revealed fluid contents analogous to those of living tissues. Malana and 
Zohra, 2013, have been prepared terpolymers of methacrylate, vinyl acetate and 
acrylic acid cross linked with ethylene glycol dimethacrylate (EGDMA) described 
analogous conclusion. They recommended that high crosslinker contents in the gel 
obstruct hydrophilicity and consequently lower EWC and AA contents exhibit reverse 
behavior in the hydrogel. 
Gel fraction of prepared hydrogels has been investigated to evaluate the degree of 
grafting and cross linking density. Figure 4.1.5 illustrates the consequences of AA, 
CMAX and crosslinking agent concentrations on the gel fraction of different 
formulations (A1-A9) of CMAX-g-AA hydrogel. Table 4.1.4 was shown that by 
raising the concentration, of AA (10-20%w/w), gel fraction increased (68.15 to 84.11) 
CMAX (1 to 2%w/w) gel fraction increased (77.67 to 83.22) but above 1.5 %w/w 
there was no significant increment in gel fraction and MBA (0.4 to 0.8%w/w) gel 
fraction increased up to 96.40.  Amin et al.,(2014) have also reported that as the 
acrylic acid and crosslinker contents increased in hydrogel formulation gel fraction 
increased because of increased degree of grafting.(Amin et al., 2014) 
5.1.4 Instrumental analysis 
a) Scanning electron microscopy 
 
One of the most important features is microstructure of hydrogel for swelling and drug 
release. Because crosslinking ratio and hydrogels composition direct the morphology 
of hydrogels and consequently affect hydrogel swelling behavior and drug release 
characteristics. Scanning electron microscopy was brought about to analyze surface 
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morphology and porosity of hydrogels. SEM analysis was performed to study the 
morphological behaviors of hydrogels presented in photomicrographs (Figure 4.1.6) 
exhibited porous surface. Porous structure of hydrogels allows water permeation and 
provides interaction sites to external stimuli with hydrophilic group of graft copolymer 
(Nihar and Patel, 2014). 
It was also observed that porous structure of hydrogel swelled in pH 7.4 buffer and 
lyophilized become more prominent by increasing contents of acrylic acid in the 
hydrogels. This fact also has been explained that hydrogels with high acrylic acid 
concentration demonstrated a more open and porous structure as a result of 
electrostatic repulsion of the (carboxyl group) ionic charges of its complex in basic 
buffer (Thakur et al., 2011).  
b) FTIR spectral analysis 
FTIR  spectral  analysis  was  used  to  verify  the  graft  copolymerization  of 
monomer on natural polymer.  The  FTIR spectrum  of  pure  
Carboxymethylarabinoxylan (Figure 4.1.7) showed  the  characteristic  peak  at  3301 
cm
-1
 due    to  –OH stretching, –C=O of –COOH at 1629 cm-1 and ether linkage at 
1425 cm
-1
.  This can be related to the absorption of carboxymethyl groups in 
arabinoxylan and peaks at 1334, 1034, 895, 626, 618 cm
-1 
are due to polymer 
backbone. FTIR spectrum of CMAX-g-AA (Figure 4.1.7) showed characteristic peaks 
of –OH at 3286cm-1, –C=O of –COOH at 1628 cm-1and  ether linkage at 1453 and 
1400 cm
-1
, and the new bands at 1551 cm
-1
(C=O stretching vibration of -COOH 
groups), showed that AA monomers were grafted onto CMAX chains. Psyllium (Psy) 
is a natural plant polysaccharide obtained from plantago ovata and psyllium mucilage 
contain arabinoxylan (arabinose 22.6%, xylose 74.6%) (Fischer et al., 2004).  Cross-
linked Psy-g-poly (AA) showed peaks at 2857 cm
-1 
(O-H stretching of carboxylic 
acid), 2361 cm
-1
 (N-H stretching), 1737 cm
-1
 (C=O stretching in carboxylic acid), 
1636 cm
-1 (strong C…O asymmetric stretching vibration) and1400 cm-1 (weak C…O 
asymmetric stretching vibration) these peaks confirmed grafting of acrylic acid on to 
psyllium backbone (Kaith et al., 2007). 
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c) Thermal analysis 
The proof of grafting can also be verified by thermal (TGA/DSC) analysis. Thermal 
behavior of polymers was peculiar, so each polymer was prophesied to demonstrate a 
distinctive thermogram of both the parent polymer and crosslinked polymer. TGA 
studies were performed as a function of percent weight loss verses temperature. 
Decomposition of CMAX has been observed in two stages given in Table 4.1.5. 
Primary decomposition started at 266 °C and continued upto 382°C with 44.8 % 
weight loss. Second stage decomposition started at 431 °C and continues upto 562 °C 
with 25 % weight loss. While CMAX-g-AA (A) also  showed decomposition in two 
stages, initial decomposition temperature (Tdi) at 443 °C and final decomposition 
temperature (Tdf) at 515 °C with 21.1 % weight loss. Second decomposition started 
from 610 °C and ended at 616 °C with 1.17% weight loss. Second stage of 
decomposition may contribute to the decomposition of different structure of the graft 
copolymer. Tdi of CMAX was lower than that of grafted polymer because CMAX-g-
AA underwent morphological changes during grafting which modified its structure 
and properties as well, whereas Tdf of grafted polymer is slightly higher than that of 
CMAX, which showed more thermal stability as compared to the raw back bone. 
Similar results have been observed that cannabis indica-g-poly (AAc) fibers are 
thermally more stable than the raw fibers (Singha and Ashvinder, 2011). 
DSC curve of CMAX and CMAX-g-AA given in Figure 4.1.9 show that in the CMAX 
has no endothermic and exothermic peak. CMAX-g-AA exhibit endothermic peak at 
387 °C and exothermic peak at 467°C. DSC curve showed that grafting preceded to 
modifications in the thermal characteristics. It has been reported that pure polymer has 
no glass transition temperature (Tg) and melting temperature (Tm) due to strong inter- 
and intra molecular hydrogen bonding (Hatakeyama and Nakamura, 1982). Above 
mentioned justification, described that slight deviation in DSC curve of graft 
copolymer is a smashing symbol for both the presence of a Tg due to the graft side 
chains on the carboxymethyl arabinoxylan backbone and for the proof of grafting. 
These results are in good agreement with Zhe et al work. They demonstrated that 
CMC does not display any transition between -40 °C and 60 °C, while poly 
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(methylacrylate)-grafted CMC and poly(methyl acrylate) have glass transition 
temperatures at 19.2 ºC and 13.75 ºC, respectively (Zhe et al., 2011). 
d) X-ray diffraction 
Prepared hydrogel CMAX-g-MAA was investigated for amorphous or crystalline 
nature by X-ray diffraction as shown in figure 4.1.10. In general at low intensities 
diffraction decreased and peaks become broader when angle was increased depicting 
partial crystallinity of substance. Diffractogram ofXRD of formulations proved that 
graft copolymerization enlarges amorphous regions resulting in decreased value of 
percentage crystallinity. Grafting was thought to be basic reason behind amorphous 
nature of hydrogels as grafting of monomer side chain on basic polymer back bone 
imparts amorphous regions to copolymer. Chandra also reported that hydrogel 
formulations did not have any peak on x-ray difractogram giving justification on its 
highly amorphous nature (Chandra et al., 2013). With the purpose to 
approve the physical state of the Rabeprazole in hydrogel, X‐ray diffraction studies of 
unloaded formulation, drug and drug loaded formulation were conceded out. X-
ray diffractograms were shown in Figure 4.1.10 exhibited  that rabeprazole was still 
present in its amorphous state. As both polymeric network with or without drug 
showed analogous diffraction patterns. Furthermore, these results demonstrated that 
hydrogel and Rabeprazole did not interfere with each other in the formulation 
(Kazimiera, 2001). 
5.1.5: In vitro release kinetics of Rabeprazole sodium CMAX-g-AA 
hydrogel 
One of the most imperative function of hydrogels is controlled release systems, drug 
release to definite areas of the body. When close contact is ascertained to the target 
site, the rate and duration of drug release depends on the swelling manners of the 
hydrogel (Edith et al., 1999; Blancofuente et al., 1996; Donini et al., 2002). 
Mechanism of drug release from polymeric network depends upon the composition of 
network, structural design of polymer network, medium to which it exposed and drug 
concentration in the polymer. In the following study the consequences of diverse 
factors on the drug release has been illustrated. Percent cumulative release of drug 
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from the polymeric carriers as a function of time and different pH values (1.2 & 7.4) 
were conducted as shown in Tables (4.1.6-4.1.8). The factors that control swelling 
fashion of hydrogel directly influenced release of drug as concentration of acrylic acid 
(formulation A1-A3), CMAX (A4-A5) and cross linker (A7-A9) given in Figures 
(4.1.11- 4.1.13) and pH of drug release medium. At acidic pH cumulative drug release 
from CMAX-g-AA hydrogels decreased (11.52 %, 7.64%, and 3.91 %) with 
progressive increase of acrylic acid (10 %, 15 % and 20 %) contents, because 
electrostatic repulsion between the carboxylic groups of backbone was low and 
decline gel swelling and reduces release of drug (Figure 4.1.11). However, at basic pH 
OH– group raises the electrostatic repulsion between carboxylate groups, thus enhance 
the gels swelling degree and so the release of drug amplified. Swelling studies 
divulged that pH and cross-linking density control polymer swelling. Polymer 
swelling take places at a pH above the pKa of the carboxyl group of acrylic acids. 
Swelling amplifies as the COO
- 
concentration increases, while by enhancing the cross-
linking density swelling was declined. As acrylic acid impart hydrophilicity and pH 
sensitivity, so drug release accordingly. These results were supported by previous 
studies that drug release enhanced by increasing concentration of acrylic acid. High 
contents of acrylic acid causes the expansion of the coiled chains and consequences in 
better swelling of the gels (Ranjha and Mudassir 2008; Michel et al., 2011). 
Furthermore, Carboxymethyl arabinoxylan has a hydrophilic nature, when the CMAX 
concentration was increased, the hydrophilic character of the hydrogel was increased. 
As swelling of hydrogels increased by increasing concentration of CMAX, swelling 
was directly proportional to drug release (92.83%, 96.76%, and 98.44% at CMAX 
concentration 1%, 1.5% and 2% respectively at basic pH). By increasing concentration 
of crosslinker over all swelling was reduced due to growing crosslinking density of 
polymer chain so drug release was also decreased given in Table 4.1.8. A number of 
authors have reported similar findings that by escalating the MBA concentration, there 
was a decline in drug release at all pH values owing to lessen in the mesh size of 
hydrogels, which hindered spreading out of the network and chain relaxation (Chen et 
al., 2005; Li et al., 2006; Sohailet al., 2014). 
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Different mathematical models have been applied for illustrating the kinetics of the 
drug release mechanism from CMAX-g-AA polymeric network. The technique that 
best fits the release data was estimated by the regression coefficient (r). For selection 
of the most suitable model criteria was based on the best fit values of regression 
coefficient (R
2
) near to 1. Regression coefficient (r)  values for Higuchi model, zero 
order, first order and KorsmeyarPeppas model were obtained from drug loaded 
CMAX-g-AA hydrogels at different contents of AA, CMAX and crosslinker have 
been given in the Table 4.1.9. For all formulations at alkaline pH the value of  
regression  co-efficient  (R
2
)  obtained  for  zero  order  release  rate constants were 
found higher than those of others. Consequently it was deliberated that drug release 
from the formulations of varying acrylic acid, CMAX, and crosslinker contents were 
according to zero order release. Effect of formulation composition on release exponent 
„n‟ values given in Table 4.1.9 between 0.5 and 1.0 are indication of non-Fickian or 
anomalous diffusion mechanism. Previous studies revealed that psyllium mucilage 
obtained from Plantagoovata has been modified by graft copolymerization by using 
N,N MBA as crosslinker and acrylic acid grafted onto mucilage employed as drug 
carrier. The release of model drugs salicylic acid and tetracycline from the hydrogels 
at alkaline pH occurred through non-Fickian diffusion mechanism (Singh et al., 2008). 
Release dynamics of insulin from psyllium–g-acrylamide has been studied for 
evaluation of release mechanism. It was found that drug release happened through non 
–fickian diffusion pattern (Singh et al., 2011). 
5.2 Characterization of CMAX-g-MAA hydrogels 
5.2.1: Effect of variation of pH, monomer, polymer and cross-linker on 
swelling behavior of CMAX-g-MAA hydrogel 
5.2.1.1 Effect of monomer concentration on swelling 
Swelling capacity of hydrogels depends on crosslinking density, hydrophilic contents, 
ionic contents of system and surroundings, environmental pH and temperature. The 
motivating force for swelling procedure is primarily equilibrium of osmotic pressure, 
electrostatic force and entropy-assisted dissolution of polymer in water. Elastic forces 
are specially made into the hydrogel structure to organize the entropy of the 
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dissolution process. These tailor made elasticity of hydrogels preclude absolute 
dissolution of hydrogel in swelling medium (Omidian and Park, 2008).  
Swelling behavior of CMAX-g-MAA hydrogel of varying contents (monomer, 
polymer, cross linker) was investigated at acidic and alkaline pH given in Table 
(4.2.1-4.2.3). To evaluate the effect of methacrylic acid contents on swelling pattern 
series of formulations (M1, M2, and M3) with varying methacrylic acid contents from 
20%w/w, 30%w/w and 35 %w/w respectively were analyzed at pH 1.2 and pH7.4. It 
was scrutinize that at alkaline pH swelling ratio (20.85, 16.70, and 14.28 of M1, M2 
and M3 respectively) was higher than at low pH (5.03, 4.09 and 3.14 of M1, M2 and 
M3 respectively). pKa values of pH-sensitive polymers and buffer solutions perform 
major task in the swelling behavior. In literature it has been proposed that at basic pH, 
carboxyl groups of methacrylic acid repel each other, causing the swelling of the 
system. At acidic pH the carboxyl groups of methacrylic acid are unionized as a result, 
the polymer network remains in collapsed state avoid swelling. Phenomenon of 
electrostatic repulsion can also be explained by Donnan effect. Polymeric network is 
worthy of attracting counterions, causing a chemical potential gradient, osmotic 
pressure within the polymer‟s realm surmounts than that of the external solution, and 
therefore, the polymer is proficient of swelling. In the past it has been proclaimed, that 
polymeric networks containing methacrylic acid act like hydrophilic systems. Upon 
crosslinking they happen to insoluble, but are seemly to swell by protonation/de 
protonation of carboxyl group (Quintanaret al., 2008). Similar findings have been 
observed by Khare and Peppas in cross-linked poly (hydroxyethyl methacrylate-co-
methacrylic acid) and poly (hydroxyethyl methacrylate-co-acrylic acid) hydrogels 
(Khare and Peppas, 1993). It has been observed that overall swelling (20.85, 16.70, 
and 14.28; 20%w/w, 30 %w/w and 35 %w/w methacrylic contents respectively) of 
CMAX-g-MAAwas reduced by increasing concentration of methacrylic acid. 
Hydrophobic nature of methacrylic acid was responsible for reduce swelling (Jafari 
and Hamid, 2005). 
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5.2.1.2 Effect of polymer concentration on swelling 
Degree of swelling is highly pH dependent and increased by increasing concentration 
of CMAX as shown in Table 4.2.2. It may be assumed that increased contents of 
CMAX impart hydrophilicity to hydrogel. As it has been reported that 
carboxymethylation of Arabinoxylan modified its fundamental properties like 
hydrophilicity and anionic nature depending on degree of substitution (Saghiret al., 
2008) 
5.2.1.3 Effect of crosslinker concentration on swelling 
Equilibrium swelling behavior of CMAX-g-MAA copolymer with varying degrees of 
cross-linking has been examined as a function of pH given in Table 4.2.3. It was 
ascertained that changing the degree of cross-linking has a significant effect on the 
swelling behavior. It has been shown in Figure 4.2.3 equilibrium swelling ratio by 
increasing N, N MBA concentration from 0.25%w/w to 0.85%w/w decrease swelling 
from 14.28 to 8.97. Decline swelling by increasing crosslinker contents could be 
mechanistically due to decreased mesh size of hydrogel and high degree of 
crosslinking obstruct ionization process. Our findings regarding relationship of 
swelling and crosslinker contents can be correlated with the results of Khalid et al., 
who prepared poly (methyl methacrylate-co-itaconic acid) hydrogels with varying 
contents of cross linker (Khalid et al., 2009).  
5.2.2: Pulsatile behavior of hydrogel 
Swelling equilibrium studies revealed that CMAX-g-MAA hydrogels are absolute pH 
sensitive system. For controlled drug delivery system, swelling process should be 
reversible to ensure that the release of drug could be triggered and stopped instantly. 
The proficiency of the contender polymer to manifest reversibility in swelling pattern 
was examined in the solutions of pH 1.2 and 7.4. It was detected that hydrogel at basic 
pH swell due to anion-anion repulsion of carboxylate ions, however, on exposing the 
swelled hydrogel in the solution of pH 1.2 it deswell with in few minutes due to 
protonation of carboxyl groups as shown in Figure 4.2.4. Now, again on immersing 
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the deswelled hydrogel in the solution of pH 7.4 swelled again, thus representing the 
pulsatile behavior.  
This impulsive swelling-deswelling fashion at different pH values renders the system 
to be highly pH-responsive and thereby it may be a suitable candidate for designing 
controlled drug delivery systems. Similar pH dependency behavior has also been 
illustrated by other ionic hydrogels like Starch-Poly (Sodium Acrylate-co-Acrylamide) 
superabsorbent hydrogel; poly (acrylamide-co-methacrylic acid) grafted Gum ghatti 
based hydrogels (Sadeghi and Hosseinzadeh, 2008; Hemant et al., 2010). 
5.2.3: Equilibrium water contents and gel fraction 
It has been observed that the xerogel starts to drink water when it was placed in an 
aqueous media. Hence, determination of the extent of water gulped within the 
hydrogel is vital measure for illustrating the hydrogel for biomedical applications and 
is frequently symbolized equilibrium water contents, directly proportional to 
hydrophilicity of copolymeric network. Equilibrium water contents of CMAX-g-MAA 
was evaluated given in Table 4.2.4, revealed the effect of composition of hydrogel 
effect water absorbing capacity of hydrogels. It was scrutinizes that CMAX contents 
(1%w/w. 1.5%w/w and 2%w/w) promoted EWC (0.95), but increasing methacrylic 
acid contents (EWC=0.95-0.91) and crosslinker concentration (EWC= 0.92-0.81) 
obstruct water diffusion through hydrogels. Amount of water imbibed within the 
hydrogel impacts the diffusional characteristics of a drug through the hydrogel. 
Generally, the higher the equilibrium water contents, higher will be the diffusion rate 
of the solute. Micro-architecture of graft copolymer also one of the major controlling 
factor of EWC(Wei et al., 2009).  
Figure 4.2.5 showed the effects of methacrylic acid, CMAX and crosslinking agent 
(N, N MBA) concentration on the gel fraction of different formulations of CMAX-g-
MAA hydrogel. It was ascertained that by raising the concentration of MAA 
(M1toM3),  and  N, N MBA  (M7 to M9)  gel  contents were increased  while  sol  
fraction decreased  and  by  increasing  the  concentration  of  CMAX (M4 to M6) gel 
fraction increase upto 1.5% of polymer contents and above that remain constant. It has 
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been reported that reactivity of the monomers and radicals in copolymerization was 
determined by the nature of substituent in the double bond of the monomer. The 
methyl group of methacrylic acid may motivate the double bond, making the monomer 
more reactive than acrylic acid. Peppas  and  Klier  prepared poly  (methacrylic  acid-
g-ethylene glycol)  hydrogels, and narrated that  high MAA  concentration  formed  
efficient network (high gel contents) due  to the  higher  concentration  of reactive  
vinyl  groups in monomer  resulting  in  highly  crosslinked  matrix (Peppas  and  
Klier, 1991). 
5.2.4: Instrumental analysis 
a) Scanning electron microscopy 
The surface morphology of CMAX-g-MAA hydrogel was investigated by scanning 
electron microscopy (SEM). Figure 4.2.6presented SEM micrograph of the polymeric 
hydrogels. These photomicrographs confirm that synthesized polymer (CMAX-g-
MAA) have a porous structure. At high magnification and lyophilized hydrogels 
(Figure 4.2.6) displayed a large, open, channel-like structure. Similar porous structure 
has been reported for crosslinked graft copolymer of methacrylic acid and gelatin 
(Sadeghi and Heidari, 2011).  These interconnected pores could be suitable for 
controlling drug release by diffusion. Porosity of hydrogels depends on diverse factors 
like nature of monomer, reaction conditions, amount of diluent (water) and 
crosslinking density (Sadeghi, 2011). 
b) FTIR spectral analysis 
For polymer characterization one of preferred method is FTIR spectroscopy. To 
confirm grafting, FT-IR spectra of three samples (CMAX, MAA, and CMAX-g-
MAA) were examined. 
The  FTIR spectrum  of  pure  Carboxymethyl arabinoxylan (Figure 4.2.7) showed  the  
characteristic  peak  at  3301 cm
-1
 due    to  –OH stretching, –C=O of –COOH at 1629 
cm
-1
 and ether linkage at 1425 cm
-1
. This can be related to the absorption of 
carboxymethyl groups in arabinoxylan and peaks at 1334, 1034, 895, 626, 618 cm
-1 
are due to polymer backbone. These results are in accordance with Saghiret al., work, 
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they prepared carboxymethylatedarabinoxylan by etherification method and 
characterized by FTIR spectra (Saghiret al., 2008). 
Spectrum of CMAX-g-MAA(Figure 4.2.7) shown three new distinctive absorption 
peaks at 1692, 1536 and 1445 cm
−1
authenticating the architecture of graft copolymer 
product. These new bands accredited to carbonyl stretching of the carboxylic acid 
groups and symmetric and asymmetric stretching modes of carboxylate anions, 
respectively. Similar findings have been illustrated for poly methacrylic acid grafted 
onto psyllium for confirmation of grafting (Ranvijay et al., 2013) 
c) Thermal analysis 
TGAthermogram of CMAX-g-MAA (Figure 4.2.8) illustrated that thermal 
degradation of graft copolymer was accomplished in two steps, 66 
o
C to 152 
o
C and 
435 
o
C to 536 
o
C with weight loss 21.1%and 31.05% respectively. Middle thermal 
degradation temperature values, of both steps are 94 
o
C and 462 
o
C.  Complete loss of 
pure methacrylic acid was detected below 200 
o
C as shown in Figure 4.2.8. Thermal 
decomposition of pure polymer CMAX was occurred in two steps initial degradation 
temperature of first segment is 266
 o
C and of second is 431
 o
C. Tdf of both steps are 
382
 o
C and 562
 o
C with 44.8% and 25% weight loss. Total weight loss of graft 
copolymer is less than raw polymer, depicted thermal stability of graft copolymer. It 
has been illustrated in previous studies that weight loss in the range of 150–250 oC is 
due to the formation of anhydride with elimination of H2O molecule from the two 
neighboring carboxylic group of the grafted chains. The second segment of 
degradation was credited to the decarboxylation of the anhydrides formed earlier. The 
change of thermal behaviors confirmed the formation of grafted copolymer. Xanthan 
gum grafted with methacrylic acid represented such type of thermal behavior (Kumar 
et al., 2007).   
DSC curve of CMAX-g-MAA hydrogel revealed exothermic peak at 401
 o
C and 
endothermic peak at 517 
o
C as shown in Figure 4.2.9. These peaks confirm grafting 
because these are absent in polymer backbone DSC curve. Thermal stability and 
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endothermic–exothermic behaviors of graft copolymer related to the increase of 
molecular weight and addition of functional groups (Wang et al., 2011). 
d) X-ray diffraction 
Prepared hydrogel CMAX-g-MAA was investigated for amorphous or crystalline 
nature by X-ray diffraction as shown in figure 4.2.10. Diffractogram of XRD of 
prepared hydrogel proved that graft copolymerization imparted amorphous 
characteristics. Grafting was thought to be basic reason behind amorphous nature of 
hydrogels as grafting of monomer side chain on basic polymer back bone imparts 
amorphous regions to copolymer. Chandra also reported that hydrogel formulations 
did not have any peak on x-ray difractogram giving justification on its highly 
amorphous nature (Chandra et al., 2013). The X-ray diffractograms of drug free 
hydrogel (M), drug (Rab) and drug loaded hydrogel (MD) were given in Figure 4.2.10. 
X-ray diffractograms documented for drug loaded and unloaded formulation did not 
express any distinctive peak, signifying that the captured drug was sustained 
amorphous state. 
4.2.5:In vitro release kinetics of Rabeprazole sodium CMAX-g-MAA 
hydrogel 
We were interested in developing a polymer which shows no swelling at low pH 
values and maximum swelling at higher pH value. In order to simulate the possible 
effect of pH on drug release rate, in vitro release studies were performed at acidic and 
alkaline pH values at physiological temperature of 37 °C. To explain release curves, 
three main factors have to be taken into account: pH sensitivity, graft copolymer 
composition and nature of individual constituent and crosslinking density of graft 
copolymer.  In vitro release study has revealed that composition of the graft 
copolymer absolutely control release of drug. Figure 4.2.11 indicated that as contents 
of methacrylic acid raised (20%, 30% and 35 %), pH sensitivity enhanced (CPDR at 
basic pH is 84.19%, 75.9%, 71.26 and at acidic pH CPDR10.3%, 7.7% and 5.33%)   
but overall swelling reduced so percent cumulative drug release has been declined. 
Swelling analysis of CMAX-g-MAA hydrogel has been represented that overall 
swelling reduced by increasing concentration of methacrylic acid. Hydrophobic nature 
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of methacrylic acid was responsible for reduce swelling (Jafari and Hamid, 2005). The 
affirmative Rabeprazole sodium release depiction could be accredited to the pH-
sensitivity of the hydrogel. Swelling of such hydrogels in the stomach was minimal so 
drug release consequently low. A similar practical approach has also been narrated by 
other researchers; pH sensitive methacrylic acid containing hydrogels can bypass the 
acidity of gastric fluid without liberating substantial amounts of the loaded drug (Lim 
and Lee, 2005). 
Figure 4.2.12 revealed that by increasing concentration of CMAX (1%, 1.5% and 2%) 
percent cumulative release was increased at basic pH (79.78%, 87.93% and 90.06 % 
respectively) and become very low at acidic pH (4.91%, 3.17% and 2.93%). These 
results indicate that by increasing CMAX content of the hydrogels enhanced pH 
sensitivity, hence cumulative drug released at basic pH.  This fact may be related with 
increased hydrophilicity of hydrogel by increasing CMAX contents, could be 
explained by free volume theory. This theory was suggested that solute diffuses only 
through aqueous region, so effective free volume available for transport of solute is 
free volume of water in gel in swollen state (Varshosaz and Koopaie, 2002). 
Effect of MBA concentration on release of drug has been shown in Figure 4.2.13 
revealed that high crosslinking density lead to low cumulative percent drug release 
i.e., 55%. This could be due to the fact that at higher crosslinking, reduced free 
volume of the matrix, thereby obstructing the transport of drug molecules through the 
matrix (Bhattarai et al 2010).  
Numerous drug release models were practiced for analyzing the rabeprazole sodium 
release kinetics. Principles for choosing the apropos model were based on the ideal fit 
specified by the values of regression coefficient (R
2
) near to 1. Regression coefficient 
(R
2
) values obtained from CMAX-g-MAA hydrogels at varying contents of MAA, 
CMAX and N, N, MBA for zero order, first order, higuchi and korsemeyer peppas 
model are given in table 4.2.9. Values of R
2
 obtained using zero order release model 
were viewed higher than other order release model, thus depicting that drug release 
from the series of hydrogels at varying amount of MAA, CMAX and N,N MBA was 
zero order. Release kinetics of drug from hydrogels have been used to describe the 
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relationship between drug dissolution and geometry of hydrogels on drug release 
patterns mathematically. It is apparent from the literature that no single approach was 
widely accepted to determine for similar dissolution profiles (Serraa et al., 2006).  
5.3 Characterization of CMC-g-AA hydrogels 
5.3.1: Effect of variation of pH, monomer, polymer and cross-linker on 
swelling behavior of CMC-g-AA hydrogel 
5.3.1.1 Effect of monomer concentration on swelling 
The rationale behind this study of grafting of acrylic acid on CMC was to increase the 
number of –COOH groups in CMC. These –COOH groups were expected to 
participate in minimizing the swelling at pH 1.2 and maximizing the swelling at pH 
7.4. The limited swelling at low pH has consequently decreased the loss of loaded 
Rabeprazole sodium in gastric region. 
Controlled release through oral drug delivery was usually based on the strong pH 
variations encountered when transitioning from the stomach to the intestine. The 
equilibrium swelling behavior of CMC-g-AA was studied as a function of pH and time 
at 37
o
C. For this purpose , a series (CA1 to CA3) with varying contents of monomer 
(AA), (CA4 to CA6)  with varying contents of CMC, (CA7 to CA9) with varying 
contents of cross-linker were synthesized. While altering the single constituent 
amount, other contents amount were kept constant.  
It was observed that swelling ratio of the hydrogel was low in acidic medium and high 
at basic pH which was due to ionization of COOH groups of Acrylic acid at pH 7.4 
(David et al., 2008). At low pH, anionic group remain protonated the gel exhibited 
syneresis and the swelling rate and ratio was low. Thus, as pH rose the carboxylic acid 
groups on the PAA became progressively more ionized. In these cases, the hydrogels 
swelled more rapidly due to a large swelling force created by the electrostatic 
repulsion between the ionized acidic groups. Thus CMC-g-AA revealed pH sensitive 
behavior and as the acrylic acid contents increased this response has been more 
pronounced. Huang et al (2007) prepared guar gum poly (acrylic acid) hydrogels and 
observed the similar swelling and drug release behavior. They reported that the 
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swelling and ketoprofen release was increased with increase of PAA content in the gel 
structure. 
Parallel rise in swelling behavior was observed with concentration of acrylic acid. This 
phenomenon can be related to the increasing of anionic –COO- groups in the 
hydrogel. In  addition,  higher  AA  content  enhanced  the  hydrophilicity  of  
hydrogel,  causing  a  higher absorption of buffer.  Toledano et al, (2005) have also 
reported that the water absorption capacity of poly (acrylic acid) (PAA)-grafted-
cellulose microfibers was found to be three times higher than that of original cellulose 
microfibers at alkaline pH. Water absorbing capacity will depend on degree of 
ionization, grafting percentage and ionic strength of swelling medium. 
5.3.1.2 Effect of polymer concentration on swelling 
It was observed that swelling of graft copolymer increased with an increasing 
concentration of CMC up to optimum level. Above that concentration swelling ratio 
was decreased. Figure 4.3.2 showed swelling ratio was increased (35.3, 37.8, and 43.3 
of CA4, CA5 and CA6 respectively)with increased CMC concentration (0.5 %, 1%, 
and 1.5%) respectively but decreased(31.6) at 2% concentration of CMC. The increase 
in CMC content within the hydrogel shifts the position of the pH threshold to a lower 
values, as well as it reduces the magnitude of the phase transition. The effect of the 
increase of CMC content on position and magnitude of such phase transition might be 
attributed to the hydrophilic character of the CMC, as well as the crosslinking density. 
However, upon further increase in the polymer concentration, increase in the reaction 
medium viscosity, restricts the movements of macroradicals that was leading to 
decrease in grafting ratio.  
Wang et al (2013) has been reported that with increasing content of CMC, the 
swelling ratio of the hydrogel increased up to optimum increment and then decreased.  
As the CMC concentration was increased the macromolecular radicals used to graft 
with monomers were increased and the grafting efficiency was enhanced. As a result, 
swelling ratio increased with increasing CMC content. Beyond this limit, increased 
contents of CMC may enhanced the viscosity of the reaction system the chain transfer 
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reaction was restricted, which decreases the grafting efficiency ultimately swelling 
decreased.  
5.3.1.3 Effect of crosslinker concentration on swelling 
Effect of crosslinker concentration (Cc) on rate of swelling of crosslinked CMC-g-
(PAA) was investigated. As shown in Figure 4.3.3, more swelling ratio (32.3g/g) was 
obtained by lower Cc (0.4%) and less swelling ratio (23.8g/g) by higher Cc (0.8%). 
Higher crosslinker concentration increased crosslinking density of graft copolymer, 
that may resulted in more stabilization of the gel network. Crosslinked rigid structure 
cannot be expanded,  resulted in  less  swelling  when  it  was  brought  into  contact  
with  solvent. During the swelling process, it was also observed that the discs having 
relatively low concentration of cross linker were de-shaped at their boundaries, which 
could be attributed to the faster rate of swelling. Chandra et al., (2013) reported  the 
good  crosslinker concentration dependent  swelling behavior of semi-IPN 
(interpenetrating network), as the crosslinker concentration was increased the swelling 
ratio decreased that was because the higher  extent of crosslinking in the polymer 
network  decrease diameter of pores of resultant hydrogels leading to decrease solvent 
mobility. 
5.3.2: Pulsatile behavior of graft copolymer 
The pH-dependent swelling reversibility of the CMC-g-AA was examined in buffered 
solutions of pH 1.2 and 7.4 as shown in Figure 4.3.4. It was evident from the plot that 
the swollen networks reverted to relatively collapsed networks whenever the pH 
decreased below pKa of the gel and that the deswelling time was faster than the 
swelling time. Swelling at pH 7.4 may take place due to anion-anion repulsion 
electrostatic forces and deswelling at low pH is due to protonation of carboxylate ions. 
After four On–Off cycles, the graft copolymer was still pH responsive. Swelling ratio 
was decreased and swelling time increased in every consecutive cycle, this may be due 
to some irreversible ionic complex. This pH reversibility makes the graft copolymer 
suitable candidates for controlled drug delivery systems. Sadeghi and Heidari (2011) 
described that hydrogels  exhibited  high pH responsive  behavior by  reversible  
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swelling- deswelling  response  in acidic and basic solutions renders hydrogels  as  a  
good  candidate  for  controlled  drug delivery systems. 
5.3.3: Equilibrium water contents and gel fraction 
Equilibrium water contents (EWC) were measured for hydrogels (CA1-CA9), 
composed of varying strength of acrylic acid, CMC and crosslinker. The data obtained 
for EWC was given in Table 4.3.4. It was shown that the amount of water taken in the 
hydrogel samples increased from 0.96-0.99. By increasing acrylic acid contents EWC 
value was increased (0.96-0.98), this may be strengthened by the fact that acrylic acid 
contain COOH functional groups. Ionization of these groups causes excessive 
repulsion between the coiled chains which is ultimately responsible for retaining more 
water. Another fact which can be used to explain the increased value of EWC was 
owing to more hydrophilic characteristics of acrylic acid. CMC also impart 
hydrophilic character to hydrogels also improve EWC value of hydrogels. Increasing 
crosslinker contents reduced EWC of hydrogel because of high crosslinking density 
may lead to depleting microchannels for water transport. Wang and Wu (2005) 
suggested that increasing hydrophobic contents in hydrogel leads to lower EWC in 
hydrogels. 
Results of gel fraction of different formulations of CMC-g-AA were presented in 
Figure 4.3.5. It was perceived that by increasing hydrogels constituents enhanced gel 
fraction and reduced sol fraction of hydrogels. Amin et al., (2014) have also reported 
that as the acrylic acid and crosslinker contents increased in hydrogel formulation gel 
fraction increased because of increased degree of grafting (Amin et al., (2014). 
5.3.4 Instrumental analysis 
a)Scanning electron microscopy 
SEM images showed dense three dimensional porous network structure. This picture 
verified that synthesized graft copolymer in this work have a porous structure. It was 
supposed that these pores were areas of solvent permeation responsible for swelling. 
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Figure 4.3.6 depicted that hydrogels at high magnification displayed large, open and 
channel like structure. 
b) FTIR spectrum analysis 
FTIR spectrum of the pure CMC, Figure 4.3.7 showed a broad absorption band at 
3352 cm
-1
, due to the stretching frequency of the –OH group and a band at 2924 cm-1 
attributable to C H stretching vibration. The presence of strong absorption band at 
1589 cm
−1  
confirmed the presence of COO− group. The bands around 1420 and 1320 
cm
−1 
are assigned to CH2 scissoring and OH bending. FTIR spectrum assigned to 
stretching vibration of carbonyl is generally used for the confirmation of grafting. As 
the new bands at 1703 cm
-1 
(C=O stretching vibration of -COOH groups), and 1450 
cm
-1
 (COO symmetrical stretching vibration of -COO groups) reveal that AA 
monomers were grafted onto the CMC chains. 
c) Thermal analysis 
The thermo gravimetric analysis (TGA) of hydrogel (CA) given in Figure 4.3.8 was 
depicted that the hydrogel was thermally stable. According to thermogram, the 
decomposition of hydrogel (CA) started at 300 ºC. The first step of degradation due to 
dehydration is observed up to 365ºC with 20 % weight loss.  Second  step  of  
degradation  is  observed  from  365-450 ºC with 15.17%  weight loss and third step 
from 450ºC -586ºC with 21.782% weight loss  due  to  degradation  of  functional 
groups of hydrogel.  
DSC is the thermal analysis method practiced to evaluate the temperatures and heat 
ﬂows linked with shifts as a function of time and temperature. Transition related with 
absorption or emission of heat created alteration in heat flow. Difference in energy 
recorded as peak. Area under the peak is directly related with enthalpy changes and 
direction of peak designates the thermal episode as endothermic or exothermic.  
The endothermic peak of CMC below 100 ºC was evidently punier than that of CMC-
g-AA, and the new endothermic peak at 450 ºC also seemed in the DSC curve of 
CMC-g-AA displayed in Figure 4.3.9. This signpost that the thermal decomposition 
160 
 
progression was comforted by grafting. Higher glass transition temperature value of 
prepared hydrogel (450 ºC) than pure parent polymer (325 ºC) can be accredited to the 
higher intermolecular hydrogen bonding as a result of grafting. Previous work has 
been described that shift to higher decomposition temperature could be accounted to 
formation of covalent bonds in the graft copolymers, and improved thermal stability 
(Wang et al., 2010). 
4.3.5:In vitro release kinetics of Rabeprazole sodium CMC-g-AA 
hydrogel 
Physiological variations of pH are present along gastrointestinal tract i.e. pH 1.2 to pH 
7.4. (Chickpetty et al., 2010). In the present study %cumulative drug release from 
CMC-g-Acrylic pH sensitive hydrogel ranges from 3.12% to 10.66% during early 24 
hrs of dissolution release in simulated acidic pH medium of stomach (i.e. pH 1.2) 
while it range from 50.68% to 80.75% depending upon varying amounts of CMC, 
acrylic acid and cross linker as shown in Tables (4.3.5, 4.3.6 and 4.3.7 respectively). 
Percent drug release from pH sensitive gel increases by increasing amounts of 
polymer and monomer (i.e. Carboxymethyl cellulose and acrylic acid). While 
%cumulative drug release decreases with increasing concentration of cross linker as 
supported by values of decreasing %cumulative release of CA7 to CA9 i.e. 4.82 to 
3.12 in 24 hrs of dissolution release in simulated acidic pH and 63.17 to50.68 in 
simulated intestinal medium. 
Increase in % cumulative drug release can be justified by increasing molar ratio of 
polymer or monomer which was due to optimized swelling ratio of formulations with 
increasing concentration of polymer/monomer by polymer chain expansion. In fact by 
increasing polymer/monomer ratio enhanced swelling capacity at alkaline pH was 
imparted to formulations. These characteristics also imparts better swelling rates and 
smart swelling behavior in pH sensitive environment i.e. pH ranging from 1.2 to 7 
which propose such formulations as good candidate for controlled drug delivery 
systems (Wang et al., 2013). 
Same type of study was conducted in 2013 which showed that swelling ratio enhanced 
with increasing CMC content until a maximum absorption which ultimately effects 
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drug release from formulation in same pattern. The approach behind was as molar 
ratio of CMC increased, macromolecular radicals that were used to graft with 
monomers were increased. As a result grafting efficiency was enhanced resulting in 
increased swelling ratio with increasing CMC content. Ultimately drug release is also 
effected by same pattern by increasing concentration of CMC (Wang et al., 2013). 
In present study pH sensitive behavior of formulations can be supported by another 
study conducted by other researchers where it was clearly elaborated that swelling 
coefficient was significantly higher at higher pH as compared to low pH. It was also 
worth mention that swelling of hydrogel was decreased by increasing the 
concentration of cross linker due to presence of more physical entanglements between 
hydrogels (Nazar and Umbreen 2014). Both factors supported the results of present 
study i.e. percent cumulative drug release increases from acid to basic pH and it 
decreased with increasing concentration of crosslinker. 
To obtain a more quantitative understanding of the transport kinetics in the hydrogel, 
the drug release data was analyzed as a function of the time. The drug release data 
from a polymeric disc in glassy state is mainly modeled with the following empirical 
kinetic power equation to estimate the release kinetic parameters. 
Mt/M∞ = k ∙ t
n     
Eq (3) 
log (Mt/M∞) = n ∙ log t + log k        Eq (4) 
where Mt/M∞ is the fractional release of drug in time t, k is a  constant  incorporating  
structural  and  geometric characteristic  of  the  system,  and  n  is  an  exponent 
indicative of the mechanism of drug release. The n and k values could be calculated 
from the slope and intercept of the plot of log (Mt/M∞) against log t using equation 
(4).  We plotted log (Mt/M∞) against log t of the experimental data according to 
equation 3. A typical plot of log (Mt/M∞) versus log t for rabeprazole sodium at 37 ºC 
showed linearity, indicating that the Peppas equation is applicable to the present 
system.  As  a  first  approach, release exponents, n, regression coefficients, (R
2
) from 
the drug delivery system were obtained  by  these  plots  and  are  listed  in  Table 
4.3.8.  The value  of  n  for  Rabeprazole sodium mentioned in Table 4.3.9 indicating 
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that the release of Rabeprazole sodium was an anomalous transport instead  of  a  
swelling‐controlled  transport (Huang and  Brazel  2001, Ritger and  Peppas , 1987, 
Korsmeyer et al,. 1983, Peppas et al,. 1987). 
5.4  Characterization of CMC-g-MAA hydrogels 
5.4.1 Effect of variation of pH, monomer, polymer and cross-linker on 
swelling behavior of CMC-g-MAA hydrogel 
5.4.1.1 Effect of monomer concentration on swelling 
The best exigent task in the development of drug delivery systems is to deal with 
instabilities of drugs in the cruel environment of the stomach. Swelling capacity in 
varying pH buffer solutions is of prime significance practical applications for 
controlled drug delivery system Equilibrium swelling capacity of hydrogels depends 
on hydrogel structure, crosslinking density, ionic contents and hydrophilicity of 
hydrogel (Omidian and Park 2008) 
In present study dynamic swelling studies of CMC-g-MAA were executed to 
scrutinize the swelling behavior of hydrogels prepared using a different molar ratio of 
carboxymethyl cellulose, methacrylic acid and N, N MBA (crosslinker).  Figure 4.4.1 
showed swelling profile at different pHs for hydrogels prepared with varying 
methacrylic acid (monomer) contents. It was observed that hydrogels revealed pH 
sensitive behavior. At pH 1.2 hydrogels remained in collapsed state, showed less 
swelling. At alkaline pH swelling ratio was increased owing to dissociation of pendant 
acidic group (carboxylate group) of hydrogel. It has been proposed that as the 
methacrylic acid contents (20%, 30% and 35%) were increased, pH sensitivity of 
hydrogels augmented. At pH 7.4 exhibited chain relaxation process due to repulsion 
among –COO- groups sideways macromolecular chains formed from the ionization of 
carboxylic groups. Electrostatic repulsion caused the network to expand and solvent 
entered causing swelling at high pH. The equilibrium water absorption of hydrogel 
manifested its swelling capacity and was a function of the network configuration, the 
crosslinking ratio, hydrophilicity and the degree of dissociation of the functional 
groups. Similar swelling behavior has been depicted by HEMA-co-MAA hydrogel. 
HEMA-co-MAA revealed highly pH sensitive behavior but less equilibrium water 
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uptake because of methyl group, promoted hydrophobicity to polymeric network thus 
obstruct expansion (Khare and Peppas, 1995). 
5.4.1.2 Effect of polymer concentration on swelling 
Effect of carboxymethyl cellulose concentration on swelling capacity and pH 
sensitivity have been depicted in Figure 4.4.2. It was observed that increased contents 
of CMC (1%, 1.5%), there was decrease in swelling (26.45, 24.89). This fact may be 
related with increase gel fraction increased number of crosslinks per unit volume, thus 
causing a decrease in the free space for lodging of water molecule. Additionally, the 
increased firmness of the network also limited the relaxation of macromolecular 
chains in the matrix, thus directing to minor degree of swelling. Swelling profile of 
CMC-g-MAA hydrogels at alkaline pH revealed pH sensitivity, owing to negatively 
charged groups (carboxymethyl groups (-COOCH3) in CMC increases the electrostatic 
repulsions between the polymer chains and permitted entry of fluid into hydrogel 
network thus enhance swelling ratio. Swelling at acidic pH was inhibited by collapsing 
the polymeric chains (protonation) and hindering the solvation of the hydrogel. 
Previous studies described similar CMC behavior in hydrogel swelling (Gabriela et 
al., 2011). 
5.4.1.3 Effect of crosslinker concentration on swelling 
In order to evaluate the effect of crosslinker contents on swelling three samples with 
varying concentration (0.2%, 0.3% and 0.4%) of N, N MBA has been prepared and 
observe their swelling profile. Figure 4.4.3 showed that increased crosslinker contents 
reduced swelling due to compact and dense polymeric network. Similar findings have 
been described by other researchers that high degree of crosslinking of hydrogels 
produce less porous network had a low swelling ratio (Lee et al., 2004). 
5.4.2: Pulsatile behavior of hydrogels 
To evaluate the pH responsive behavior of prepared hydrogels reversible oscillatory 
swelling experiment has been conducted. Pulsatile behavior of CMC-g-MAA has been 
shown in Figure 4.4.4, demonstrated that hydrogels undergo volume phase transition 
at acidic and basic pH due to protonation/and deprotonation of pendant groups 
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attached with copolymer chain leads to conformational changes. The pH-responsive 
swelling and collapsing style of CMC-g-MAA hydrogel was required for controlled 
release of acid sensitive model drug (rabeprazole sodium) in our study. Literature has 
been supported our findings that ionic hydrogels represent reversible swelling and 
deswelling behavior in response to pH transition due to electrostatic interactions of 
hydrogels and swelling medium. The most common pH-sensitive hydrogels were 
poly(acrylic acid) (PAA), poly (methacrylic acid) (PMAA), poly (diethylaminoethyl 
methacrylate) (PDEAEMA), and poly (dimethylaminoethyl methacrylate) 
(PDMAEMA), and their copolymers (Zhang and Peppas, 2000). 
5.4.3: Equilibrium water contents and gel fraction  
It has been reported that constituent that impart hydrophilic character to hydrogel 
improve water contents of hydrogels. Table 4.4.4 showed the variation of EWC of 
CMC-g-MAA hydrogels in varying quantities of CMC, MAA and croslinker. The 
values of EWC increased with increase of CMC content in the hydrogels. It was 
increased from 0.95-0.97 for the concentration of CMC in the range 1 to 2% in the 
hydrogels.  CMC has high attraction to water due to existence of carboxyl group in it, 
as a result EWC of CMC-g-MAA hydrogels increased. Such characteristics of 
carboxymethyl cellulose (CMC) has also been reported that it improves EWC 
properties of poly (vinyl alcohol)/sago blend hydrogel due to  the presence of the 
carboxylic group in the CMC molecules. Results also described that by increasing 
methacrylic acid amount and crosslinker contents decreased EWC values of hydrogels 
because of hydophobic nature (Dafader et al., 2009). 
Figure 4.4.5 showed the effect of different concentrations of carboxymethyl cellulose, 
methacrylic acid and crosslinker (N, N MBA) on gel fraction. It can be explained on 
the basis of results that by increasing concentration of individual constituents 
increased gel fraction. Optimized reaction conditions and increased contents provide 
sufficient grafting site, monomers and crosslinking density favor high gel fraction. It 
was also reported that by increasing crosslinker contents in hydrogels resulted in high 
crosslinking density ultimately higher gel contents (Chen et al., 2010).  
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5.4.4: Instrumental analysis 
a) Scanning electron microscopy analysis 
Porous structure of hydrogel is prerequisite for their application in controlled drug 
delivery. Because porosity enhance the swelling capacity so, reduce drug transport 
resistance. CMC-g-MAA photomicrographs shown in Figure 4.4.6 were exhibiting 
that hydrogel was compact, smooth and dense surface at low magnification and at high 
magnification exhibited heterogeneous pore distribution in the structure. These 
morphological modifications related to grafting of methacrylic acid on to CMC 
accelerate penetration of water, promote swelling. The porosity plays the multiple role 
for drug loading and release from the hydrogels. Similar findings have been reported 
for pH-Sensitive Poly(ethylene oxide) grafted methacrylic acid and acrylic acid 
hydrogels (Lim and Lee, 2005). 
b) FTIR spectrum analysis 
In Figure 4.4.7 FTIR spectrum of pure sample showed, evidently exposes the major 
peaks allied with NaCMC. Previous studies have described that absorption bands seem 
at wave numbers of 1500-1700 cm
-1 
due to carboxyl groups and its salts respectively 
(Daniela et al., 2012).The band at 1030 cm
-1
 was due to carboxymethyl ether group  
(CH O CH2-) stretching. Strong absorption band at 1589 cm
-1
 shown in Figure 4.4.7 
confirmed the presence of C=O group, designated CMC. The band at 2924 cm
-1 
was 
due to C–H stretching of the –CH2 and CH3 groups.The band around 1322 cm
-1
 was 
assigned to OH bending vibration. General absorption band at 3200 - 3600 cm
-1
, due 
to the stretching frequency of the –OH group. (Auda et al., 2014) 
FTIR spectrum in Figure 4.4.7  is associated with CMC-g-MAA (CMA) hydrogel.It 
can be perceived that important peaks at 1691, 1641 and  1443cm
−1
 authenticating  the 
development of graft copolymer product. These peaks  ascribed to carbonyl stretching 
of the carboxylic acid groups and symmetric and asymmetric stretching styles of 
carboxylate anions, respectively.This fact practically proved grafting of vinyl 
monomer onto carboxymethyl cellulose polymer backbone.  Previous study revealed 
that FTIR spectra of the grafted (starch garfted with methacrylic acid) sample specify 
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the advent of identical absorption bands which were  not observed in the spectrum of 
polymer backbone (Deepak and Reena, 2012). 
c)Thermal analysis 
Thermogram given in Figure4.4.8 CMC exhibited two distinct decomposition phases 
in its thermogravimetric curve. The first one was in temperature range of 51-89
o
C 
allied with loss of moisture (4.76 wt %), and the second one was in the range 255-
314
o
C with maximum weight loss (36.08%), related with decomposition of 
carboxymethyl group. The maximum decomposition of the CMC-g-MAA 
hydrogels occurred in a temperature range of 447 - 531
o
C, with approximately 21.79 
% weight. Significantly, the remaining weight of the hydrogels at Tdf was far higher 
than the parent constituents. Higher remaining mass in the thermal profile of hydrogels 
designated higher thermal stability of the hydrogels than of the individual constituents. 
Preceding research has also been designated that graft copolymerization of natural 
polymer with vinyl monomers could augment their thermal stability (Silva et al., 
2007). DSC is the thermal analysis method practiced to evaluate the temperatures and 
heat ﬂows linked with shifts as a function of time and temperature. Transition related 
with absorption or emission of heat created alteration in heat flow. Difference in 
energy recorded as peak. Area under the peak is directly related with enthalpy changes 
and direction of peak designates the thermal episode as endothermic or exothermic.  
The endothermic peak of CMC below 100 ºC was evidently punier than that of CMC-
g-MAA, and the new endothermic peak at 495ºC also seemed in the DSC curve of 
CMC-g-MAA (Figure 4.4.9).This signposts that the thermal decomposition 
progression was comforted by grafting. Previous work has been described that shift to 
higher decomposition temperature could be accounted to formation of covalent bonds 
in the graft copolymers, and improved thermal stability (Wang et al., 2010). 
4.4.5:In vitro release kinetics of Rabeprazole sodium CMC-g-MAA 
hydrogel 
Rabeprazole sodium release studies were conducted to a maximum period of 24 hrs in 
buffer of pH 1.2 and Tris buffer of pH 8 in accordance with the US Food and Drug 
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Administration. Results displayed in Figure 4.4.10showed rabeprazole sodium 
released from a gel  containing 20 %, 30 % and 35 %w/w MAA at constant CMC and 
cross- linker contents. It was viewed that maximum  drug released at pH 1.2 was 
(11.69 %, 7.80 %, and 5.59 % respectively) after 24 hrs with increasing contents of 
methacrylic acid. However, 63.11 % to 71.85 % of the total drug loaded was released 
at pH 8 in 24 hrs. These results are correlated with pH responive swelling of 
hydrogels. Analogous findings were depicted in previous studies, pH sensitive 
poly(methacrylic acid-g karaya gum) synthesized graft copolymer exhibited pH 
responsive swelling and drug release pattern (Momin et al., 2014). 
Effect of carboxymethyl cellulose contents on percent cumulative drug reease have 
been studied. Results displayed in Figure 4.4.11 revealed that percent cumulative drug 
release  at acidic pH (1.2) and at alkaline pH (8) were in accordence with swelling 
fashion of CMC-g-MAA hydrogels. High CMC contents increase hydrophilicity and 
dominent anionic properties to hydrogels, augment pH sensitivity and drug release 
accordingly. 
Effect of concentration of crosslinker has also been studied, results presented in Table 
4.4.8. Figure 4.4.12 revealed that by modulation in crosslinking density of hydrogels, 
decreased percent cumulative drug release due to compact and highly dense network 
restricted permeation of release medium ultimately declined swelling. Our findings are 
correlated with previous work that high crosslinker contents reduced free spaces for 
drug transport from meshwork of polymer (Varshosaz and Niloufar, 2002). 
To evaluate the release mechanism from hydrogels drug release data was analysed by 
various release kinetics models, zero order kinetics, first order kinetics, Higuchi 
model, and Korsemeyer Peppas equation. Most appropriate mechanism was explained 
on the basis of best fitness of release model. The release model can be anticipated by 
deliberating the regression value nearby 1. The  kinetics  of  drug  release governed by  
comparative drive  of  the  erosion  and  swelling/diffusion fronts.  
To comprehend the rabeprazole sodium release from loaded graft copolymeric 
network, in vitro release studies data were  fitted  into release models as shown in 
Table 4.4.9, and release profile at basic pH was best explained by Higuchi model, as 
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plots expressed high linearity with regression value of between 0.992-0.998 of series 
of hydrogels with varying composition weight ratios. Drawback of Higuchi model was 
that it is unable to explain effect of swelling on matrix upon hydration. Therefore, in 
vitro release data were also ﬁtted to exponential Korsmeyere Peppas equation and 
value of release exponent (n) explains the exact release mechanism. The detected „n‟ 
values for release proﬁles of hydrogels were fall in between 0.50 and 1 indicated 
anomalous release behavior. Similar release kinetics have been exhibited by Poly 
(Vinyl caprolactam) grafted on to sodium alginate, the values of „n‟ were  in the range 
of 0.616-0.918 were accredited to the anomalous type of diffusive transport of drug 
(Madhusudana et al., 2013) 
5.5: Characterization of PEG-g-MAA hydrogels 
5.5.1 Effect of variation of pH, monomer and polymer on swelling 
behavior of PEG-g-MAA hydrogel 
Swelling capacity in varying pH buffer solutions is of prime practical applications for 
controlled drug delivery system. Foremost dynamics that effect the swelling ratio of 
ionic hydrogels include polymer characteristics (charge, concentration and pKa of the 
ionizable group, degree of ionization, cross-link density and hydrophilicity or 
hydrophobicity) and features of the swelling medium (pH, ionic strength and the 
counterion and its valency) (Piyush et al., 2002). 
Unique properties of PEG-based hydrogels renders them best nominee for drug 
delivery applications. Stimuli sensitive nature of PEG -based hydrogels referred as 
smart hydrogels. To evaluate the intelligent properties of PEG-based hydrogel we 
have prepared a series of hydrogels with varying PEG and methacrylic acid 
concentration by free radical polymerization technique. Swelling behavior of these 
hydrogel mentioned in Figure(4.5.1 and 4.5.2) and Table (4.5.1 and 4.5.2) revealed 
that swelling of the hydrogels was highly dependent on MAA contents and triggered a 
decrease in gel swelling in acidic buffer and increase in gel swelling in basic medium. 
MAA imparts pH sensitivity to hydrogels. The hydrogen-bonding and electrostatic 
interactions augmented with MAA content in the copolymer networks. Since, high 
169 
 
MAA contents in the hydrogels offers supplementary hydrogen bonds at low pH and 
more electrostatic repulsion at high pH. Present study has also been depicted that 
increasing concentration of PEG 600 increased swelling because of low crosslinking 
density. As high molecular weight PEG increased crosslinking density and reduced 
diffusion of solvent consequently reduced swelling. Similar results have been reported 
in previous study of poly (methacrylic acid-co-PEG) hydrogel (Bell and Peppas, 
1996). 
5.5.2: Pulsatile behavior of hydrogels 
Equilibrium swelling analysis of PEG-g-MAA hydrogels revealed their pH sensitive 
attitude. Sharp swelling/deswelling pattern of pH sensitive hydrogels was studied to 
evaluate controlled drug release behavior from PEG-g-MAA hydrogel. Since hydrogel 
swells antagonistically at simulated gastric and intestinal pH as shown in Figure 4.5.3. 
At basic pH hydrogel swells because of repulsive electrostatic forces, while at acidic 
pH it contracts within a few minutes due to protonation of carboxyl groups.  Similar 
pulsatile behavior exhibited other ionic hydrogels like chitosan-g-poly(Acrylic acid-
co-HEMA) in acidic and alkaline solution (Sadeghi, 2010). 
5.5.3: Equilibrium water contents and Gel fraction 
EWC of hydrogels is the most substantial property, imparts them uniqueness for 
applications in biomedical fields. EWC of hydrogel be governed by the explicit 
interaction between water molecules and polymer chain. Table 4.5.3 denoted EWC of 
PEG-g-MAA hydrogels, as the PEG contents increased from 5-20% EWC values 
enhanced 0.89 to 0.95. Such propensity may be elucidated by a larger number of water 
molecules binding to the PEG chain through hydrogen bonds (Cursaru et al., 2010). 
Sol-gel analysis is an important tool to measure crosslinking density or gelation which 
is related with its other physico-chemical properties. Sol–gel fraction analysis 
measures uncross linked or soluble residue of polymer or monomers and crosslinker in 
hydrogels. For this purpose sol–gel fraction analysis was performed on different series 
of hydrogels. Figure 4.5.4 showed the effect of varying  amounts of PEG, and MAA 
170 
 
on gel fraction. Results showed that gel fraction was directly proportional to the 
concentration of individual constituents. 
5.5.4: Instrumental analysis 
a) Scanning electron microscopy 
Scanning electron microscopy is an influential method extensively used to envisage 
the distinctive „network‟ structure in hydrogels. The evidences attained through this 
technique explore the characteristics, useful for interaction of the hydrogels with 
living systems. Figure 4.5.5 displayed that PEG-g-MAA hydrogels having rough and 
porous surface morphology. SEM micrograph of PEG-g-MAA present high 
heterogeneity in pore size and shape. Numerous hydrogels with varying pore sizes and 
shapes have been published in the literature and pore size smart hydrogels can be 
controlled by external stimuli as temperature, pH, electrical discharge (You and 
Auguste, 2010; Li et al., 2010). 
b) FTIR spectrum analysis 
Hydrogels prepared by free radical polymerization were characterized by an ATR-
FTIR spectroscopy. In Figure 4.5.6, ATR-FTIR spectra of the PEG, MAA, and PEG-
g-MAA were presented. PEG exhibited the absorption peaks at 2914 cm
-1
 and around 
1094 cm
-1
. Other peaks  were  assigned  to  the  –CH2 scissoring  band  of  ethylene 
glycol  units  at  1480  cm
−1
 and  the  antisymmetric  and  symmetric stretching bands 
(–O–R)  of  ethylene  glycol  units  at  1160  cm−1, respectively. FTIR spectrum of 
PEG-g-MAA an intense band (1710 cm
-1
) conforming to the carbonyl group lifted by 
the hydrogen bonding between the ether group of the PEG and the hydroxyl group of 
the carboxyl group of Methacrylic acid (Bumsang and Peppas, 2003). 
c) Thermal analysis 
Thermal analysis of hydrogel is edifying regarding various features like, intrinsic 
crystallinity, melting behavior, ﬂow properties, and nature of degradation. TGA was 
analyzed to explore the thermal stability of the PEG-g-MAA hydrogels in the 
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temperature range of 0–600°C under inert nitrogen atmosphere. Thermal degradation 
of copolymer (Figure 4.5.7) was shown by three phases befalling in the temperature 
ranges 60–110°C , 150–410°C and 450–543°C. First step of weight loss between 60°C 
and 110°C relates to a loss of moisture from the copolymer. The maximum weight 
loss occurred between 450°C and 543°C. DSC curve was shown in 
Figure4.5.8denoted first endothermic peak at 70°C indicated the loss of water 
molecules from the hydrogel. Furthermore, the copolymer revealed two endothermic 
transitions; one at 125°C and another at 135°C, owing to boosted intramolecular 
relations between carbonyl groups in the copolymer. However, endothermic peak at 
490°C was endorsed to the melting of copolymeric hydrogel. Similarly novel pH-
sensitive poly (methacrylamide-co-methacrylic acid) hydrogel system exhibited 
thermal behavior (Sunil and Surinderpal, 2006). 
5.5.5: In vitro release kinetics of Rabeprazole sodium PEG-g-MAA 
hydrogel 
Figure 4.5.9 showed the rabeprazole sodium release profile of the hydrogels at pH 1.2 
and subsequently at pH 8. The amount of rabeprazole sodium released at pH 1.2 was 
below 15%, whereas released at pH 8 increased considerably (93%). The auspicious 
Rabeprazole sodium release pattern could be credited to the pH sensitivity of the 
hydrogel. On contrary to literature PEG-g-MAA revealed no burst release which 
might be due to the washing of hydrogels after preparation. Variations in the PEG and 
methacrylic acid concentration also have a significant effect on the drug release rate 
from the hydrogel formulations. It was noticed that by increasing PEG contents from 5 
%-20 % cumulative drug release enhanced from 73% to 93%. Swelling analysis of 
hydrogels also behave in same fashion. Methacrylic acid as shown in Figure 4.5.10 act 
as swelling retardant because of hydrophobic methyl group, by increasing methacrylic 
acid contents hydrogels exhibited highly pH sensitive response but cumulative drug 
release was reduced due to low degree of swelling. Swelling of such hydrogel in the 
stomach was minimal and thus the drug release was also minimal. Attributable to 
increase in pH, the extent of swelling increased as the hydrogel passed down the 
intestinal tract, the hydrogel swelled and the controlled release of rabeprazole sodium 
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was influenced. Previous studies correlated with our findings that drug release 
increased by increasing the pH of the medium in cross-linked poly (hydroxyethyl 
methacrylate-co-methacrylic acid) and poly (hydroxyethyl methacrylate-co-acrylic 
acid) hydrogels (Khare and Peppas,1994) 
PEG-g-MAA hydrogels showed good fit into higuchi order with the highest 
correlation coefficient (R
2
=0.994). The value of n ranges from 0.5-0.715. Results 
presented in Table 4.5.6 showing that  release  in most of  the conditions exhibit 
anomalous manner   with  a  mixture  of  polymer  swelling (relaxation) and 
drug diffusion (Fickian) mechanisms. Similar behavior has been depicted by other 
anionic hydrogels (Changez et al., 2003). 
5.6: Characterization of PEG (HEMA-co-AA) hydrogels 
5.6.1 Effect of variation of pH and individual constituents on swelling 
behavior of PEG (HEMA-co-AA) hydrogel 
Water absorbing property of hydrogel is attractive for their biomedical application. 
The effect of HEMA and AA on the swelling curve of prepared hydrogels at acidic 
and basic pH was studied by varying concentrations. PEG concentration in the 
polymerization medium was fixed to 10% w/w. Swelling profile of hydrogels attained 
with different HEMA and AA contents were given in Figures 4.6.1 and 4.6.2. As seen 
in Figure 4.6.1 that with varying contents of AA (7.5 %, 10%, 12.5% and 15%) 
swelling ratio (q) in acidic medium decreased gradually (3.58, 3.30, 2.66, and 2.24 of 
PHA1, PHA2, PHA3 and PHA4 respectively) but at alkaline pH swelling ratio (12.89, 
14.07, 16.13 and 19.72 of PHA1, PHA2, PHA3 and PHA4respectively) increased. 
Swelling profile indicated that increasing AA contents enhanced pH sensitivity and 
also swelling capacity of hydrogels. Hydrogels prepared with varying contents of 
HEMA (1%, 1.5%, 2% and 3%) showed low swelling ratio (4.03, 3.34, 3.16, 2.24 at 
acidic pH and 26.94, 24.65, 21.42 and 16.35 at high pH) with increasing its contents 
and concentration of other constituents keeping constant. Hence, HEMA promoted 
strong, mechanically strong hydrogels for drug delivery applications thus limiting 
swelling ratio of hydrogels. It could be concluded that swelling ratio is primarily 
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associated to features of the external stimuli, along with the nature of polymer, i.e. 
pliability of the network, existence of hydrophilic functional groups, and extent of 
crosslinking density. It has been described by previous work that HEMA/AA based 
hydrogels reveal similar swelling fashion (Belma, 2000). 
5.6.2: Pulsatile behavior of hydrogel 
To characterize the diverse nature of PEG (HEMA-co-AA) hybrid hydrogel, pH 
reversibility was studied in acidic and basic buffer. Ionic group present in matrix are 
responsible for abrupt swelling transition by pH modulation. Hydrogels 
collapsing/expanding behavior revealed in Figure 4.6.3 with pH transition. Such 
abrupt swelling/ deswelling behavior of hydrogels renders them as good candidate for 
controlled drug delivery application. Our results are related with previous work that 
ionic hydrogels showed more sensitive and reversible behavior under the oscillatory 
stimulus of pH (Lee et al., 2006) 
5.6.3: Equilibrium water contents and Gel fraction 
Equilibrium water contents of PEG(HEMA-co-AA)hydrogels summarized in Table 
4.6.3 illustrated that AA contents enhanced EWC from 0.84 to 0.94  and decreased 
(0.92 to 0.53) with increased concentration of HEMA (1-3%) in copolymer 
hydrogel.The probableintentionsof HEMA and AA in hydrogels are stronger 
hydrophobic interactions and hydrogen bonding among them lead to modify EWC 
characteristics (De et al., 2002).Sol-gel fraction analysis of PEG (HEMA-co-AA) 
hydrogel was performed to determine the unreacted fraction of reactants. Figure 4.6.4 
indicated % gel fraction of prepared hydrogels samples. It was detected that by raising 
contents of HEMA from 1-3 % gel fraction increased from 70-97 %. Gel fraction was 
also observed along with increased concentration of acrylic acid. Similar results were 
demonstrated by sung et al., (Sung et al., 2010). 
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5.6.4: Instrumental analysis 
a) Scanning electron microscopy 
Surface morphologies of hydrogels PEG (HEMA-co-AA) swollen at different pH 
values were shown in Figure 4.6.5 although SEM is useful to describe the hydrogel 
structure. The hydrogel examined at low magnification showed a compact and 
collapsed structure with few pores. Polymeric network (Figure 4.6.5) showed a highly 
porous structure. Hydrogel composition defines surface morphology of hydrogel. In 
present study PEG (HEMA-co-AA)hydrogel the pore size in hydrogels with 
increasing HEMA concentrations reduced because of their compact structure and low 
water content. The morphology of PEG (HEMA-co-AA) can be varied with high 
crosslinking density. Our results are supported by Hana et al., work, they prepared 
P(HEMA-co-SMA) hydrogels and studied surface morphology by SEM analysis, 
concluded that compact structure with varying contents of monomer and crosslinker 
modified surface morphology of hydrogels (Hana et al., 2009). 
b) FTIR spectrum analysis 
Figure 4.6.6demonstrated FTIR spectrum of HEMA which displayed distinctive peaks 
at 3394 cm
-1
 attributed to vibration of OH group, 2956 cm
-1
 from antisymetric 
vibration of CH2 and CH3, 1720  cm
-1
of stretching C=O, a small shoulder around  
1636  cm
-1
 from stretching C=C and  1164 cm
-1 
vibration of C-O-C. 
FTIR  spectroscopic  analysis  was  used  to  elucidate  the  chemical  structure 
modifications of  prepared hydrogels  and  the  nature  of  new bonds formation.  All 
distinguishing bands of components (HEMA and AA), and polymer (PEG) of FTIR 
spectra have appeared into the FTIR spectrum of the resultant hydrogel (Figure 4.6.6).  
The  spectral  characteristics  of  PEG(HEMA-co-AA), shown  the  characteristic  
stretching  vibration  band  of  hydrogen-bonded  alcohol  (O–H)  around  3281  cm−1, 
the C=O   stretching  vibration  of  the  ester  group  also  appeared  at 1712  cm
−1
,  
and  an  absorption  band  with  a  weak  shoulder  around 2930  cm
−1
,  which  relate  
to  the  stretching  of  aliphatic  –CH2–,C–H  and  –CH3 groups,  respectively. The  
increased  peak intensity  of  the  C=O  group  at  1712  cm
−1
 in  the  spectrum  of 
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PEG(HEMA-co-AA), hydrogel  was  linked  with  further C=O groups  from  AA.  
Moreover,  some  peaks seemed  in  the  ﬁngerprint  region  for  ethylene  glycol  
units,  instigating from PEG element, between 1555 and 1078 cm
−1
.These  bands  were  
allotted  to  the  –CH2 scissoring  band  of  ethylene glycol  units  at  1449  cm
−1
 and  
the  antisymmetric  and  symmetric stretching bands (–O–R)  of  ethylene  glycol  
units  at  1148  cm
−1
,respectively.  Other  distinctive  bands  signify  C–C  and  C–H 
vibrations  of  –CH3 and  –CH2–  groups. Therefore, FTIR spectroscopy results 
conﬁrmed the amalgamation of PEG and acrylic acid and HEMA into PHA hydrogel. 
c) Thermal analysis. 
The thermal characteristics of PEG (HEMA-co-AA) copolymers were deliberated by 
TGA and DSC analyses. The TGA curves of PEG (HEMA-co-AA) hydrogel 
contained two separate degradation steps. The first decomposition curve is detected in 
the range of 180 to 400°C with maximum weight loss. The second decomposition 
phase follows at 390 to 517 °C with 15% weight loss. It has been proposed that first 
decomposition phase related with ester bonds breakdown in the structure of 
copolymers, while the second one could be accredited to the entire degradation of 
copolymers. The TGA curves of PEG (HEMA-co-AA) as shown in Figure 4.6.7 
indicated that resultant hydrogel was thermally more stable than its individual 
constituents (PEG, HEMA and acrylic acid). Generally it can be concluded that 
grafting improves thermal stability of copolymers. The DSC curves of parent 
components and resultant copolymer are presented in Figure 4.6.8 verified the above 
mentioned findings. One endothermic peak 83.3 to 125.4°C connected with loss of 
loose and bound water present in structure. However peak at 450°C showed the 
decomposition of cross-linked polymeric networks. Grafting evidence and thermal 
stability of hydrogels have been predicted by other researchers, thermal stability is due 
to the molecular rigidity of hosted crosslinkers (Hoffman, 2002). 
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5.6.5: In vitro release kinetics of Rabeprazole sodium PEG-g-MAA 
hydrogel 
The drug release from hydrogels could be the result of macromolecular chain 
relaxation, since the swelling of glassy polymers is accompanied by chain relaxation 
processes. pH of external environment is controlling factor for chain relaxation and 
resultant swelling.  
As PEG (HEMA-co-AA) hydrogels express pH sensitivity and pH responsive 
reversible behavior by swelling analysis and pulsatile behavior analysis. Cumulative 
drug release was also investigated at pH 1.2 and pH 8. Figures 4.6.9 & 4.6.10 showed 
the release profiles of rabeprazole sodium from the hydrogels containing different 
amount of HEMA and acrylic acid at two different pH (pH 1.2 and 8). At pH 1.2 the 
amount of drug released within 24 hrs was 7.04% with 7.5 % AA, 6.27% with 10% 
AA 5.15 % with 12.5% AA and 4.81% with 15% AA contents (Table 4.6.4). As 
described prior, the degree of swelling at pH 1.2 in 24hrs was found to be low. At 
lower pH, the carboxyl groups remain undissociated, results in compaction of 
polymeric matrix. Release of rabeprazole sodium from these hydrogels would be 
useful as matrix to protect the drug from the harsh environment of stomach.  At high 
pH swelling of hybrid hydrogel increased due to ionization of carboxyl groups of 
acrylic acid, release of rabeprazole sodium also high. It was also observed that by 
increasing contents of acrylic acid cumulative drug release also increased, 71.99%, 
77.09%, 82.61% and 90.06% from 7.5%, 10%, 12.5% and 15% acrylic acid 
concentration respectively.  Previous studies demonstrated that drug release through 
hydrogels preferred pore mechanism. As hydrogels containing interconnecting 
microchannels through which drug molecules diffuse out. Diffusivity rises with gel 
water contents with increasing acrylic acid concentration (Dong and Hoffman, 1991). 
Present study also investigated that by increasing HEMA contents while PEG and 
acrylic acid contents kept constant, drug release declined. These findings are 
correlated with swelling analysis of PEG(HEMA-co-AA). As HEMA is neutral 
monomer, which has no ionize able groups and exhibited very small swelling in buffer 
solution. But water swelling properties of HEMA could be improved by co-
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polymerization with more hydrophilic monomer like acrylic acid (Hongyan et al., 
2004). 
Hydrogel polymeric network are reflected swelling-controlled systems, since the drug 
release is measured by the inward movement of solvent. Drug release kinetics of 
hydrogels are commonly scrutinized with Fickian and non-Fickian diffusional manner 
kinetics described by Peppas et al.  On the basis of diffusion exponent „n‟ release 
kinetics can be concluded. Present study demonstrated that by fitting in vitro release 
data into various release kinetics mathematical models, drug release follow the higuchi 
model (R
2 
values of series of hydrogels are 0.991-0.995) as given in Table 4.6.6. 
Diffusion exponent „n‟ was 0.5-0.6 that exhibited non Fickian diffusion (swelling and 
polymer relaxation pattern) (Peppas et al., 2000). 
5.7 Acute oral toxicity study of prepared hydrogels 
Most of the complications connected with hydrogel concerning toxicity, are the 
unreacted monomers, oligomers and initiators that percolate out during application. So 
it is compulsory to assess the toxicity of the hydrogel components like monomers, 
initiators and other building blocks involved in hydrogel synthesis. Meanwhile the 
safety assessment of the smart hydrogel can have a substantial inference on additional 
uses as a biocompatible carrier for oral drug delivery carrier. 
Acute toxicity study of hydrogel is the knowledge of interaction of chemical 
composition of the biomaterial and tissue exposure. Hydrogels as oral drug delivery 
carrier must be safe, nontoxic and biocompatible matrix. Acute oral toxicity study of 
prepared hydrogels (CMC-g-AA, CMC-g-MAA, CMAX-g-MAA and CMAX-g-AA) 
were implemented consistent with the “Organization of Economic Co-operation and 
Development (OECD) guideline for chemicals toxicity study (Oecd, 2001). 
5.7.1: Clinical observations 
All groups of mice revealed a normal boost in body weight without radical alteration 
between both control and treated groups. The results publicized that, the vital organs 
such as kidney, liver, heart, lung, stomach and spleen were not harmfully affected 
throughout the treatment. Table 4.7.1 showed the effect of oral intake of hydrogels on 
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body weight, nutrients consumption, and other poisoning related symptoms. All of the 
mice gained weight and displayed no significant changes in behavior. Physical 
features such as skin, fur, eyes and physical activity of animals were found to be 
normal. All these observations depicted that the administration of the oral hydrogels 
have negligible level of toxicity on the growth and physical characteristics of the 
animals. Moreover, casual food and water intake evaluation of animals is an essential 
parameter for toxicity study, because proper consumption of nutrients is signal for 
normal physiological status. Present study illustrated that food intake and water 
consumption also was not influenced by hydrogels treatment.  No mortality was found 
within study period. No signs of illness (vomiting, eye secretion, running nose, 
salivation) were observed after hydrogels administration. According to globally 
harmonized system (GHS), LD50 value of testing chemical is higher than the 2000 
mg/kg dose then it will be categorize under the “Category 5” and toxicity score will be 
“zero.” Therefore, prepared hydrogels (CMC-g-AA, CMC-g-MAA, CMAX-g-MAA 
and CMAX-g-AA) can be categorized under the Category 5 and toxicity grade is zero. 
5.7.2: Biochemical blood analysis 
The blood is the most sensitive target site for toxic chemicals and an imperative 
indication of physiological and pathological grade. Tables 4.7.2 and 4.7.3 showed 
complete blood chemistry, liver, kidney and lipid profile of control and hydrogel 
treated animals. Notch of boost of AST and ALT level were valuable in unique liver 
abnormalities direct linked with mutilation of liver parenchyma. It was observed that  
the  ALT  value  of control  animal  was  54  IU/L,  hydrogels treated animals  were 53 
IU/L  (Group II), 66 (Group III), 63 IU/L  (Group IV) and 55 IU/L  (Group V). The 
reference range was 28–184 IU/L in mouse.  Likewise, AST value  of  control  group 
was  206 IU/L, animal treated with hydrogels revealed AST level 144 IU/L  (Group 
II), 184 IU/L  (Group III),  185 IU/L  (Group IV),  and 203 IU/L  (Group V), reference 
range of AST level in mice was reported as 55-251 IU/L. Kidney function was 
assessed by creatinine, and urea level and lipid profile shown in Table 4.7.3 all values 
were in normal range illustrated that there was no sign of toxicity in blood, liver, 
kidney and lipid profile of mice was assessed. All vital organs of control and treated 
mice were in normal functioning mode. There was mild variations in WBCs count in 
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group IV and group V, may indicate stimulation of immune system. Such mild 
alterations are not considered to be adverse. Almost all hematological parameters in 
control and treated groups are comparable and in safe zone (Piyasi et al., 2014). 
5.7.3: Histopathological Study 
Microscopic examination of samples obtained from control and hydrogels treated 
groups of mice revealed that no clear histopathological lesions found in vital organs 
(heart, liver, kidney, stomach, intestine and spleen). Figure 4.7.2 described that section 
from the heart showed normal myocardium. No significant pathology was present with 
in myocardial tissues. Figure 4.7.3 revealed hepatic parenchyma with normal 
preserved lobular architecture, but there was focal mild inflammation in occasional 
portal tracts.Figure 4.7.4 described that there was no significant pathology present in 
spleen. Figure 4.7.5 demonstrated that no mild tube degenerative changes and focal 
mild interstitial inflammation. Figure 4.7.1 and 4.7.6 showed normal mucosa of 
stomach and intestine free from any significant pathology. 
Thus, the maximal tolerance dose of hydrogels was estimated to be higher than 10 
g/kg b.w. in mice. It was suggested that the tested hydrogel were nontoxic, safe and 
biocompatible following oral administration and it might be auspicious candidate as an 
innovative oral drug carrier. 
5.8: Pharmacokinetic evaluation of rabeprazole sodium  
Graft copolymeric networks (CMC-g-AA (CA), CMAX-g-AA (A)) have been 
prepared by free radical polymerization and characterized by swelling analysis, FTIR 
spectroscopy, thermal analysis, surface morphology study and in vitro cumulative 
drug release study. Equilibrium swelling studies and impulsive swelling-deswelling 
attitude at different pH values renders the system to be highly pH-responsive and 
thereby it may be a suitable candidate for controlled drug delivery systems. In vitro 
release study of these polymer matrices also represented their smart and sustained 
release fashion of Rabeprazole sodium. On the basis of preliminary investigations 
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these two formulations (CA5 and A6) with maximum in vitro cumulative drug release 
were selected for in vivo evaluation. 
The pharmacokinetic parameters of Rabeprazole sodium from CMAX-g-AA, CMC-g-
AA hydrogels and drug solution were analyzed from the plasma levels in rabbits by 
noncompartmental pharmacokinetic analysis using the software package kinetica v 
4.4. The peak plasma concentration (Cmax) and time to reach peak plasma 
concentration (Tmax) was obtained from the visual inspection of the plasma 
concentration-time curves. The area under the plasma concentration curve (AUC0-t) 
was determined using the trapezoidal rule. 
Mean plasma concentration at specific time interval after administration of hydrogel 
formulations (CA5 and A6) to each group was depicted in Figure 4.8.2 and 4.8.3. 
Mean plasma concentration after oral drug solution of same strength as that of 
hydrogels was shown in Figure 4.8.6. Mean values of pharmacokinetic parameters of 
rabeprazole sodium after oral administration of hydrogel formulations and drug 
solution was shown in Table 4.8.5. Pharmacokinetic data was statistically analyzed by 
one way ANOVA, summarized in Table 4.8.6. 
Graft copolymeric carrier networks (CMC-g-AA and CMAX-g-AA) and same oral 
dose of rabeprazole sodium drug solution showed signiﬁcantly dissimilar (P < 0.05) 
Cmax values of (CMC-g-AA) CA and (CMAX-g-AA) A and same oral dose of 
rabeprazole sodium were 87.28±12.671, 103.71±16.081 and 61.263±5.37 ng/ml, 
respectively. Cmax values of rabeprazole sodium after administration of CA and A 
hydrogel formulations were also correlated with in vitro drug release (98.44 % of A6 
and 80.75 % of CA5). Observed mean plasma AUC0-24 values for CA (952.25±191 
ng.h/ml) and A(1084.57±148.68ng.h/ml) was signiﬁcantly (P < 0.05) higher than drug 
solution (83.67±8.28ng.h/ml) which indicated improvement in relative bioavailability 
might be related to pH sensitive characteristics of graft copolymeric networks protect 
drug from harsh stomach environment. The Tmax value of graft copolymer matrices 
CA(4.43 h) and A (4h) was signiﬁcantly (P < 0.05) higher than drug solution (1h), 
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which indicated the slow absorption rate in graft copolymer due to extended release 
effect of polymer matrix (Zhang et al.,2011).  
The elimination half life (t½) of the CA (5.36 h) and A (4.5h) was more than drug 
solution (0.5h), which conﬁrmed prolonged availability of rabeprazole sodium in 
body. The MRT and Tmax of rabeprazole sodium in the plasma were significantly 
higher in hydrogels than oral drug solution. Therefore, therapeutic effective period for 
rabeprazole sodium were longer than for free rabeprazole sodium. It was also observed 
that Rabeprazole sodium was released from hydrogels in controlled manner with 
increased blood circulation time as well as drug concentration peak in rabbits 
(Bhavesh et al., 2013). 
The relative bioavailability of hydrogel formulations (CA and A) containing 
rabeprazole sodium than free rabeprazole sodium in drug solution, containing the 
same dose of the same drug, is obtained by comparing their respective AUCs (952.25 
ng.l/hr for CA and 1084.57ng.l/hr for A hydrogel) were higher (Oprea et al., 2013). 
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6.   Conclusion 
Present research deals with development of graft copolymeric systems for acid labile 
drug, rabeprazole sodium to accomplish a lingering therapeutic  outcome  by  
continuously  releasing  the  drug  over extended  period  of  time. To achieve desired 
drug carrier system, different hydrogel formulations were prepared with 
carboxymethyl arabin oxylan, carboxymethyl cellulose and polyethylene glycol 
(polymer), methacrylic acid and acrylic acid as monomer with varying concentrations 
of crosslinker by free radical polymerization technique were prepared and their 
potentials for controlled drug delivery have been premeditated. 
Following conclusions have been assessed from present substantial research work. 
 Carboxymethyl arabinoxyllan anionic polysaccharide obtained from Ispaghola 
husk by alkali extraction, exhibited variety of ideal characteristics for 
controlled drug delivery carrier. Free radical polymerization by KPS can be 
successfully employed to formulate pH responsive copolymeric network of 
carboxymethyl arabin oxylan with acrylic acid and methacrylic acid. FTIR, 
SEM and thermo gravimetric analysis verify graft copolymerization. Porous 
structure of hydrogel become more prominent at pH 7.4 by increasing 
contents of acrylic acid, as compared to methacrylic acid contents. CMAX-g-
AA and CMAX-g-MAA underwent morphological changes during grafting 
which modified their structure and properties as well, which showed more 
thermal stability as compared to the raw back bone. Graft copolymers 
revealed highly pH responsive swelling, consequently drug release. At higher 
pH carboxylic acid group present in graft copolymer became progressively 
more ionized, hydrogels swelled more rapidly. Degree of swelling depends on 
crosslinked monomer concentration, polymer concentration and also on 
crosslinking density of hydrogels. Swelling of such hydrogels in the stomach 
is minimal so drug release consequently low at acidic pH. Values of R
2
 
obtained using zero order release model were viewed higher than other order 
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release model, thus depicting that drug release from the series of hydrogels at 
varying amount of polymer, monomer and crosslinker was zero order. 
 Among various graft copolymer formulations prepared with varying contents 
of carboxymethyl cellulose, acrylic acid and N, N MBA CA4 present superior 
properties in regards with swelling, pulsatile behavior, mechanical strength, 
sustained, and pH responsive drug release. CMC-g- MAA  hydrogels with 
high methacrylic acid concentration  may  lead  to  more  efficient network  
formation  (a  lower  sol  fraction)  due  to the  higher  concentration  of 
reactive  vinyl  groups in  the  polymer  mixture. These hydrogels swelled 
slowly and give more sustained release.  
 Polyethylene glycol is FDA accepted polymer for diverse biomedical 
functions because of biocompatibility, biodegradability, low toxicity, and non 
immunogenic nature. PEG-g-MAA hydrogels showed the rabeprazole sodium 
release profile of the hydrogels at pH 1.2 and subsequently at pH 8. The 
amount of rebeprazole sodium released at pH 1.2 was below 15%, whereas 
released at pH 8 increased considerably (93%). PEG is non ionic hydrophilic 
liquid. Other formulations prepared by other polymers (CMAX and CMC) 
released below 10% rabeprazole sodium at acidic pH. Therefore pH 
responsiveness of PEG hydrogels is low as compared to others. 
 Acute toxicity study of hydrogel is the knowledge of interaction of chemical 
composition of the biomaterial and tissue exposure. Acute oral toxicity studies 
of prepared hydrogels suggested that the tested hydrogels were nontoxic, safe 
and biocompatible following oral administration and it might be auspicious 
candidate as a innovative oral drug carrier. 
  Pharmacokinetic parameters evaluation indicated improvement in relative 
bioavailability of hydrogels as compared to drug solution, might be related to 
pH sensitive characteristics of graft copolymeric networks protect drug from 
harsh stomach environment. Also exhibited prolonged release owing to 
crosslinking of graft copolymer promote sustained effect. 
 The  concept  of  formulating  graft copolymer  containing  Rabeprazole 
sodium offers a appropriate, sensible approach to accomplish a lingering 
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therapeutic  outcome  by  continuously  releasing  the  drug  over extended  
period  of  time.  Graft copolymerization is faster and more cost-effective 
technique to modify imperative properties of the existing drugs than 
developing new drug entities hence this research work will be windfall to 
novel drug carrier system. 
 This Research work opens a new platform for potential use of chemically 
crosslinked smart materials for oral controlled release applications. 
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